

APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations




The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 12**

JAN'93-DEC'93



APPROVED DRUG PRODUCTS

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

13TH EDITION


U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

**PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION**

SUBSCRIBE NOW!

Available in March 1994

New 14th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

**14TH EDITION
1994**

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List
- Discontinued Drug Product List
- USP Monograph Title Additions or Changes
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

13TH EDITION

Cumulative Supplement 12

DECEMBER 1993

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Products Requiring Revised Labeling for Full Approval	v
1.3 Applicant Name Changes	vi
1.4 USP Monograph Title Additions or Changes	viii
1.5 Report of Counts for the Prescription Drug Product List	ix
2.0 DRUG PRODUCT LISTS	
2.1 Prescription Drug Product List	1
2.2 OTC Drug Product List	88
2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	92
2.4 Orphan Drug Product Designations	93
2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	100
2.6 Biopharmaceutic Guidance Availability	101
2.7 ANDA Suitability Petitions	102
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Exclusivity Terms	105
B. Patent and Exclusivity Lists	106

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

13TH EDITION

CUMULATIVE SUPPLEMENT 12

DECEMBER 1993

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 13th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "•" symbol to designate their non-marketed status. All products having a "•" symbol in the 12th Cumulative Supplement of the 13th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 14th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

<u>Products</u>	<u>Federal Register Reference</u>
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AH ROBINS CO
(ROBINS)

AH ROBINS CO
(ROBINS AH)

ALLERGAN HERBERT SKIN CARE
DIV ALLERGAN INC
(ALLERGAN HERBERT)

ALLERGAN HERBERT
DIV ALLERGAN INC
(ALLERGAN)

ANAQUEST DIV BOC INC
(ANAQUEST)

ANAQUEST INC
(ANAQUEST) **then changed to**
OHMEDA PHARMACEUTICAL
PRODUCTS DIVISION INC
(OHMEDA PHARM)

ANAQUEST INC
(ANAQUEST)

OHMEDA PHARMACEUTICAL
PRODUCTS DIVISION INC
(OHMEDA PHARM)

ASTRA PHARMACEUTICAL PRODUCTS INC
(ASTRA)

ASTRA USA INC
(ASTRA)

BAKER CUMMINS PHARMACEUTICALS INC
(BAKER CUMMINS)

BAKER NORTON PHARMACEUTICALS INC
(BAKER NORTON)

BENEDICT NUCLEAR PHARMACEUTICALS INC
(BENEDICT)

NORTH AMERICAN CHEMICAL CORPORATION
(NORTH AM CHEM)

BOLAR PHARMACEUTICAL CO INC
(BOLAR)

CIRCA PHARMACEUTICALS INC
(CIRCA)

CIS US INC
(CIS)

CIS US INC
(CIS)
formerly
(CIS US)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

CUTTER BIOLOGICAL DIV
MILES LABORATORIES INC
(CUTTER)

MILES LABORATORIES INC
(MILES LABS)

DANBURY PHARMACAL INC
(DANBURY)

DANBURY PHARMACAL INC
(DANBURY PHARMA)

FUJISAWA PHARMACEUTICAL CO
(FUJISAWA)

FUJISAWA USA INC
(FUJISAWA)

GENSIA PHARMACEUTICAL INC
(GENSIA)

GENSIA INC
(GENSIA)

HERBERT LABORATORIES DIV
SMITH KLINE AND FRENCH CO
(HERBERT)

ALLERGAN HERBERT
DIV ALLERGAN INC
(ALLERGAN HERBERT)

ICI PHARMACEUTICALS GROUP
DIV ICI AMERICAS
(ICI)

ZENECA PHARMACEUTICALS GROUP
DIV ZENECA INC
(ZENECA)
formerly
ZENECA PHARMACEUTICALS GROUP

KABIVITRUM INC
(KABIVITRUM)

KABI PHARMACIA INC
(KABI)

LEMMON CO
(LEMMON)

LEMMON CO SUB TEVA PHARMACEUTICALS
(LEMMON)

LYPHOMED DIV FUJISAWA USA INC
(LYPHOMED)

FUJISAWA USA INC
(FUJISAWA)

OWEN GALDERMA LABORATORIES INC
(OWEN GALDERMA)

GALDERMA LABORATORIES INC
(GALDERMA)

PIONEER PHARMACEUTICALS INC
(PIONEER PHARMS)

PIONEER PHARMACEUTICALS CO INC
(PIONEER PHARMS)

ROXANE LABORATORIES INC
(ROXANE)

ROXANE LABORATORIES INC
(ROXANE)
formerly
(ROXANE LABS)

RW JOHNSON PHARMACEUTICAL RESEARCH
INSTITUTE DIV MCNEILAB
(JOHNSON RW)

RW JOHNSON PHARMACEUTICAL RESEARCH
INSTITUTE DIV ORTHO PHARMACEUTICAL
CORP
(JOHNSON RW)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

SCHIAPPARELLI SEARLE
(SCHIAPPARELLI SEARLE)

SCS PHARMACEUTICALS
(SCS PHARMS)

SCHWARZ PHARMA KERMERS URBAN
(SCHWARZ PHARMA)

SCHWARZ PHARMA DIV KREMERS URBAN CO
(SCHWARZ PHARMA)

SOMERSET PHARMACEUTICALS INC
(SOMERSET)

SOMERSET PHARMACEUTICALS INC
(SOMERSET PHARMS)

STERLING DRUG INC
(STERLING)

STERLING WINTHROP INC
(STERLING WINTHROP)

1.4 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE
(FORMER ADP DOSAGE FORM; ROUTE)

NEW USP MONOGRAPH TITLE
(NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF DECEMBER 1993.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1992) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 1992</u>	<u>JUN 1993</u>	<u>SEP 1993</u>	<u>DEC 1993</u>
DRUG PRODUCTS LISTED	9488	9194	9142	9140
SINGLE SOURCE	2245 (23.7%)	2119 (23.0%)	2151 (23.5%)	2144 (23.5%)
MULTISOURCE	7243 (76.3%)	7075 (77.0%)	6991 (76.5%)	6996 (76.5%)
THERAPEUTICALLY EQUIVALENT	6516 (68.6%)	6357 (69.1%)	6276 (68.7%)	6292 (68.8%)
NOT THERAPEUTICALLY EQUIVALENT	577 (6.1%)	555 (6.1%)	532 (5.8%)	527 (5.8%)
EXCEPTIONS ¹	150 (1.6%)	163 (1.8%)	183 (2.0%)	177 (1.9%)
NEW MOLECULAR ENTITIES APPROVED	--	2	9	15
NUMBER OF APPLICANTS	477	508	515	526

¹Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

PRESCRIPTION DRUG PRODUCT LIST
13TH EDITION
CUMULATIVE SUPPLEMENT NUMBER 12 / JAN'93 - DEC'93

1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL			
<u>ANOCUAN</u>			
/AA/	/MALLARD/	/325MG;50MG;40MG/	/N87628/001/ /OCT/01./1986/
AB	ROBERTS HAUCK	325MG;50MG;40MG	N87628 001 OCT 01, 1986
TABLET; ORAL			
<u>ESGIC</u>			
/AA/	/FOREST/PHARMS/	/325MG;50MG;40MG/	/N89660/001/ /DEC/23./1988/
	Q FOREST PHARMS	325MG;50MG;40MG	N89660 001 DEC 23, 1988

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL			
<u>COMPAL</u>			
AA	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001 MAR 04, 1986
/AA/	/SOLVAY/	/356.4MG;30MG;16MG/	/N88584/001/ /MAR/04./1986/

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL			
ACETAMINOPHEN AND CODEINE PHOSPHATE			
	Q LEMMON	300MG;30MG	N88324 001 DEC 29, 1983
<u>ACETAMINOPHEN/W/CODEINE/03/</u>			
	/LEMMON/	/300MG;30MG/	/N88324/001/ /DEC/29./1983/
SOLUTION; ORAL			
<u>ACETAMINOPHEN AND CODEINE PHOSPHATE</u>			
AA	PENNEX PHARMS	120MG/5ML;12MG/5ML	N87006 001
/AA/	/PHARM/BAISCS/	/120MG/5ML;12MG/5ML/	/N87006/001/
TABLET; ORAL			
<u>ACETAMINOPHEN AND CODEINE PHOSPHATE</u>			
/AA/	/PHARMAFAIR/	/300MG;30MG/	/N87762/001/ /DEC/10./1982/
AA	PHARMERAL	300MG;30MG	N87762 001 DEC 10, 1982

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL			
<u>ALLAY</u>			
/AA/	/LUCHEN/	/500MG;5MG/	/N89907/001/ /JAN/13./1989/
AA	NORTON HN	500MG;5MG	N89907 001 JAN 13, 1989
<u>BANCAP HC/</u>			
/AA/	/FOREST/PHARMS/	/500MG;5MG/	/N87961/001/ /MAR/17./1983/
	Q FOREST PHARMS	500MG;5MG	N87961 001 MAR 17, 1983
TABLET; ORAL			
<u>ANEXSTA</u>			
AA	BOEHRINGER MANNHEIM	500MG;5MG	N89160 001 APR 23, 1987
/AA/	/SKCP/	/500MG;5MG/	/N89160/001/ /APR/23./1987/
<u>ANEXSTA 7.5/650</u>			
AA	BOEHRINGER MANNHEIM	650MG;7.5MG	N89725 001 SEP 30, 1987
/AA/	/SKCP/	/650MG;7.5MG/	/N89725/001/ /SEP/30./1987/
<u>DURADINE DHC/</u>			
/AA/	/FOREST/PHARMS/	/500MG;5MG/	/N87809/001/ /MAR/17./1983/
	Q FOREST PHARMS	500MG;5MG	N87809 001 MAR 17, 1983
<u>HYDROCODONE BITARTRATE AND ACETAMINOPHEN</u>			
/AA/	/LUCHEN/	/500MG;5MG/	/N89696/001/ /APR/21./1988/
AA	NORTON HN	500MG;5MG	N89696 001 APR 21, 1988
<u>NORCET/</u>			
/AA/	/ABANA/	/500MG;5MG/	/N88871/001/ /MAY/15./1986/
	Q ABANA	500MG;5MG	N88871 001 MAY 15, 1986
<u>TYCOLET/</u>			
/AA/	/JOHNSON/RW/	/500MG;5MG/	/N89385/001/ /AUG/27./1986/
	Q JOHNSON RW	500MG;5MG	N89385 001 AUG 27, 1986

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

/AB/	/HALSEY/	/325MG;50MG/	/N72105/001/
			/MAY/13./1988/
/AB/		/650MG;100MG/	/N72106/001/
			/MAY/13./1988/
	Q HALSEY	325MG;50MG	N72105 001
			MAY 13, 1988
	Q	650MG;100MG	N72106 001
			MAY 13, 1988

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

/AP/	/QUAD/	/EQ 500MG/VIAL/	/N89619/001/
			/JAN/13./1988/
	Q QUAD	EQ 500MG/VIAL	N89619 001
			JAN 13, 1988

DIAMOX

/AP/	/LEDERLE/	/EQ 500MG/VIAL/	/N09388/001/
			/DEC/05./1990/
	LEDERLE	EQ 500MG/VIAL	N09388 001
			DEC 05, 1990

ACETYLCOLINE CHLORIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC

MIOCHOL-E

+	IOLAB	20MG/VIAL	N20213 001
			SEP 22, 1993

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ZOVIRAX

+	BURROUGHS WELLCOME	EQ 1GM BASE/VIAL	N18603 002
			JUN 29, 1989
	Q	EQ 250MG BASE/VIAL	N18603 003
			AUG 30, 1983

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	COPLEY	EQ 0.083% BASE	N73495 001
			MAY 28, 1993

SYRUP; ORAL

ALBUTEROL SULFATE

AA	WATSON LABS	EQ 2MG BASE/5ML	N73165 001
			APR 29, 1993

TABLET; ORAL

ALBUTEROL SULFATE

AB	NOVOPHARM	EQ 2MG BASE	N72779 001
			JUN 25, 1993
AB		EQ 4MG BASE	N72780 001
			JUN 25, 1993

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL

/BC/	/+//SCHERING/	/EQ 4MG/BASE/	/N19383/001/
			/JUL/13./1987/
BC	SCHERING	EQ 4MG BASE	N19383 001
			JUL 13, 1987

VOLMAX

/BC/	/BLAXO/	/EQ 4MG/BASE/	/N19604/002/
			/DEC/23./1992/
/+//		/EQ 8MG/BASE/	/N19604/001/
			/DEC/23./1992/

BC +	MURO	EQ 4MG BASE	N19604 002
			DEC 23, 1992

+		EQ 8MG BASE	N19604 001
			DEC 23, 1992

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

	ROXANE	1MG/ML	N74312 001
			OCT 31, 1993

SOLUTION; ORAL

ALPRAZOLAM

	ROXANE	0.5MG/5ML	N74314 001
			OCT 31, 1993

ALPRAZOLAMTABLET; ORAL
ALPRAZOLAM

AB	ALPHAPHARM	<u>0.25MG</u>	N74046 001 OCT 19, 1993
AB		<u>0.5MG</u>	N74046 002 OCT 19, 1993
AB		<u>1MG</u>	N74046 003 OCT 19, 1993
AB	LEDERLE	<u>0.25MG</u>	N74174 001 OCT 19, 1993
AB		<u>0.5MG</u>	N74174 002 OCT 19, 1993
AB		<u>1MG</u>	N74174 003 OCT 19, 1993
AB		<u>2MG</u>	N74174 004 OCT 19, 1993
AB	PUREPAC	<u>0.25MG</u>	N74342 001 OCT 31, 1993
AB		<u>0.5MG</u>	N74342 002 OCT 31, 1993
AB		<u>1MG</u>	N74342 003 OCT 31, 1993
AB		<u>2MG</u>	N74342 004 OCT 31, 1993
AB	ROXANE	<u>0.25MG</u>	N74199 001 OCT 19, 1993
AB		<u>0.5MG</u>	N74199 002 OCT 19, 1993
AB		<u>1MG</u>	N74199 003 OCT 19, 1993
<u>XANAX</u>			
AB	UPJOHN	<u>0.25MG</u>	N18276 001
AB		<u>0.5MG</u>	N18276 002
AB	+	<u>1MG</u>	N18276 003
AB		<u>2MG</u>	N18276 004 NOV 27, 1985

AMANTADINE HYDROCHLORIDECAPSULE; ORAL
AMANTADINE HCL

/AB/	/CIRCA/	/100MG/	/N71382/001/ /JAN/21/1987/
	Q CIRCA	100MG	N71382 001 JAN 21, 1987

AMANTADINE HYDROCHLORIDESYRUP; ORAL
AMANTADINE HCL

AA	MIKART	<u>50MG/5ML</u>	N74028 001 JUN 28, 1993
<u>/TABLET;/ORAL/</u>			
<u>/SYMMETREL/</u>			
<u>/+//DUPONT/</u>			
	Q DUPONT	<u>100MG/</u> 100MG	<u>/N18101/001/</u> N18101 001

AMDINOCILLIN/INJECTABLE;/INJECTION/
/COACTIN/
/ROCHE/

		<u>/250MG/VIAL/</u>	<u>/N50565/001/</u> <u>/DEC/21/1984/</u>
		<u>/500MG/VIAL/</u>	<u>/N50565/002/</u> <u>/DEC/21/1984/</u>
		<u>/1GM/VIAL/</u>	<u>/N50565/003/</u> <u>/DEC/21/1984/</u>
	Q ROCHE	250MG/VIAL	N50565 001 DEC 21, 1984
	Q	500MG/VIAL	N50565 002 DEC 21, 1984
	Q	1GM/VIAL	N50565 003 DEC 21, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN

AP	DUPONT MERCK	<u>EQ 50MG BASE/ML</u>	N63350 001 JUL 30, 1993
AP		<u>EQ 250MG BASE/ML</u>	N63350 002 JUL 30, 1993
AP	GENSIA	<u>EQ 50MG BASE/ML</u>	N64045 001 SEP 28, 1993
AP		<u>EQ 250MG BASE/ML</u>	N64045 002 SEP 28, 1993
<u>AMIKIN</u>			
/AP/	/BRISTOL/	<u>/EQ 250MG BASE/ML/</u>	<u>/N50495/002/</u>
AP	+	<u>EQ 250MG BASE/ML</u>	N50495 002

AMIKACIN SULFATE

INJECTABLE; INJECTION

/AMIKIN/IN/SODIUM/CHLORIDE/0.9%/IN/PLASTIC/CONTAINER/ /BRISTOL/	/EQ/5MG/BASE/ML/	/N50618/002/ NOV/30./1987/
	/EQ/10MG/BASE/ML/	/N50618/001/ NOV/30./1987/
Q BRISTOL	EQ 5MG BASE/ML	N50618 002 NOV 30, 1987
Q	EQ 10MG BASE/ML	N50618 001 NOV 30, 1987

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER		
BAXTER	15%	N20107 001 FEB 05, 1993
/NOVAMINE/8.5%/ /KABIVITRUM/	/8.5%/ /N17957/002/ /N17957/001/ /APR/03./1986/	
Q KABIVITRUM	8.5%	N17957 002 AUG 09, 1982
TRAVASOL 10% IN PLASTIC CONTAINER		
BAXTER	10%	N18931 003 AUG 23, 1984
/TRAVASOL/10%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/ /BAXTER/	/10%/ /N18931/004/ /APR/27./1988/	
TRAVASOL 5.5% IN PLASTIC CONTAINER	5.5%	N18931 001 AUG 23, 1984
/TRAVASOL/5.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/ /BAXTER/	/5.5%/ /N18931/001/ /AUG/23./1984/	
TRAVASOL 8.5% IN PLASTIC CONTAINER	8.5%	N18931 002 AUG 23, 1984
/TRAVASOL/8.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/ /BAXTER/	/8.5%/ /N18931/002/ /AUG/23./1984/	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

> DLT >	/INJECTABLE; INJECTION/	
> DLT >	/VEINAMINE/8%/ /KABIVITRUM/	/8%;61MG/100ML;211MG/100ML;/ /56MG/100ML;388MG/100ML;/
> DLT >		/N17957/001/
> ADD >	Q KABI	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML N17957 001
> ADD >		

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

/AMINOSYN/11/7%/W/O/ELECTROLYTES/ /ABBOTT/	/7%;102MG/100ML;45MG/100ML;/ /522MG/100ML;410MG/100ML;/	/N19437/006/ /APR/03./1986/
Q ABBOTT	7%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML	N19437 006 APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

/AMINOSYN/11/3.5%/M/ /ABBOTT/	/3.5%;30MG/100ML;97MG/100ML;/ /120MG/100ML;49MG/100ML;/	/N19437/007/ /APR/03./1986/
Q ABBOTT	3.5%;30MG/100ML;97MG/100ML; 120MG/100ML;49MG/100ML	N19437 007 APR 03, 1986

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AP + IMMUNEX	250MG/ML	N15229 002
/AP/ /LEDERLE/	/250MG/ML/	/N15229/002/
/AP/ /AMINOCAPROIC ACID/	/250MG/ML/	/N10522/001/
/AP/ /LYPHOMED/	/250MG/ML/	/JUN/17./1986/
Q LYPHOMED	250MG/ML	N70522 001 JUN 17, 1986

SYRUP; ORAL

AMICAR

IMMUNEX

1.25GM/5ML

N15230 002

AMINOCAPROIC ACID

SYRUP; ORAL

AMICAR

/LEDERLE/

/1.25GM/5ML/

/N15236/002/

TABLET; ORAL

AMICAR

+ IMMUNEX

/LEDERLE/

500MG

/500MG/

N15197 001

/N15197/001/

AMINOPHYLLINE/ENEMA; RECTAL/
/SOMOPHYLLIN/
/FISONS/

/300MG/5ML/

/N18232/001/
/APR/02/1982/

3 FISONS

300MG/5ML

N18232 001

APR 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLINE

/AP/

/BRISTOL/

/25MG/ML/

/N87431/001/

/AP/

FUJISAWA

25MG/ML

N88407 001

JAN 25, 1984

3

25MG/ML

N87431 001

/AP/

/LYPHOMED/

/25MG/ML/

/N88407/001/

/JAN/25/1984/

SOLUTION; ORAL

AMINOPHYLLINE

3 PENNEX PHARMS

105MG/5ML

N88156 001

DEC 05, 1983

/AA/

/PHARM/BASICS/

/105MG/5ML/

/N88156/001/

/DEC/05/1983/

/AA/

/SOMOPHYLLIN/

/105MG/5ML/

/N86466/001/

/AA/

/FISONS/

/105MG/5ML/

/N86466 001

3 FISONS

105MG/5ML

/AA/

/SOMOPHYLLIN-DE/

/105MG/5ML/

/N87045/001/

/AA/

/FISONS/

/105MG/5ML/

/N87045 001

3 FISONS

105MG/5ML

TABLET; ORAL

AMINOPHYLLINE

/AB/

/SEARLE/

/100MG/

/N02386/002/

/AB/

/SEARLE/

/200MG/

/N02386/003/

3 SEARLE

100MG

N02386 002

3

200MG

N02386 003

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

/AB/

/ROXANE/

/100MG/

/N87500/001/

/FEB/09/1982/

AB

+ ROXANE

100MG

N87500 001

FEB 09, 1982

/AB/

/200MG/

/N87501/001/

/FEB/09/1982/

AB

+

200MG

N87501 001

FEB 09, 1982

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ELAVIL

/AP/

/MSD/

/10MG/ML/

/N12704/001/

AP

ZENECA

10MG/ML

N12704 001

TABLET; ORAL

AMITRIPTYLINE HCL

> DLT > /AB/

/CHELSEA/

/10MG/

/N85816/001/

> DLT > /AB/

/CHELSEA/

/25MG/

/N85817/001/

> DLT > /AB/

/CHELSEA/

/50MG/

/N85815/001/

> DLT > /AB/

/CHELSEA/

/75MG/

/N85819/001/

> DLT > /AB/

/CHELSEA/

/100MG/

/N85820/001/

> ADD >

3 CHELSEA

10MG

N85816 001

> ADD >

3

25MG

N85817 001

> ADD >

3

50MG

N85815 001

> ADD >

3

75MG

N85819 001

> ADD >

3

100MG

N85820 001

ELAVIL

/AB/

/MSD/

/10MG/

/N12703/001/

/AB/

/MSD/

/25MG/

/N12703/003/

/AB/

/MSD/

/50MG/

/N12703/004/

/AB/

/MSD/

/75MG/

/N12703/005/

/AB/

/MSD/

/100MG/

/N12703/006/

/AB/

/MSD/

/150MG/

/N12703/007/

AB

ZENECA

10MG

N12703 001

AB

+

25MG

N12703 003

AB

50MG

N12703 004

AB

75MG

N12703 005

AB

100MG

N12703 006

AB

150MG

N12703 007

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

/AB/	/PAR/	/10MG;2MG/	/N74565/001/
			/SEP/11,/1986/
/AB/		/10MG;4MG/	/N70620/001/
			/SEP/11,/1986/
/AB/		/25MG;2MG/	/N70621/001/
			/SEP/11,/1986/
/AB/		/25MG;4MG/	/N70595/001/
			/SEP/11,/1986/
/AB/		/50MG;4MG/	/N70574/001/
			/SEP/11,/1986/
2	PAR	10MG;2MG	N70565 001
			SEP 11, 1986
2		10MG;4MG	N70620 001
			SEP 11, 1986
2		25MG;2MG	N70621 001
			SEP 11, 1986
2		25MG;4MG	N70595 001
			SEP 11, 1986
2		50MG;4MG	N70574 001
			SEP 11, 1986

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

/AB/	/ABBOTT/	/5MEQ/ML/	/N83130/001/
			/N83130 001

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

/AB/	/ABBOTT/	/5MEQ/ML/	/N88366/001/
			/JUN/13,/1984/
+	ABBOTT	5MEQ/ML	N88366 001
			JUN 13, 1984

AMOXICILLIN

CAPSULE; ORAL

/AB/	/POLYMAX/	/250MG/	/N61885/001/
			/N61885/002/
/AB/	/BRISTOL/	/500MG/	
/AB/	/TRIMOX/	/250MG/	/N62098/001/
			/N62098/002/
/AB/	/SQUIBB/	/250MG/	/N62152/001/
			/N62152/002/
/AB/		/250MG/	
/AB/		/500MG/	
/AB/		/500MG/	

AMOXICILLIN

CAPSULE; ORAL

TRIMOX

AB	APOTHECON	250MG	N61885 001
AB		500MG	N61885 002
2	APOTHECON	250MG	N62098 001
2		250MG	N62152 001
2		500MG	N62098 002
2		500MG	N62152 002

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

AB	CLONMEL	125MG/5ML	N62927 001
			NOV 25, 1988
AB		250MG/5ML	N62927 002
			NOV 25, 1988
/BX/		/125MG/5ML/	/N62927/001/
			/NOV/25,/1988/
/BX/		/250MG/5ML/	/N62927/002/
			/NOV/25,/1988/
/AB/	/POLYMAX/	/125MG/5ML/	/N61886/002/
			/N61886/001/
/AB/	/BRISTOL/	/50MG/ML/	/N61886/003/
/AB/		/250MG/5ML/	/N61886/001/
/AB/	/BRISTOL/MEYERS/	/125MG/5ML/	/N62885/001/
			/MAR/08,/1988/
/AB/		/250MG/5ML/	/N62885/002/
			/MAR/08,/1988/
/AB/	/TRIMOX/	/125MG/5ML/	/N62099/001/
/AB/	/SQUIBB/	/125MG/5ML/	/N62154/001/
/AB/		/250MG/5ML/	/N62099/002/
/AB/		/250MG/5ML/	/N62154/002/

TRIMOX

AB	APOTHECON	125MG/5ML	N61886 002
AB		125MG/5ML	N62885 001
			MAR 08, 1988
AB		50MG/ML	N61886 001
AB		250MG/5ML	N61886 003
AB		250MG/5ML	N62885 002
			MAR 08, 1988
2	APOTHECON	125MG/5ML	N62099 001
2		125MG/5ML	N62154 001
2		250MG/5ML	N62099 002
2		250MG/5ML	N62154 002

AMPHOTERICIN B

CREAM; TOPICAL
FUNGIZONE
+ APOTHECON
/SQUIBB/

3%
13%!

N50314 001
/N50314/001/

INJECTABLE; INJECTION

FUNGIZONE
AP + APOTHECON 50MG/VIAL
/AP/ /SQUIBB/ /50MG/VIAL/

N60517 001
/N60517/001/

LOTION; TOPICAL
FUNGIZONE
+ APOTHECON
/SQUIBB/

3%
13%1

N60570 001
/N60570/001/

OINTMENT; TOPICAL

FUNGIZONE	
+ APOTHECON	3%
/SQUIBB/	/3%/

N50313 001
/N50313/001/

AMPICILLIN SODIUM

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

INJECTABLE; INJECTION

```

/EQ/6.25MG/BASE;/
/EQ/6.25MG/BASE;/N10093/007/
EQ 6.25MG BASE;
EQ 6.25MG BASE      N10093 007

```

<u>AMPICILLIN SODIUM</u>		
<u>AP</u>	HANFORD	<u>EQ 125MG BASE/VIAL</u>
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>
<u>AP</u>	IBI	<u>EQ 125MG BASE/VIAL</u>
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>

N63143 001
APR 15, 1993
N63145 001
APR 15, 1993
N63146 001
APR 15, 1993
N63147 001
APR 15, 1993
N62772 001
APR 15, 1993
N63139 001
APR 15, 1993
N63140 001
APR 15, 1993
N63141 001
APR 15, 1993
N63142 001
APR 15, 1993
N62797 001
JUL 12, 1993
N62797 002
JUL 12, 1993

```

/ EQ 10MG BASE; /
/ EQ 10MG BASE; /N10093/003/
EQ 10MG BASE;
EQ 10MG BASE N10093 003

```

2 F150NS

AMPICILLIN SODIUMINJECTABLE; INJECTIONAMPICILLIN SODIUM

/AP/	/LILLY/	/EQ 500MG BASE/VIAL/	/N62565/001/
			/APR/04./1985/
/AP/		/EQ 1GM BASE/VIAL/	/N62565/002/
			/APR/04./1985/
/AP/		/EQ 2GM BASE/VIAL/	/N62565/003/
			/JUN/24./1986/
	Q LILLY	EQ 500MG BASE/VIAL	N62565 001
			APR 04, 1985
	Q	EQ 1GM BASE/VIAL	N62565 002
			APR 04, 1985
	Q	EQ 2GM BASE/VIAL	N62565 003
			JUN 24, 1986
	PENBRITIN-S		
	/WYETH/AYERST/	/EQ 4GM BASE/VIAL/	/N50072/006/
	Q WYETH AYERST	EQ 4GM BASE/VIAL	N50072 006
	/POLYICILLIN-N/		
/AP/	/BRISTOL/	/EQ 125MG BASE/VIAL/	/N61395/001/
/AP/		/EQ 125MG BASE/VIAL/	/N62860/001/
			/FEB/05./1988/
/AP/		/EQ 250MG BASE/VIAL/	/N61395/002/
/AP/		/EQ 250MG BASE/VIAL/	/N62860/002/
			/FEB/05./1988/
/AP/		/EQ 500MG BASE/VIAL/	/N61395/003/
/AP/		/EQ 500MG BASE/VIAL/	/N62860/003/
			/FEB/05./1988/
/AP/		/EQ 1GM BASE/VIAL/	/N61395/004/
/AP/		/EQ 1GM BASE/VIAL/	/N62738/001/
			/FEB/19./1987/
/AP/		/EQ 1GM BASE/VIAL/	/N62860/004/
			/FEB/05./1988/
/AP/		/EQ 2GM BASE/VIAL/	/N61395/005/
/AP/		/EQ 2GM BASE/VIAL/	/N62738/002/
			/FEB/19./1987/
/AP/		/EQ 2GM BASE/VIAL/	/N62860/005/
			/FEB/05./1988/
/AP/		/EQ 10GM BASE/VIAL/	/N61395/006/

AMPICILLIN SODIUMINJECTABLE; INJECTIONPRINCIPEN

AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001
AP		EQ 125MG BASE/VIAL	N62860 001
			FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002
AP		EQ 250MG BASE/VIAL	N62860 002
			FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003
AP		EQ 500MG BASE/VIAL	N62860 003
			FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004
AP		EQ 1GM BASE/VIAL	N62738 001
			FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004
			FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005
AP		EQ 2GM BASE/VIAL	N62738 002
			FEB 19, 1987
AP	+	EQ 10GM BASE/VIAL	N62860 005
			FEB 05, 1988
			N61395 006

AMPICILLIN SODIUM; SULBACTAM SODIUMINJECTABLE; INJECTIONUNASYN

/PFIZER/	/EQ 500MG BASE/VIAL/	/N50608/003/
	/EQ 250MG BASE/VIAL/	/DEC/31./1986/
Q PFIZER	EQ 500MG BASE/VIAL;	N50608 003
	EQ 250MG BASE/VIAL	DEC 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATECAPSULE; ORALPOLYICILLIN

/AB/	/+BRISTOL/	/EQ 250MG BASE/	/N61392/001/
/AB/		/EQ 500MG BASE/	/N61392/002/
/AB/	/BRISTOL/AYERST/	/EQ 250MG BASE/	/N62888/001/
			/MAR/04./1988/
/AB/	/+/	/EQ 500MG BASE/	/N62888/002/
			/MAR/04./1988/

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

PRINCIPEN

AB + APOTHECON	EQ 250MG BASE	N61392 001
AB	EQ 250MG BASE	N62888 001
		MAR 04, 1988
AB	EQ 500MG BASE	N61392 002
AB +	EQ 500MG BASE	N62888 002
		MAR 04, 1988

/AB/	<u>PRINCIPEN '250'</u>		
/AB/	/SQUIBB/	/EQ '250MG' BASE/	/N50056/001/
		/EQ '250MG' BASE/	/N62157/002/
	2 APOTHECON	EQ 250MG BASE	N50056 001
	2	EQ 250MG BASE	N62157 002
/AB/	<u>PRINCIPEN '500'</u>		
/AB/	/SQUIBB/	/EQ '500MG' BASE/	/N50056/002/
		/EQ '500MG' BASE/	/N62157/001/
	2 APOTHECON	EQ 500MG BASE	N50056 002
	2	EQ 500MG BASE	N62157 001

TOTACILLIN

/AB/	/SMITHKLINE/BEECHAM/	/EQ '250MG' BASE/	/N60060/001/
/AB/		/EQ '500MG' BASE/	/N60060/002/
	2 SMITHKLINE BEECHAM	EQ 250MG BASE	N60060 001
	2	EQ 500MG BASE	N60060 002

POWDER FOR RECONSTITUTION; ORAL

/AB/	<u>POLYCYLLIN</u>		
/AB/	/BRISTOL/	/EQ '125MG' BASE/5ML/	/N61394/002/
		/EQ '250MG' BASE/5ML/	/N61394/003/
		/EQ '100MG' BASE/ML/	/N61394/001/

PRINCIPEN

AB	APOTHECON	EQ 125MG BASE/5ML	N61394 002
AB		EQ 250MG BASE/5ML	N61394 003
AB		EQ 100MG BASE/ML	N61394 001
/AB/	<u>PRINCIPEN '125'</u>		
/AB/	/SQUIBB/	/EQ '125MG' BASE/5ML/	/N60127/002/
/AB/		/EQ '125MG' BASE/5ML/	/N62151/001/
	2 APOTHECON	EQ 125MG BASE/5ML	N60127 002
	2	EQ 125MG BASE/5ML	N62151 001
/AB/	<u>PRINCIPEN '250'</u>		
/AB/	/SQUIBB/	/EQ '250MG' BASE/5ML/	/N60127/001/
		/EQ '250MG' BASE/5ML/	/N62151/002/
	2 APOTHECON	EQ 250MG BASE/5ML	N60127 001
	2	EQ 250MG BASE/5ML	N62151 002

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL

PRINCIPEN/N/PROBENECID

/+//SQUIBB/	/EQ '389MG' BASE/111MG/	/N50488/001/
	/EQ '389MG' BASE/111MG/	/N62150/001/
2 APOTHECON	EQ 389MG BASE/111MG	N50488 001
2	EQ 389MG BASE/111MG	N62150 001

POWDER FOR RECONSTITUTION; ORAL

POLYCYLLIN-PRB

AB + APOTHECON	EQ 3.5GM BASE/BOT;	
	1GM/BOT	N61898 001
/AB//+//BRISTOL/	/EQ '3.5GM' BASE/BOT:/	
	/1GM/BOT/	/N61898/001/

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

/VALPIN/50/		
/DUPONT/	/50MG/	/N13428/001/
2 DUPONT	50MG	N13428 001

APRACLOINIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

IOPIDINE		
+ ALCON	EQ 0.5% BASE	N20258 001
		JUL 30, 1993

> ADD > APROTEININ BOVINE

> ADD > INJECTABLE; INJECTION

> ADD >	TRASYLOL	
> ADD >	+ MILES	10,000KIU/ML
> ADD >		N20304 001
		DEC 29, 1993

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;
ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE;
RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

/INJECTABLE; INJECTION/
/M.V.C. 2+3/
/ASTRA/

Q ASTRA

/100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL/
/15MG/VIAL; 5UGM/VIAL; 0.4MG/VIAL/
/40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL/
/3MG/VIAL; 1MG/VIAL/
/10MG/VIAL/
/N18933/002/
/AUG 08, 1985/
 100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL
 15MG/VIAL; 5UGM/VIAL; 0.4MG/VIAL;
 40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL;
 3MG/VIAL; 1MG/VIAL;
 10MG/VIAL N18933 002
 AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;
ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE
HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 2+3

AP FUJISAWA

10MG/ML; 0.006MG/ML; 0.5UGM/ML;
1.5MG/ML; 20 IU/ML; 0.04MG/ML; 4MG/ML;
0.4MG/ML; 0.36MG/ML; 0.3MG/ML;
330 UNITS/ML; 1 IU/ML
 N18440 002
 AUG 08, 1985

/AB/ /LYPHOMED/

/10MG/ML; 0.006MG/ML; 0.5UGM/ML/
/1.5MG/ML; 20 IU/ML; 0.04MG/ML; 4MG/ML/
/0.4MG/ML; 0.36MG/ML; 0.3MG/ML/
/330 UNITS/ML; 1 IU/ML/
/N18440/002/
/AUG 08, 1985/

> ADD > ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC
 > ADD > ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE;
 > ADD > PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE;
 > ADD > VITAMIN E

> ADD > INJECTABLE; INJECTION
 > ADD > KABIVITE PED F + M KIT
 > ADD > KABI
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >
 > ADD >

80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL;
 400IU/10ML; 0.14MG/VIAL; 17MG/VIAL;
 5MG/VIAL; 0.2MG/10ML; 1MG/VIAL;
 1.4MG/VIAL; 1.2MG/VIAL;
 EQ 2300 UNITS BASE/10ML;
 7IU/10ML N20176 003
 DEC 29, 1993

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

/+//ADRIA/

/650MG; 50MG/

/N88305/001/
/OCT 13, 1983/
 N88305 001
 OCT 13, 1983

+ SAVAGE

650MG; 50MG

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL W/ ASPIRIN & CAFFEINE

/AB/ /PHARMAFAIR/

/325MG; 50MG; 40MG/

/N87048/002/
/DEC 09, 1983/
 N87048 002
 DEC 09, 1983

AB PHARMERAL

325MG; 50MG; 40MG

BUTALBITAL, ASPIRIN AND CAFFEINE

> DLT > /AB/ /CHELSEA/

/325MG; 50MG; 40MG/

/N86237/002/
/MAR 23, 1984/
 N86237 002
 MAR 23, 1984

> DLT >

> ADD >

> ADD >

Q CHELSEA

325MG; 50MG; 40MG

ASPIRIN; PROPOXYPHENE NAPSYLATE

/TABLET; ORAL/

/DARYON-N/W/ASA/

/+//LILLY/

Q LILLY

/325MG; 100MG/
 325MG; 100MG

/N16863/001/
 N16863 001

ATENOLOL

TABLET; ORAL

ATENOLOL

AB MUTUAL PHARM

50MG

N73475 001
 MAR 30, 1993

AB

100MG

N73476 001
 MAR 30, 1993

AB

NOVOPHARM

50MG

N73315 001
 MAY 28, 1993

AB

100MG

N73316 001
 MAY 28, 1993

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	MUTUAL PHARM	50MG;25MG	N73581 001
			APR 29, 1993
AB		100MG;25MG	N73582 001
			APR 29, 1993
AB	MYLAN	50MG;25MG	N74203 001
			OCT 31, 1993
AB		100MG;25MG	N74203 002
			OCT 31, 1993

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

AA	PHARMAFAIR	0.025MG;2.5MG	N65635/001
AA	PHARMERAL	0.025MG;2.5MG	N85035 001

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AB	AZATHIOPRINE	EQ 100MG BASE/VIAL	N71056/001
	QUAD		JUN/08, 1988
		EQ 100MG BASE/VIAL	N71056 001
			JUN 08, 1988

AB	BURROUGHS WELLCOME	EQ 100MG BASE/VIAL	N17391/001
	BURROUGHS WELLCOME	EQ 100MG BASE/VIAL	N17391 001

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

/MILES/

2 MILES

2

2

2

/EQ/2GM/BASE/VIAL/

EQ 2GM BASE/VIAL

/EQ/2GM/BASE/VIAL/

EQ 2GM BASE/VIAL

/EQ/4GM/BASE/VIAL/

EQ 4GM BASE/VIAL

/EQ/4GM/BASE/VIAL/

EQ 4GM BASE/VIAL

/N62388/001/

/SEP/08, 1982/

N62388 001

SEP 08, 1982

/N62417/001/

/OCT/12, 1982/

N62417 001

OCT 12, 1982

/N62388/003/

/SEP/08, 1982/

N62388 003

SEP 08, 1982

/N62417/003/

/OCT/12, 1982/

N62417 003

OCT 12, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM IN PLASTIC CONTAINER

/SQUIBB/

2 SQUIBB

10MG/ML

10MG/ML

/N50632/003/

/MAY/24, 1989/

N50632 003

MAY 24, 1989

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

> DLT >

> DLT >

> DLT >

> DLT >

> ADD >

> ADD >

/OINTMENT; OPHTHALMIC/

/MYCITRACIN/

/UPJOHN/

2 UPJOHN

/500 UNITS/GM; EQ 3.5MG BASE/GM;/

/10,000 UNITS/GM;/

500 UNITS/GM; EQ 3.5MG BASE/GM;

10,000 UNITS/GM

/N61048/001/

N61048 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

AT	BURROUGHS WELLCOME	400 UNITS/GM; EQ 3.5MG BASE/GM;/	
		10,000 UNITS/GM;/	N50416/002/
	BURROUGHS WELLCOME	400 UNITS/GM; EQ 3.5MG BASE/GM;	
		10,000 UNITS/GM	N50416 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

/ZINC BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE &/
/HYDROCORTISONE/

/At/	/PHARMAFAIR/	/400 UNITS/GM; 12; EQ 3.5MG BASE/GM;/	/N62389/001/
		/10,000 UNITS/GM/	/JUL/02/1982/
	a PHARMAFAIR	400 UNITS/GM; 12; EQ 3.5MG BASE/GM;	
		10,000 UNITS/GM	N62389 001
			JUL 02, 1982

OINTMENT; TOPICAL

CORTISPORIN

/At/	/BURROUGHS/WELLCOME/	/400 UNITS/GM; 12; EQ 3.5MG BASE/GM;/	/N50168/002/
		/5,000 UNITS/GM/	/MAY/04/1984/
	+ BURROUGHS WELLCOME	400 UNITS/GM; 12; EQ 3.5MG BASE/GM;	
		5,000 UNITS/GM	N50168 002
			MAY 04, 1984

/NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC &/

/At/	/PHARMAFAIR/	/400 UNITS/GM; 12; EQ 3.5MG BASE/GM;/	/N62381/001/
		/5,000 UNITS/GM/	/SEP/06/1985/
	a PHARMAFAIR	400 UNITS/GM; 12; EQ 3.5MG BASE/GM;	
		5,000 UNITS/GM	N62381 001
			SEP 06, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

/BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE/

/At/	/PHARMAFAIR/	/400 UNITS/GM; EQ 3.5MG BASE/GM;/	/N62386/001/
		/10,000 UNITS/GM/	/SEP/09/1982/
	a PHARMAFAIR	400 UNITS/GM; EQ 3.5MG BASE/GM;	
		10,000 UNITS/GM	N62386 001
			SEP 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

/PHARMADERM/	/400 UNITS/GM; EQ 3.5MG BASE/GM;/	/N62167/001/
	/5,000 UNITS/GM/	
a PHARMADERM	400 UNITS/GM; EQ 3.5MG BASE/GM;	
	5,000 UNITS/GM	N62167 001

BACLOFEN

> DLT >	/INJECTABLE; INJECTION/	
> DLT >	/LIORESAL/	
> DLT >	/MEDTRONIC/	/0.5MG/ML/
> DLT >		/N20075/001/
> DLT >		/JUN/17/1992/
> DLT >		/N20075/002/
> DLT >		/JUN/17/1992/

> ADD >	INJECTABLE; INTRATHECAL	
> ADD >	LIORESAL	
> ADD >	MEDTRONIC	0.5MG/ML
> ADD >		N20075 001
> ADD >		JUN 17, 1992
> ADD >		N20075 002
> ADD >		JUN 17, 1992

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

/ADRIA/

/500MG/7.5ML/

/N18366/001/
/DEC/29/1983/
N18366 001
DEC 29, 1983

SAVAGE

500MG/7.5ML

BENTONITE; SULFUR/POWDER; TOPICAL//BENSULFOID//POYTHRESS/

a POYTHRESS

/66.64%; 33.32%/
66.64%; 33.32%

/N02918/001/
N02918 001

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA

PHARMACAPS

100MG

N81297 001
JAN 29, 1993

AA

TESSALON

FOREST LABS

100MG

N11210 001

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DIDREX

/UPJOHN/

a UPJOHN

/25MG/
25MG

/N12427/003/
N12427 003

BENZTHIAZIDE

TABLET; ORAL		
/AB/	/AQUATAG/ a SOLVAY	/50MG/ 50MG
		/N16001/002/ N16001 002
EXNA		
/BP/+	/ROBINS/AH/ + ROBINS AH	/50MG/ 50MG
		/N12489/001/ N12489 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL		
/AB/	/BEPADIN/ WALLACE	/200MG/ 200MG
		/N19001/001/ DEC 28, 1990
/AB/		/300MG/ 300MG
		/N19001/002/ DEC 28, 1990
/AB/		/400MG/ 400MG
		/N19001/003/ DEC 28, 1990
	a WALLACE	200MG
	a	300MG
	a	400MG

<u>VASCOR</u>		
/AB/	/JOHNSON/RW/	/200MG/ 200MG
		/N19002/001/ DEC 28, 1990
/AB/		/300MG/ 300MG
		/N19002/002/ DEC 28, 1990
/AB/+		/400MG/ 400MG
		/N19002/003/ DEC 28, 1990
	+ JOHNSON RW	400MG
		200MG
		300MG

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL		
<u>BETAMETHASONE DIPROPIONATE</u>		
/AB/	/PHARMADERM/	/EQ 0.05% BASE/ EQ 0.05% BASE
	a PHARMADERM	
		/N19136/001/ JUN 26, 1984
		N19136 001 JUN 26, 1984

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL		
<u>BETAMETHASONE DIPROPIONATE</u>		
/AB/	/PHARMADERM/	/EQ 0.05% BASE/ EQ 0.05% BASE
	a PHARMADERM	
		/N70274/001/ AUG 12, 1985
		N70274 001 AUG 12, 1985

OINTMENT; TOPICAL		
<u>BETAMETHASONE DIPROPIONATE</u>		
/AB/	/PHARMADERM/	/EQ 0.05% BASE/ EQ 0.05% BASE
	a PHARMADERM	
		/N19140/001/ SEP 04, 1984
		N19140 001 SEP 04, 1984

BETAMETHASONE VALERATE

CREAM; TOPICAL		
<u>BETAMETHASONE VALERATE</u>		
/AB/	/PHARMADERM/	/EQ 0.1% BASE/ EQ 0.1% BASE
	a PHARMADERM	
		/N18860/002/ AUG 31, 1983
		N18860 002 AUG 31, 1983

LOTION; TOPICAL		
<u>BETAMETHASONE VALERATE</u>		
/AB/	/PHARMADERM/	/EQ 0.1% BASE/ EQ 0.1% BASE
	a PHARMADERM	
		/N18870/001/ AUG 31, 1983
		N18870 001 AUG 31, 1983

OINTMENT; TOPICAL		
<u>BETAMETHASONE VALERATE</u>		
AB	NMC	/EQ 0.1% BASE/ EQ 0.1% BASE
		N70051 001 OCT 10, 1984

<u>BETAMETHASONE VALERATE</u>		
/AB/	/PHARMADERM/	/EQ 0.1% BASE/ EQ 0.1% BASE
	a PHARMADERM	
		/N18864/001/ AUG 31, 1983
		N18864 001 AUG 31, 1983

<u>BETAMETHASONE VALERATE</u>		
/AB/	/VALNAC/ NMC	/EQ 0.1% BASE/ EQ 0.1% BASE
		/N70051/001/ OCT 10, 1984

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ZIAC

+ LEDERLE

10MG;6.25MG

N20186 002

MAR 26, 1993

2.5MG;6.25MG

N20186 003

MAR 26, 1993

5MG;6.25MG

N20186 001

MAR 26, 1993

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE;
PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

MYPHETANE DC

AA

PENNEX PHARMS

2MG/5ML;10MG/5ML;

12.5MG/5ML

N88904 001

FEB 21, 1985

/AA/ /PHARM/BASICS/

/2MG/5ML;10MG/5ML;/

/12.5MG/5ML/

/N88904/001/

/FEB/21/1985/

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

/AP/

/ASTRA/

/50MG/ML/

/N71152/001/

/AUG/10/1987/

a ASTRA

50MG/ML

N71152 001

AUG 10, 1987

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE;
PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

MYPHETANE DX

AA

PENNEX PHARMS

2MG/5ML;10MG/5ML;

30MG/5ML

N88811 001

JUN 07, 1985

/AA/ /PHARM/BASICS/

/2MG/5ML;10MG/5ML;/

/30MG/5ML/

/N88811/001/

/JUN/07/1985/

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

MYBANTIL

AA

PENNEX PHARMS

12.5MG/5ML;10MG/5ML

N88626 001

OCT 12, 1984

/AA/

/PHARM/BASICS/

/12.5MG/5ML;10MG/5ML/

/N88626/001/

/OCT/12/1984/

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

BIPHETAP

a PENNEX PHARMS

4MG/5ML;25MG/5ML

N88687 001

SEP 26, 1984

/a/PHARM/BASICS/

/4MG/5ML;25MG/5ML/

/N88687/001/

/SEP/26/1984/

BROMPHENIRAMINE MALEATE

TABLET; ORAL

BROMPHENIRAMINE MALEATE

/AA/

/ANABOLIC/

/4MG/

/N86187/001/

a ANABOLIC

4MG

N86187 001

/AA/

/NEWTRON/

/4MG/

/N86987/001/

a NEWTRON

4MG

N86987 001

AA

NYLOS TRADING

4MG

N85592 001

> DLT >

/AA/

/TABLICAPS/

/4MG/

/N85592/001/

> DLT >

/AA/

/ZENITH/

/4MG/

/N84351/001/

> DLT >

a ZENITH

4MG

N84351 001

> DLT >

> ADD >

> ADD >

> ADD >

> ADD >

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

/Bristol/

/10MG/

/N18731/002/

/SEP/29/1986/

/N18731/001/

/SEP/29/1986/

+ BRISTOL MYERS SQUIBB 10MG

N18731 002

SEP 29, 1986

N18731 001

SEP 29, 1986

BUTABARBITAL SODIUM

ELIXIR; ORAL
BUTABARBITAL SODIUM
 @ PENNEX PHARMS 30MG/5ML N85383 001
 /AA/ /PHARM/BASICS/ /30MG/5ML/ /N85383/001/

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
 STADOL
 + APOTHECON 1MG/ML N17857 001
 + 2MG/ML N17857 002
 /BRISTOL/ /1MG/ML/ /N17857/001/
 /2MG/ML/ /N17857/002/

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL
 CALDEROL
 + ORGANON 0.05MG N18312 002
 0.02MG N18312 001
 /JUNIPORN/ /0.05MG/ /N18312/002/
 /0.02MG/ /N18312/001/

> ADD > CALCIPOTRIENE

> ADD > OINTMENT; TOPICAL
 > ADD > DOVONEX
 > ADD > + BRISTOL MYERS SQUIBB 0.005%
 > ADD >

N20273 001
 DEC 29, 1993

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCIMAR
 /AP/ /RHONE/POULENC/RORER/ /200 IU/ML/ /N17769/001/
 AP + RHONE POULENC RORER 200 IU/ML N17769 001
 MIACALCIN
 /SANDOZ/ /100 IU/ML/ /N17808/001/
 @ SANDOZ 100 IU/ML N17808 001
 JUL 03, 1986

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
ENDOSOL EXTRA
 AT ALLERGAN 0.154MG/ML; 0.92MG/ML; 0.184MG/ML;
 0.2MG/ML; 0.38MG/ML; 2.1MG/ML;
 7.14MG/ML; 0.42MG/ML N20079 001
 NOV 27, 1991
ENDOSOL PLUS
 /AT/ /ALLERGAN/ /0.154MG/ML; 0.92MG/ML; 0.184MG/ML;/
 /0.2MG/ML; 0.38MG/ML; 2.1MG/ML;/
 /7.14MG/ML; 0.42MG/ML/ /N20079/001/
 /NOV/27/1991/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
 ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
 MCGAW 37MG/100ML; 56M/100ML; 31MG/100ML;
 120MG/100ML; 330MG/100ML;
 88MG/100ML N19864 001
 JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
 ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
 MCGAW 35MG/100ML; 56M/100ML; 30MG/100ML;
 74MG/100ML; 640MG/100ML; 500MG/100ML;
 74MG/100ML N19867 001
 DEC 20, 1993

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE
 /AP/ /ABBOTT/ /EQ 90MG CALCIUM/5ML/ /N80001/001/
 + ABBOTT EQ 90MG CALCIUM/5ML N80001 001
 /AP/ /LILLY/ /EQ 90MG CALCIUM/5ML/ /N06470/001/
 @ LILLY EQ 90MG CALCIUM/5ML N06470 001
 /AP/ /LYPHOMED/ /EQ 90MG CALCIUM/5ML/ /N89373/001/
 @ LYPHOMED EQ 90MG CALCIUM/5ML N89373 001
 APR 30, 1987

CARBACHOL

INJECTABLE; INJECTION

/AP/	/CARBACHOL/	/0.012/	/N70292/001/
	/PHARMAFAIR/		/MAY 21, 1986/
	Q PHARMAFAIR	0.01%	N70292 001
			MAY 21, 1986

/AP/	MIOSTAT	/0.012/	/N16968/001/
	+ ALCON	0.01%	N16968 001

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

/AP/	GEOPEN	/EQ 1GM BASE/VIAL/	/N50306/001/
/AP/	/ROERIG/	/EQ 2GM BASE/VIAL/	/N50306/004/
/AP/		/EQ 5GM BASE/VIAL/	/N50306/002/
/AP/		/EQ 10GM BASE/VIAL/	/N50306/006/
	ROERIG	EQ 1GM BASE/VIAL	N50306 001
		EQ 2GM BASE/VIAL	N50306 004
		EQ 5GM BASE/VIAL	N50306 002
		EQ 10GM BASE/VIAL	N50306 006

/AP/	PYOPEN	/EQ 1GM BASE/VIAL/	/N50298/001/
/AP/	/SMITHKLINE/BEECHAM/	/EQ 2GM BASE/VIAL/	/N50298/002/
/AP/		/EQ 5GM BASE/VIAL/	/N50298/003/
/AP/		/EQ 10GM BASE/VIAL/	/N50298/006/
	Q SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N50298 001
	Q	EQ 2GM BASE/VIAL	N50298 002
	Q	EQ 5GM BASE/VIAL	N50298 003
	Q	EQ 10GM BASE/VIAL	N50298 006
		/EQ 20GM BASE/VIAL/	/N50298/007/
	Q	EQ 20GM BASE/VIAL	N50298 007

CARBIDOPA; LEVODOPA

TABLET; ORAL

AB	CARBIDOPA AND LEVODOPA	10MG;100MG
	PUREPAC	
AB		25MG;100MG
AB		25MG;250MG

N74260 001
SEP 03, 1993
N74260 002
SEP 03, 1993
N74260 003
SEP 03, 1993

CARBIDOPA; LEVODOPA

TABLET; ORAL

AB	CARBIDOPA AND LEVODOPA	10MG;100MG
	WATSON LABS	
AB		25MG;100MG
AB		25MG;250MG

N73381 001
SEP 28, 1993
N73382 001
SEP 28, 1993
N73383 001
SEP 28, 1993

CARBINOXAMINE MALEATE

/TABLET; ORAL/

/CLISTIN/	/4MG/	/N08915/001/
Q JOHNSON RW	4MG	N08915 001

CARISOPRODOL

/CAPSULE; ORAL/

/SOMA/	/250MG/	/N11792/003/
Q WALLACE	250MG	N11792 003

TABLET; ORAL

AB	CARISOPRODOL	/350MG/	/N89390/001/
	/PIONEER/PHARMS/		/OCT 13, 1988/
	Q PIONEER PHARMS	350MG	N89390 001
			OCT 13, 1988
AA	RELA	/350MG/	/N12155/001/
	Q SCHERING	350MG	N12155 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIPRESS	/1% /
/BURROUGHS/WEILLCOME/	

OTSUKA	1%
--------	----

/N19972/001/
/MAY 23, 1990/
N19972 001
MAY 23, 1990

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

DURICEF

AB + BRISTOL MYERS SQUIBB	EQ 500MG BASE	N50512 001
/AB//+//MEAD/JOHNSON/	/EQ 500MG BASE/	/N50512/001/

POWDER FOR RECONSTITUTION; ORAL

DURICEF

AB + BRISTOL MYERS SQUIBB	EQ 125MG BASE/5ML	N50527 002
AB +	EQ 250MG BASE/5ML	N50527 003
AB +	EQ 500MG BASE/5ML	N50527 001
/AB//+//MEAD/JOHNSON/	/EQ 125MG BASE/5ML/	/N50527/002/
/AB//+//	/EQ 250MG BASE/5ML/	/N50527/003/
/AB//+//	/EQ 500MG BASE/5ML/	/N50527/001/

TABLET; ORAL

DURICEF

AB + BRISTOL MYERS SQUIBB	EQ 1GM BASE	N50528 001
/AB//+//MEAD/JOHNSON/	/EQ 1GM BASE/	/N50528/001/

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

+ LILLY	EQ 10GM BASE/VIAL	N50504 004
---------	-------------------	------------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

/AP/	/BEN/VENUE/	/EQ 250MG BASE/VIAL/	/N62894/001/
/AP/		/EQ 500MG BASE/VIAL/	/JUL/21/1988/
/AP/		/EQ 1GM BASE/VIAL/	/N62894/002/
/AP/		/EQ 5GM BASE/VIAL/	/JUL/21/1988/
/AP/		/EQ 10GM BASE/VIAL/	/N62894/003/
	Q BEN VENUE	EQ 250MG BASE/VIAL	/JUL/21/1988/
	Q	EQ 500MG BASE/VIAL	N62894 001
	Q	EQ 1GM BASE/VIAL	JUL 21, 1988
	Q	EQ 5GM BASE/VIAL	N62894 003
	Q	EQ 10GM BASE/VIAL	JUL 21, 1988
AP	SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62894 004
			JUL 21, 1988
			N62894 005
			JUL 21, 1988
			N64033 001
			OCT 31, 1993

CEFMENOXIME HYDROCHLORIDE

/INJECTABLE; INJECTION/

/CEFMAX/
/TAP/

	/EQ 500MG BASE/VIAL/	/N50571/001/
	/EQ 1GM BASE/VIAL/	/DEC/30/1987/
	/EQ 2GM BASE/VIAL/	/N50571/002/
		/DEC/30/1987/
		/N50571/003/
		/DEC/30/1987/
Q TAP	EQ 500MG BASE/VIAL	N50571 001
Q	EQ 1GM BASE/VIAL	DEC 30, 1987
Q	EQ 2GM BASE/VIAL	N50571 002
		DEC 30, 1987
		N50571 003
		DEC 30, 1987

CEFONICID SODIUMINJECTABLE; INJECTION
MONOCID

SMITHKLINE BEECHAM

EQ 1GM BASE/VIAL

N63295 001

JUL 26, 1993

/EQ 2GM BASE/VIAL/

/N50579/003/

/MAY 23, 1984/

a

EQ 2GM BASE/VIAL

N50579 003

MAY 23, 1984

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CLAFORAN

HOECHST ROUSSEL

EQ 500MG BASE/VIAL

N50547 001

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

/AP/ /STUART/

/EQ 1GM BASE/VIAL/

/N50588/001/

/DEC 27, 1985/

/AP/

/EQ 2GM BASE/VIAL/

/N50588/002/

/DEC 27, 1985/

/AP/ /ZENECA/

/EQ 1GM BASE/VIAL/

/N63293/001/

/APR 29, 1993/

/AP/

/EQ 2GM BASE/VIAL/

/N63293/002/

/APR 29, 1993/

+ ZENECA

EQ 1GM BASE/VIAL

N50588 001

DEC 27, 1985

+

EQ 2GM BASE/VIAL

N50588 002

DEC 27, 1985

EQ 1GM BASE/VIAL

N63293 001

APR 29, 1993

EQ 2GM BASE/VIAL

N63293 002

APR 29, 1993

CEFOTAN IN PLASTIC CONTAINER

+ ZENECA

EQ 20MG BASE/ML

N50694 002

JUL 30, 1993

+

EQ 40MG BASE/ML

N50694 001

JUL 30, 1993

CEFOTIAM HYDROCHLORIDE/INJECTABLE; INJECTION/
/CERADON/

/TAKEDA/

/EQ 1GM BASE/VIAL/

/N50601/001/

/DEC 30, 1988/

CEFOTIAM HYDROCHLORIDE/INJECTABLE; INJECTION/
/CERADON/

a TAKEDA

EQ 1GM BASE/VIAL

N50601 001

DEC 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN IN PLASTIC CONTAINER

MERCK

EQ 20MG BASE/ML

N63182 001

JAN 25, 1993

EQ 40MG BASE/ML

N63182 002

JAN 25, 1993

CEFPYRAMIDE SODIUM/INJECTABLE; INJECTION/
/CEFPYRAMIDE SODIUM/

/WYETH AYERST/

/EQ 1GM BASE/VIAL/

/N50633/002/

/JAN 31, 1989/

/EQ 2GM BASE/VIAL/

/N50633/003/

/JAN 31, 1989/

/EQ 10GM BASE/VIAL/

/N50633/005/

/JAN 31, 1989/

a WYETH AYERST

EQ 1GM BASE/VIAL

N50633 002

JAN 31, 1989

a

EQ 2GM BASE/VIAL

N50633 003

JAN 31, 1989

a

EQ 10GM BASE/VIAL

N50633 005

JAN 31, 1989

CEFTAZIDIME

INJECTABLE; INJECTION

TAZICEF

AP

SMITHKLINE BEECHAM

1GM/VIAL

N64032 001

OCT 31, 1993

AP

2GM/VIAL

N64032 002

OCT 31, 1993

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER
 AP BAXTER EQ 10MG BASE/ML N63221 001
 APR 29, 1993
 AP EQ 20MG BASE/ML N63221 002
 APR 29, 1993
 AP EQ 40MG BASE/ML N63221 003
 APR 29, 1993
FORTAZ IN PLASTIC CONTAINER
 AP GLAXO EQ 10MG BASE/ML N50634 001
 APR 28, 1989
 AP EQ 20MG BASE/ML N50634 002
 APR 28, 1989
 AP EQ 40MG BASE/ML N50634 003
 APR 28, 1989

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
 CEFIZOX
 FUJISAWA EQ 500MG BASE/VIAL N50560 001
 SEP 15, 1983
 EQ 10GM BASE/VIAL N50560 005
 MAR 19, 1993

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
 ROCEPHIN
 ROCHE EQ 250MG BASE/VIAL N63239 001
 AUG 13, 1993
 EQ 500MG BASE/VIAL N63239 002
 AUG 13, 1993
 EQ 1GM BASE/VIAL N63239 003
 AUG 13, 1993
 ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
 /ROCHE/ /EQ 10MG BASE/ML/ N50624 001
 /FEB 11, 1987/
 @ ROCHE EQ 10MG BASE/ML N50624 001
 FEB 11, 1987

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME
 AP MARSAM EQ 750MG BASE/VIAL N64035 001
 FEB 26, 1993
 AP EQ 1.5GM BASE/VIAL N64035 002
 FEB 26, 1993
 AP EQ 7.5GM BASE/VIAL N64036 001
 FEB 26, 1993
KEFUROX
 AP LILLY EQ 7.5GM BASE/VIAL N62591 003
 DEC 17, 1987
ZINACEF
 AP GLAXO EQ 7.5GM BASE/VIAL N50558 004
 OCT 23, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL
 CALCIBIND
 /:/MISSION/PHARMA/ /2.5GM/PACKET/ /N18757/002/
 /DEC 28, 1982/
 @ MISSION PHARMA 2.5GM/PACKET N18757 002
 DEC 28, 1982

CEPHALEXIN

CAPSULE; ORAL
CEFANEX
 AB APOTHECON EQ 250MG BASE N63063 001
 SEP 29, 1989
 AB EQ 500MG BASE N63063 002
 SEP 29, 1989
 /AB/ /BRISTOL/MYERS/ /EQ 250MG BASE/ /N63063/001/
 /SEP 29, 1989/
 /AB/ /EQ 500MG BASE/ /N63063/002/
 /SEP 29, 1989/
CEPHALEXIN
 AB APOTHECON EQ 250MG BASE N62973 001
 NOV 08, 1988
 AB EQ 500MG BASE N62974 001
 NOV 23, 1988
 /AB/ /SQUIBB/MARK/ /EQ 250MG BASE/ /N62973/001/
 /NOV 08, 1988/
 /AB/ /EQ 500MG BASE/ /N62974/001/
 /NOV 23, 1988/

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM

/AP/	/ABBOTT/	/EQ 1GM BASE/VIAL/	/N62548/001/
			/SEP 11, 1985/
/AP/		/EQ 2GM BASE/VIAL/	/N62548/002/
			/SEP 11, 1985/
	Q ABBOTT	EQ 1GM BASE/VIAL	N62548 001
			SEP 11, 1985
	Q	EQ 2GM BASE/VIAL	N62548 002
			SEP 11, 1985

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

	Q APOTHECON	EQ 500MG BASE/VIAL	N50446 005
		EQ 500MG BASE/VIAL	N62961 001
			SEP 20, 1988
	Q	EQ 1GM BASE/VIAL	N50446 001
		EQ 1GM BASE/VIAL	N61769 001
		EQ 1GM BASE/VIAL	N62724 001
			DEC 23, 1986
		EQ 1GM BASE/VIAL	N62961 002
			SEP 20, 1988
	Q	EQ 2GM BASE/VIAL	N50446 002
		EQ 2GM BASE/VIAL	N61769 002
		EQ 2GM BASE/VIAL	N62724 002
			DEC 23, 1986
		EQ 2GM BASE/VIAL	N62961 003
			SEP 20, 1988
	Q	EQ 4GM BASE/VIAL	N50446 003
		EQ 4GM BASE/VIAL	N61769 003
		EQ 4GM BASE/VIAL	N62961 004
			SEP 20, 1988
	Q	EQ 20GM BASE/VIAL	N50446 004
/AP/	/BRISTOL/	/EQ 500MG BASE/VIAL/	/N50446/005/
/AP/		/EQ 1GM BASE/VIAL/	/N50446/001/
/AP/		/EQ 1GM BASE/VIAL/	/N61769/001/
/AP/		/EQ 1GM BASE/VIAL/	/N62724/001/
			/DEC 23, 1986/
/AP/		/EQ 2GM BASE/VIAL/	/N50446/002/
/AP/		/EQ 2GM BASE/VIAL/	/N61769/002/
/AP/		/EQ 2GM BASE/VIAL/	/N62724/002/
			/DEC 23, 1986/
/AP/		/EQ 4GM BASE/VIAL/	/N50446/003/
/AP/		/EQ 4GM BASE/VIAL/	/N61769/003/
/AP/		/EQ 20GM BASE/VIAL/	/N50446/004/

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

/AP/	/BRISTOL/	/EQ 500MG BASE/VIAL/	/N62961/001/
			/SEP 20, 1988/
/AP/		/EQ 1GM BASE/VIAL/	/N62961/002/
			/SEP 20, 1988/
/AP/		/EQ 2GM BASE/VIAL/	/N62961/003/
			/SEP 20, 1988/
/AP/		/EQ 4GM BASE/VIAL/	/N62961/004/
			/SEP 20, 1988/
/AP/	/CEPHAPIRIN SODIUM/		
/AP/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62723/001/
			/NOV 17, 1986/
/AP/		/EQ 1GM BASE/VIAL/	/N62723/002/
			/NOV 17, 1986/
/AP/		/EQ 2GM BASE/VIAL/	/N62723/003/
			/NOV 17, 1986/
/AP/		/EQ 4GM BASE/VIAL/	/N62723/004/
			/NOV 17, 1986/
	Q LYPHOMED	EQ 500MG BASE/VIAL	N62723 001
			NOV 17, 1986
	Q	EQ 1GM BASE/VIAL	N62723 002
			NOV 17, 1986
	Q	EQ 2GM BASE/VIAL	N62723 003
			NOV 17, 1986
	Q	EQ 4GM BASE/VIAL	N62723 004
			NOV 17, 1986

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

MYCHEL-S

Q ANGUS

/Q/RACHELLE/

EQ 1GM BASE/VIAL

/EQ 1GM BASE/VIAL/

N60132 001

/N60132/001/

CHLORDIAZEPOXIDE

/CAPSULE; EXTENDED RELEASE; ORAL/

/LIBRELEASÉ/

/Q/ROCHE/

/30MG/

Q ROCHE

30MG

/N17813/001/

/SEP 12, 1983/

N17813 001

SEP 12, 1983

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

/AB/ /PIONEER/PHARMS/ /25MG/

a PIONEER PHARMS 25MG

LIBRIUM

/AB/ /ROCHE/ /5MG/

/AB/ /ROCHE/ /10MG/

/AB/ /+/ /25MG/

/AB/ /+/ /25MG/

AB + ROCHE 25MG

a 5MG

a 10MG

a 25MG

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

/AB/ /MSD/ /150MG;250MG/

MSD 150MG;250MG

ALDOCLOR-250

/AB/ /+/ /MSD/ /250MG;250MG/

+ MSD 250MG;250MG

METHYLDOPA AND CHLOROTHIAZIDE

/AB/ /PAR/ /150MG;250MG/

/AB/ /+/ /250MG;250MG/

a PAR 150MG;250MG

a 250MG;250MG

CHLOROTRIANISENE

CAPSULE; ORAL

TACE

/MERRELL/DOW/ /72MG/

a MERRELL DOW 72MG

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLOR-TRIMETON

> DLT > /AP/ /SCHERING/ /10MG/ML/

> DLT > /a/ /100MG/ML/

/N89558/001/

/JUL/15./1988/

N89558 001

JUL 15, 1988

/N12249/002/

/N12249/001/

/N12249/003/

/N85475/001/

N85475 001

N12249 002

N12249 001

N12249 003

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLOR-TRIMETON

> ADD > AP + SCHERING PLOUGH 10MG/ML

> ADD > a 100MG/ML

N08826 001

N08794 001

CHLORPHENIRAMINE MALEATE

/AB/ /BEL/MAR/ /10MG/ML/

/AB/ a BEL MAR 10MG/ML

/AB/ /STERIS/ /100MG/ML/

STERIS 100MG/ML

/AB/ /PYRIDAMAL '100/ /100MG/ML/

/AB/ a BEL MAR 100MG/ML

a BEL MAR 100MG/ML

/N88821/001/

N80821 001

/N86095/001/

N86095 001

/N83733/001/

N83733 001

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

/AA/ /NEWTRON/ /4MG/

a NEWTRON 4MG

/a/ /PHARMALAT/ /4MG/

a PHARMERAL 4MG

/N86519/001/

N86519 001

/N83753/001/

N83753 001

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HCL

a PENNEX PHARMS 30MG/ML

a 100MG/ML

/AA/ /PHARM/BASICS/ /30MG/ML/

/AA/ /100MG/ML/

N87032 001

JUL 08, 1982

N87053 001

/N87832/001/

/JUL/08./1982/

/N87853/001/

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

/AB/ /LYPHOMED/ /25MG/ML/

a LYPHOMED 25MG/ML

/N84911/001/

N84911 001

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

> DLT > /AB/ /CHELSEA/ /100MG/

> DLT > a 100MG

> ADD > a CHELSEA 100MG

> ADD >

/N86865/001/

/SEP/24./1984/

N86865 001

SEP 24, 1984

CHLORTHALIDONE

TABLET; ORAL			
<u>CHLORTHALIDONE</u>			
/AB/	/ABBOTT/	/50MG/	/N87384/001/
	Q ABBOTT	50MG	N87384 001
> DLT >	/AB/	/50MG/	/N87082/001/
> ADD >	Q CHELSEA	50MG	N87082 001
	/AB/	/50MG/	/N89052/001/
	/PHARM BASICS/		/JUN/01,1987/
	Q PHARM BASICS	50MG	N89052 001
			JUN 01, 1987

CHLORTHALIDONE; METOPROLOL TARTRATE

/CAPSULE; ORAL/			
/LOPRESSIDONE/			
/CIBA/	/25MG;200MG/	/N19451/001/	
		/DEC/31,1987/	
	/25MG;100MG/	/N19451/001/	
		/DEC/31,1987/	
Q CIBA	25MG;100MG	N19451 001	
		DEC 31, 1987	
Q	25MG;200MG	N19451 002	
		DEC 31, 1987	

CHLORZOXAZONE

TABLET; ORAL			
<u>CHLORZOXAZONE</u>			
> ADD >	AA	OHM	250MG
> ADD >			
> ADD >	AA		500MG
> ADD >			
/AA/	/PIONEER PHARMS/	/250MG/	/N89592/001/
			/JAN/06,1989/
/AA/		/500MG/	/N89948/001/
			/JAN/06,1989/
Q PIONEER PHARMS	250MG	N89592 001	
		JAN 06, 1989	
Q	500MG	N89948 001	
		JAN 06, 1989	

CHYMOPAPAININJECTABLE; INJECTION
CHYMODIACTIN

/BOOTS/	/10,000/UNITS/VIAL/	/N18663/001/
Q BOOTS	10,000 UNITS/VIAL	/NOV/10,1982/
		N18663 001
		NOV 10, 1982

CHYMOTRYPSINPOWDER FOR RECONSTITUTION; OPHTHALMIC
CATARASE

+ IOLAB	300 UNITS/VIAL	N16938 001
	/150/UNITS/VIAL/	/N18121/001/
Q	150 UNITS/VIAL	N18121 001
	/300/UNITS/VIAL/	/N16938/001/

CISAPRIDE MONOHYDRATETABLET; ORAL
PROPULSID

+ JANSSEN	EQ 20MG BASE	N20210 002
		DEC 23, 1993
	EQ 10MG BASE	N20210 001
		JUL 29, 1993
> DLT >	/2/	/N20210/002/
> DLT >		/JUL/29,1993/

CLADRIBINEINJECTABLE; INJECTION
LEUSTATIN

+ JOHNSON RW	1MG/ML	N20229 001
		FEB 26, 1993

CLARITHROMYCINGRANULE, FOR RECONSTITUTION; ORAL
BIAXIN

+ ABBOTT	250MG/5ML	N50698 002
		DEC 23, 1993
	125MG/5ML	N50698 001
		DEC 23, 1993

CLARITHROMYCIN

TABLET; ORAL
BIAXIN
ABBOTT 250MG N50697 001
> ADD > DEC 23, 1993
500MG N50697 002
> ADD > DEC 23, 1993

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE
AA BARRE EQ 0.5MG BASE/5ML N74075 001
OCT 31, 1993

TABLET; ORAL
CLEMASTINE FUMARATE
AB GENEVA 2.68MG N73459 001
OCT 31, 1993

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN
AB + UPJOHN EQ 75MG BASE N50162 001
/AB//+/ EQ 75MG BASE/ N61809/001/
AB + EQ 150MG BASE N50162 002
/AB//+/ EQ 150MG BASE/ N61809/002/
@ EQ 75MG BASE N61809 001
@ EQ 150MG BASE N61809 002

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLEOCIN PHOSPHATE
AP + UPJOHN EQ 150MG BASE/ML N50441 001
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
+ UPJOHN EQ 18MG BASE/ML N50639 003
APR 10, 1991
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
/AP/ /LYPHOMED/ EQ 12MG BASE/ML/ N50636/001/
/DEC/22./1989/
@ LYPHOMED EQ 12MG BASE/ML N50636 001
DEC 22, 1989

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE
> DLT > /AB/ /CHELSEA/ /500MG/ N71603/001/
> DLT > /SEP/18./1987/
> ADD > @ CHELSEA 500MG N71603 001
> ADD > SEP 18, 1987

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL
/AB/ /BIOCRAFT/ /0.1MG/ N70747/001/
/AB/ /0.2MG/ N70702/001/
/AB/ /0.3MG/ N70659/001/
@ BIOCRAFT 0.1MG N70747 001
@ 0.2MG JUL 08, 1986
@ 0.3MG N70702 001
JUL 08, 1986
@ 0.3MG N70659 001
JUL 08, 1986
/AB/ /PAR/ /0.1MG/ N70461/001/
/AB/ /0.2MG/ N70460/001/
/AB/ /0.3MG/ N70459/001/
@ PAR 0.1MG N70461 001
@ 0.2MG JUL 08, 1986
@ 0.3MG N70460 001
JUL 08, 1986
@ 0.3MG N70459 001
JUL 08, 1986

CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE
AB TARO 1% N72640 001
AUG 31, 1993
LOTIRMEN
/BT//+/SCHERING/ 1% N17619/001/
AB + SCHERING PLOUGH 1% N17619 001

CLOTRIMAZOLE

/CREAM;/VAGINAL/		
/BT/ /SYNE-LOTIMIN/	/12/	/N18852/001/
/BT/ /SCHERING/		
/BT/ /MYCELEX-G/	/12/	/N18838/001/
/BT/ /MILES/		

/TABLET;/VAGINAL/		
/BT/ /SYNE-LOTIMIN/	/100MG/	/N17717/001/
/BT/ /SCHERING/		
/BT/ /MYCELEX-G/	/100MG/	/N18182/001/
/BT/ /MILES/		

CLOXACILLIN SODIUM

CAPSULE; ORAL

TEGOPEN

AB + APOTHECON	EQ 250MG BASE	N61452 001
AB +	EQ 500MG BASE	N61452 002
/AB//+/ /Bristol/	/EQ 250MG BASE/	/N61452/001/
/AB//+/	/EQ 500MG BASE/	/N61452/002/

POWDER FOR RECONSTITUTION; ORAL

CLOXACILLIN SODIUM

> DLT > /AA/ /NOVOPHARM/	/EQ 125MG BASE/5ML/	/N62978/001/
> DLT >		/APR/06/1989/
> ADD >	@ NOVOPHARM	N62978 001
> ADD >		APR 06, 1989

TEGOPEN

AA APOTHECON	EQ 125MG BASE/5ML	N61453 001
/AA/ /Bristol/	/EQ 125MG BASE/5ML/	/N61453/001/

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC W/ CODEINE

@ PENNEX PHARMS	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88896 001
		JAN 04, 1985
/AA/ /PHARM/BASICS/	/10MG/5ML;5MG/5ML;/	/N88896/001/
	/6.25MG/5ML/	/JAN/04/1985/

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ CODEINE

/AA/ /PENNEX/PHARMS/	/10MG/5ML;6.25MG/5ML/	/N88875/001/
		/DEC/17/1984/
@ PENNEX PHARMS	10MG/5ML;6.25MG/5ML	N88875 001
		DEC 17, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA PENNEX PHARMS	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88833 001
		NOV 16, 1984
/AA/ /PHARM/BASICS/	/10MG/5ML;30MG/5ML;/	/N88833/001/
	/1.25MG/5ML/	/NOV/16/1984/

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

> DLT > /AA/ /COLESTID/		
> DLT >	/5GM/PACKET/	/N17563/001/
> DLT >	/5GM/SCOOPFUL/	/N17563/002/
> ADD >	FLAVORED COLESTID	
> ADD >	+ UPJOHN	N17563 001
> ADD >	UPJOHN	N17563 002

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

> DLT > /AP/ /PARKE/DAVIS/	/25 UNITS/VIAL/	/N08317/002/
> ADD >	@ PARKE DAVIS	N08317 002

ACTHAR

/AP/ /ARMOUR/	/40 UNITS/VIAL/	/N07504/003/
> DLT > /AP/ /RHONE/POULENC/RORER/	/25 UNITS/VIAL/	/N07504/002/
AP	40 UNITS/VIAL	N07504 003
> ADD >	25 UNITS/VIAL	N07504 002

H.P. ACTHAR GEL

/BC/ /ARMOUR/	/40 UNITS/ML/	/N08372/006/
/BC//+/	/80 UNITS/ML/	/N08372/008/
BC	40 UNITS/ML	N08372 006
BC +	80 UNITS/ML	N08372 008

CLOTRIMAZOLE

/CREAM;/VAGINAL/
/SYNE-LOTIMIN/
/BT/ /SCHERING/ /12/ /N18852/001/
/BT/ /MYCELEX-G/ /12/ /N18838/001/
/BT/ /MILES/

/TABLET;/VAGINAL/
/SYNE-LOTIMIN/
/BT/ /SCHERING/ /100MG/ /N17717/001/
/BT/ /MYCELEX-G/ /100MG/ /N18182/001/
/BT/ /MILES/

CLOXACILLIN SODIUM

CAPSULE; ORAL

TEGOPEN

AB + APOTHECON EQ 250MG BASE N61452 001
AB + EQ 500MG BASE N61452 002
/AB//+/BRISTOL/ /EQ 250MG BASE/ /N61452/001/
/AB//+/ /EQ 500MG BASE/ /N61452/002/

POWDER FOR RECONSTITUTION; ORAL

CLOXACILLIN SODIUM

> DLT > /AA/ /NOVOPHARM/ /EQ 125MG BASE/5ML/ /N62978/001/
> DLT > /APR/06;/1983/ /N62978 001
> ADD > @ NOVOPHARM EQ 125MG BASE/5ML APR 06, 1989
> ADD >

TEGOPEN

AA APOTHECON EQ 125MG BASE/5ML N61453 001
/AA/ /BRISTOL/ /EQ 125MG BASE/5ML/ /N61453/001/

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC W/ CODEINE

@ PENNEX PHARMS 10MG/5ML;5MG/5ML; N88896 001
6.25MG/5ML JAN 04, 1985
/AA/ /PHARM/BASICS/ /10MG/5ML;5MG/5ML;/ /N88896/001/
/6.25MG/5ML/ /JAN/04;/1985/

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ CODEINE

/AA/ /PENNEX/PHARMS/ /10MG/5ML;6.25MG/5ML/ /N88875/001/
@ PENNEX PHARMS 10MG/5ML;6.25MG/5ML N88875 001
DEC 17, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA PENNEX PHARMS 10MG/5ML;30MG/5ML; N88833 001
1.25MG/5ML NOV 16, 1984
/AA/ /PHARM/BASICS/ /10MG/5ML;30MG/5ML;/ /N88833/001/
/1.25MG/5ML/ /NOV/16;/1984/

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

> DLT > /COLESTID/ /5GM/PACKET/ /N17563/001/
> DLT > /+/UPJOHN/ /5GM/SCOOPFUL/ /N17563/002/
> ADD > FLAVORED COLESTID
> ADD > + UPJOHN 5GM/PACKET N17563 001
> ADD > UPJOHN 5GM/SCOOPFUL N17563 002

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

> DLT > /AP/ /PARKE/DAVIS/ /25 UNITS/VIAL/ /N08317/002/
> ADD > @ PARKE DAVIS 25 UNITS/VIAL
/AP/ /ARMOUR/ /40 UNITS/VIAL/ /N07504/003/
> DLT > /AP/ /RHONE/POULENC/RORER/ /25 UNITS/VIAL/ /N07504/002/
/AP/ /RHONE POULENC RORER 40 UNITS/VIAL N07504 003
> ADD > 25 UNITS/VIAL N07504 002

H.P. ACTHAR GEL

/BC/ /ARMOUR/ /40 UNITS/ML/ /N08372/006/
/BC//+/ /80 UNITS/ML/ /N08372/008/
BC RHONE POULENC RORER 40 UNITS/ML N08372 006
BC + 80 UNITS/ML N08372 008

CORTICOTROPIN

INJECTABLE; INJECTION			
/PURIFIED CORTROPHIN/BEL/			
/BC/	/ORGANON/	/40 UNITS/ML/	/N08975/001/
/BC/		/80 UNITS/ML/	/N08975/002/
	3 ORGANON	40 UNITS/ML	N08975 001
	3	80 UNITS/ML	N08975 002

CORTICOTROPIN-ZINC HYDROXIDE

/INJECTABLE; INJECTION/			
/CORTROPHIN-ZINC/			
/*/	/ORGANON/	/40 UNITS/ML/	/N09854/001/
	3 ORGANON	40 UNITS/ML	N09854 001

CORTISONE ACETATE

TABLET; ORAL			
CORTISONE ACETATE			
/BP/	/HEATHER/	/25MG/	/N85736/001/
	3 HEATHER	25MG	N85736 001

CROMOLYN SODIUM

/SOLUTION; NASAL/			
/NASALCROM/			
	/FISONS/	/42/	/N18306/001/
			/MAR 18, 1983/

SPRAY, METERED; NASAL			
NASALCROM			
+	FISONS	5.2MG/INH	N18306 001
			MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION			
<u>CYANOCOBALAMIN</u>			
/AP/	/DELL/	/0.03MG/ML/	/N00689/001/
	DELL	0.03MG/ML	N00689 001
/AP/	/FUJISAWA/	/1MG/ML/	/N83075/001/
	3 FUJISAWA	1MG/ML	N83075 001

CYANOCOBALAMIN

INJECTABLE; INJECTION			
/RUBIVITE/			
/AP/	/BEL/MAR/	/0.03MG/ML/	/N10791/004/
/AP/		/0.1MG/ML/	/N10791/002/
/AP/		/1MG/ML/	/N10791/003/
		/0.05MG/ML/	/N10791/001/
		/0.12MG/ML/	/N10791/005/
	3 BEL MAR	0.03MG/ML	N10791 004
	3	0.05MG/ML	N10791 001
	3	0.1MG/ML	N10791 002
	3	0.12MG/ML	N10791 005
	3	1MG/ML	N10791 003

CYCLACILLIN

/POWDER FOR RECONSTITUTION; ORAL/			
/CYCLAPEN-W/			
/*/	/WYETH AYERST/	/500MG/5ML/	/N50508/003/
		/125MG/5ML/	/N50508/001/
		/250MG/5ML/	/N50508/002/
	3 WYETH AYERST	125MG/5ML	N50508 001
	3	250MG/5ML	N50508 002
	3	500MG/5ML	N50508 003

CYCLIZINE LACTATE

/INJECTABLE; INJECTION/			
/MAREZINE/			
	/BURROUGHS WELLCOME/	/50MG/ML/	/N09495/001/
	3 BURROUGHS WELLCOME	50MG/ML	N09495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL			
<u>CYCLOBENZAPRINE HCL</u>			
AB	INVAMED	10MG	N73683 001
			FEB 26, 1993

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

<u>NEOSAR</u>		
AP	ADRIA	<u>100MG/VIAL</u>
		N40015 001
		APR 29, 1993
AP		<u>200MG/VIAL</u>
		N40015 002
		APR 29, 1993
AP		<u>500MG/VIAL</u>
		N40015 003
		APR 29, 1993
AP		<u>1GM/VIAL</u>
		N40015 004
		APR 29, 1993
AP		<u>2GM/VIAL</u>
		N40015 005
		APR 29, 1993

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

<u>CYPROHEPTADINE HCL</u>		
a PENNEX PHARMS		2MG/5ML
		N87001 001
		NOV 04, 1982
/AA/	/PHARM/BASICS/	<u>/2MG/5ML/</u>
		/N87001/001/
		/NOV/04./1982/

TABLET; ORAL

<u>CYPROHEPTADINE HCL</u>		
/AA/	/MYLAN/	<u>/4MG/</u>
	a MYLAN	4MG
		/N86678/001/
		N86678 001

DESIPRAMINE HYDROCHLORIDE/CAPSULE;/ORAL//PERTOFRANE//+ / RHONE/POULENC/RORER/50MG//25MG/

a RHONE POULENC RORER 25MG

a 50MG

/N13621/002//N13621/001/

N13621 001

N13621 002

DESLANOSIDE/INJECTABLE;/INJECTION//CEDILANID-D//SANDOZ/a SANDOZ /0.2MG/ML/

0.2MG/ML

/N09282/002/

N09282 002

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

DDAVP

RHONE POULENC RORER 0.01MG/INH

N17922 002

FEB 06, 1989

DESOXYCORTICOSTERONE PIVALATE/INJECTABLE;/INJECTION//PERCORTEN//CIBA/

a CIBA

/25MG/ML/

25MG/ML

/N08822/001/

N08822 001

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONEAA BARRE 0.5MG/5ML

N88997 001

OCT 10, 1986

/AA/ /NASKA/ /0.5MG/5ML//N88997/001//OCT/10./1986/DEXAMETHASONEAA PENNEX PHARMS 0.5MG/5ML

N88254 001

JUL 27, 1983

/AA/ /PHARM/BASICS/ /0.5MG/5ML//N88254/001//JUL/27./1983/

SOLUTION; ORAL

DEXAMETHASONE

/a/ROXANE//0.5MG/5ML//N88248/001//SEP/01./1983/

ROXANE

0.5MG/5ML

N88248 001

SEP 01, 1983

TABLET; ORAL

DECADRONAB MSD 0.5MG

N11664 001

AB + 0.75MG

N11664 002

AB 1.5MG

N11664 003

AB 4MG

N11664 005

/BP/ /0.5MG//N11664/001//BP/+ / /0.75MG//N11664/002//BP/ /1.5MG//N11664/003//BP/ /4MG//N11664/005/

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

AB	ROXANE	0.5MG	N84611 001
AB		0.75MG	N84613 001
AB		1.5MG	N84610 001
AB		4MG	N84612 001
/BP/		/0.5MG/	/N84611/001/
/BP/		/0.75MG/	/N84613/001/
/BP/		/1.5MG/	/N84610/001/
/BP/		/4MG/	/N84612/001/

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXASPORIN/

/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/GM;/	/N62411/001/
		/10,000 UNITS/GM/	/MAY/16,1983/
	3 PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;	N62411 001
		10,000 UNITS/GM	MAY 16, 1983

SUSPENSION/DROPS; OPHTHALMIC

DEXASPORIN/

/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/ML;/	/N62428/001/
		/10,000 UNITS/ML/	/MAY/18,1983/
	3 PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;	N62428 001
		10,000 UNITS/ML	MAY 18, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

/AP/	/BEL/MAR/	/EQ 4MG PHOSPHATE/ML/	/N84752/001/
	3 BEL MAR	EQ 4MG PHOSPHATE/ML	N84752 001
/AP/	/BRISTOL/	/EQ 4MG PHOSPHATE/ML/	/N87065/001/
	3 FUJISAWA	EQ 4MG PHOSPHATE/ML	N87065 001
/AP/	/WYETH/AYERST/	/EQ 4MG PHOSPHATE/ML/	/N85641/001/
	3 WYETH AYERST	EQ 4MG PHOSPHATE/ML	N85641 001
	HEXADROL		
	/ORGANON/	/EQ/20MG/PHOSPHATE/ML/	/N14694/004/
	3 ORGANON	EQ 20MG PHOSPHATE/ML	N14694 004

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

MYLARAMINE

AA	PENNEX PHARMS	2MG/5ML	N88251 001
			MAR 23, 1984
/AA/	/PHARMA/BASICS/	/2MG/5ML/	/N88251/001/
			/MAR/23,1984/

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXAMPEN/

/AA/	/LEMMON/	/5MG/	/N83735/001/
/AA/		/10MG/	/N83735/002/
	3 LEMMON	5MG	N83735 001
	3	10MG	N83735 002
/AA/	/FERNDAL/	/5MG/	/N84001/001/
	3 FERNDAL	5MG	N84001 001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ DEXTROMETHORPHAN/

/AA/	/PHARMA/BASICS/	/15MG/5ML;6.25MG/5ML/	/N88864/001/
			/JAN/04,1985/
	3 PENNEX PHARMS	15MG/5ML;6.25MG/5ML	N88864 001
			JAN 04, 1985

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50% IN PLASTIC CONTAINER

/AP/	/ABBOTT/	/500MG/ML/	/N19445/001/
			/JUN/03,1986/
	3 ABBOTT	500MG/ML	N19445 001
			JUN 03, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	5GM/100ML;31MG/100ML;130MG/100ML;
	26MG/100ML;320MG/100ML
	N19873 001
	JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM
ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW 5GM/100ML;30MG/100ML;97MG/100ML;
220MG/100ML;140MG/100ML N19844 001
JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM
ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER
AP MCGAW 5GM/100ML;30MG/100ML;37MG/100ML;
370MG/100ML;530MG/100ML;
500MG/100ML N19843 001
AUG 09, 1993

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC;
SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW 5GM/100ML;150MG/100ML;130MG/100ML;
280MG/100ML;91MG/100ML N19870 001
JUN 10, 1993

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

/HYPAQUE-M, 75%/
/STERLING/ /50%;25%/
a STERLING 50%;25% N10220 003
/HYPAQUE-M, 30%/
/STERLING/ /60%;30%/
a STERLING 60%;30% N10220 002

DIATRIZOATE SODIUM

/SOLUTION;URETERAL/
/HYPAQUE/SODIUM, 20%/
/STERLING/ /20%/
a STERLING 20% N09561 002

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

AP MARSAM 5MG/ML
AP 5MG/ML
AP 5MG/ML

VALIUM

/AP/ /ROCHE/ /5MG/ML/
AP + ROCHE 5MG/ML

INJECTABLE; INTRAVENOUS

DIZAC
+ KABI 5MG/ML

TABLET; ORAL

DIAZEPAM

a FERNDAL 2MG
a 5MG
a 10MG
/AB/ /PHARM/BASICS/ /2MG/
/AB/ /5MG/
/AB/ /10MG/
/AB/ /ZENITH/ /2MG/
/AB/ /5MG/
a ZENITH 2MG
a 5MG

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM
+ BAKER NORTON 50MG
/+/MEDCL/MKTG/ /50MG/

N72370 001
JAN 29, 1993
N72371 001
JAN 29, 1993
N72397 001
JAN 29, 1993

/N16087/001/
N16087 001

N19287 001
JUN 18, 1993

N70903 001
APR 01, 1987
N70904 001
APR 01, 1987
N70905 001
APR 01, 1987
/N70903/001/
/APR/01/1987/
/N70904/001/
/APR/01/1987/
/N70905/001/
/APR/01/1987/
/N70360/001/
/SEP/04/1985/
/N70361/001/
/SEP/04/1985/
N70360 001
SEP 04, 1985
N70361 001
SEP 04, 1985

N17425 001
/N17425/001/

DIAZOXIDE

INJECTABLE; INJECTION

/AB/	/DIAZOXIDE/ QUAD	/15MG/ML/	/N71908/001/ JAN/26./1988/ N71908 001 JAN 26, 1988
	QUAD	15MG/ML	

HYPERSTAT

/AB/	/SCHERING/ SCHERING	/15MG/ML/	/N16996/001/ N16996 001
------	------------------------	-----------	----------------------------

SUSPENSION; ORAL

	PROGLYCEM		
	+ BAKER NORTON	50MG/ML	N17453 001
/+//	/MEPCIL/MKTG/	/50MG/ML/	/N17453/001/

DICLOFENAC POTASSIUM

TABLET; ORAL

	CATAFLAM		
	+ GEIGY	50MG	N20142 002
		25MG	NOV 24, 1993
			N20142 001
			NOV 24, 1993

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

	VOLTAREN		
/CIBA/		/0.1%/	/N20037/001/ MAR/28./1991/ N20037 001 MAR 28, 1991
	CIBA VISION	0.1%	

DICLOXACILLIN SODIUM

CAPSULE; ORAL

	<u>DYCLL</u>		
/AB/	/SMITHKLINE/BEECHAM/	/EQ 250MG BASE/	/N60254/002/
/AB/		/EQ 500MG BASE/	/N60254/003/
	SMITHKLINE BEECHAM	EQ 250MG BASE	N60254 002
		EQ 500MG BASE	N60254 003
	<u>DYNAPEN</u>		
AB	APOTHECON	EQ 125MG BASE	N61454 002
AB		EQ 250MG BASE	N61454 001
/AB/	/BRISTOL/	/EQ 125MG BASE/	/N61454/002/
/AB/		/EQ 250MG BASE/	/N61454/001/

DICLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL

AB	<u>DYNAPEN</u>		
	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001
/AB/	/BRISTOL/	/EQ 62.5MG BASE/5ML/	/N61455/001/

DICUMAROL

TABLET; ORAL

	DICUMAROL		
/+//	/ABBOTT/	/50MG/	/N05545/004/
	ABBOTT	50MG	N05545 004

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	<u>DICYCLOMINE HCL</u>		
/AB/	/PIONEER/PHARMS/	/10MG/	/N89361/001/ JAN/10./1989/ N89361 001 JAN 10, 1989
	PIONEER PHARMS	10MG	

TABLET; ORAL

	<u>DICYCLOMINE HCL</u>		
/AB/	/PIONEER/PHARMS/	/20MG/	/N88585/001/ AUG/20./1986/ N88585 001 AUG 20, 1986
	PIONEER PHARMS	20MG	

DIETHYLSTILBESTROL

/INJECTABLE; INJECTION/

	/STILBESTROL/		
	/SQUIBB/	/0.2MG/ML/	/N04056/003/
		/0.5MG/ML/	/N04056/004/
		/1MG/ML/	/N04056/005/
		/5MG/ML/	/N04056/006/
	SQUIBB	0.2MG/ML	N04056 003
		0.5MG/ML	N04056 004
		1MG/ML	N04056 005
		5MG/ML	N04056 006

/SUPPOSITORY; VAGINAL/

	/STILBESTROL/		
/+//	/SQUIBB/	/0.1MG/	/N04056/001/
/+//		/0.5MG/	/N04056/002/

DIETHYLSTILBESTROL/SUPPOSITORY/VAGINAL/
/STILBESTROL/a SQUIBB 0.1MG
a 0.5MG

TABLET, DELAYED RELEASE; ORAL

STILBETIN
/BE/ /SQUIBB/ /0.1MG/
a SQUIBB 0.1MG /N04056/011/
N04056 011DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD

> ADD >	BC +	CARDERM	120MG	N20062 001
> ADD >	BC +		180MG	AUG 10, 1992
	BC +		240MG	N20062 002
				DEC 27, 1991
> DLT >	/+/		120MG	N20062 003
> DLT >	+		300MG	DEC 27, 1991
	/BC/+/	MARION/MERRELL/DOW	180MG	/N20062/001/ AUG/10/1992/
	/BC/+/		240MG	N20062 004
	/+/		300MG	DEC 27, 1991
				/N20062/002/ DEC/27/1991/
				/N20062/003/ DEC/27/1991/
				/N20062/004/ DEC/27/1991/

CARDIZEM SR

AB	+	MARION MERRELL DOW	60MG	N19471 001
AB	+		90MG	JAN 23, 1989
AB	+		120MG	N19471 002
				JAN 23, 1989
				N19471 003
				JAN 23, 1989

DILACOR XR

> ADD >	BC	RHONE POULENC RORER	120MG	N20092 001
> ADD >				MAY 29, 1992
> DLT >	/+/		120MG	/N20092/001/ MAY/29/1992/
> DLT >				

DILTIAZEM HCL

AB		PROGRAPHARM	60MG	N74079 001
AB			90MG	NOV 30, 1993
AB			120MG	N74079 002
				NOV 30, 1993
				N74079 003
				NOV 30, 1993

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

AB	<u>DILTIAZEM HCL</u>	
	APOTHECON	30MG
AB		60MG
AB		90MG
AB		120MG

N74051 001
MAR 31, 1993
N74051 002
MAR 31, 1993
N74051 003
MAR 31, 1993
N74051 004
MAR 31, 1993

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

/AA/	<u>DIPHENHYDRAMINE HCL</u>		
/AA/	/LEMMON/	/25MG/	/N85874/001/
	a LEMMON	25MG	/N85874/002/
	a	50MG	N85874 001
			N85874 002

INJECTABLE; INJECTION

/AB/	<u>DIPHENHYDRAMINE HCL</u>		
/AB/	/BEL/MAR/	/10MG/ML/	/N80822/001/
	a BEL MAR	10MG/ML	N80822 001
/AB/	/BRISTOL/	/10MG/ML/	/N87066/001/
	a FUJISAWA	10MG/ML	N87066 001

DIPHENYLPYRALINE HYDROCHLORIDE/CAPSULE/EXTENDED/RELEASE;/ORAL/
/HISPRIL/

/+/	/SMITHKLINE/BEECHAM/	/5MG/	/N11945/001/
	a SMITHKLINE BEECHAM	5MG	N11945 001

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

/AB/	<u>DISOPYRAMIDE PHOSPHATE</u>		
/AB/	/KV/	/EQ 100MG BASE/	/N71929/001/
B*	KV	EQ 100MG BASE	/AUG/19/1988/
			N71929 001
			AUG 19, 1988

DIVALPROEX SODIUM/TABLET;/DELAYED/RELEASE;/ORAL//DEPAKOTE/CP/
/ABBOTT//EQ/250MG/BASE//N19794/001//AP/DOPAMINE HYDROCHLORIDEINJECTABLE; INJECTIONDOPAMINE HCL/ASTRA//40MG/ML//N70087/001//OCT/23,/1985//EQ/500MG/BASE//N19794/002//AP//80MG/ML//N70089/001//OCT/23,/1985/

a ABBOTT

EQ 250MG BASE

N19794 001

/AP//80MG/ML//N70090/001//OCT/23,/1985/

a

EQ 500MG BASE

N19794 002

/AP//160MG/ML//N70093/001//OCT/23,/1985/

JUL 11, 1990

/AP//160MG/ML//N70094/001//OCT/23,/1985/DOBUTAMINE HYDROCHLORIDEINJECTABLE; INJECTIONDOBUTAMINE HCL

AP ABBOTT

EQ 12.5MG BASE/ML

N74086 001

a ASTRA

40MG/ML

N70087 001

OCT 23, 1985

AP GENSLA

EQ 12.5MG BASE/ML

N74206 001

a

80MG/ML

N70089 001

OCT 23, 1985

AP STERIS

EQ 12.5MG BASE/ML

N74114 001

a

80MG/ML

N70090 001

OCT 23, 1985

OCT 19, 1993

a

160MG/ML

N70093 001

OCT 23, 1985

NOV 30, 1993

a

160MG/ML

N70094 001

OCT 23, 1985

DOBUTAMINE HCL IN DEXTROSE 5%

AP + ABBOTT

EQ 50MG BASE/100ML

N20269 001

/AP/ /BRISTOL//40MG/ML//N18549/001//MAR/11,/1983/

AP +

EQ 100MG BASE/100ML

N20269 002

a FUJISAWA

40MG/ML

N18549 001

MAR 11, 1983

AP +

EQ 200MG BASE/100ML

N20269 003

/AP/ /LYPHOMED//40MG/ML//N70012/001//JUN/12,/1985/

OCT 19, 1993

a LYPHOMED

40MG/ML

N70012 001

JUN 12, 1985

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP ABBOTT

EQ 50MG BASE/100ML

N20201 003

DOXEPIN HYDROCHLORIDE

AP

EQ 100MG BASE/100ML

N20201 002

CAPSULE; ORAL

AP

EQ 200MG BASE/100ML

N20201 001

> DLT >

/ADAPIN//EQ 10MG BASE//N16987/001/

AP + BAXTER

EQ 50MG BASE/100ML

N20255 001

> DLT > /AB/

/FISONS//EQ 25MG BASE//N16987/002/

AP +

EQ 100MG BASE/100ML

N20255 003

> DLT > /AB/

/EQ 50MG BASE//N16987/003/

AP +

EQ 200MG BASE/100ML

N20255 004

> DLT > /AB/

/EQ 75MG BASE//N16987/006/

+

EQ 400MG BASE/100ML

N20255 005

> DLT > /AB/

/EQ 100MG BASE//N16987/004/

> DLT > /AB/

/EQ 150MG BASE//N16987/007/

OCT 19, 1993

> DLT >

DOXEPIN HCL

AP + LILLY

EQ 12.5MG BASE/ML

N17820 002

> ADD >

a FISONS

EQ 10MG BASE

N16987 001

> ADD >

a

EQ 25MG BASE

N16987 002

> ADD >

a

EQ 50MG BASE

N16987 003

> ADD >

a

EQ 75MG BASE

N16987 006

> ADD >

a

EQ 100MG BASE

N16987 004

> ADD >

a

EQ 150MG BASE

N16987 007

> ADD >

APR 13, 1987

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPIN HCL

AA	PENNEX PHARMS	EQ 10MG BASE/ML	N71918 001
			JUL 20, 1988
/AA/	/PHARM/BASICS/	/EQ 10MG BASE/ML/	/N71918/001/
			/JUL/20./1988/

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE MONOHYDRATE

/+/	/MEDICOPHARMA/	/EQ 100MG BASE/	/N50641/001/
			/DEC/29./1989/
+	VINTAGE	EQ 100MG BASE	N50641 001
			DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

/AB/	/PAR/	/EQ 50MG BASE/	/N62434/001/
			/OCT/19./1984/
/AB/		/EQ 100MG BASE/	/N62442/001/
			/DEC/22./1983/
	2 PAR	EQ 50MG BASE	N62434 001
			OCT 19, 1984
	2	EQ 100MG BASE	N62442 001
			DEC 22, 1983

TABLET; ORAL

DOXY-TABS

2 RACHELLE

DOXYCYCLINE HYCLATE

/AB/	/HEATHER/	/EQ 100MG BASE/	/N62462/001/
			/MAY/11./1983/
	2 HEATHER	EQ 100MG BASE	N62462 001
			MAY 11, 1983

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

/AP/	/QUAD/	/2.5MG/ML/	/N71941/001/
			/AUG/17./1988/
	2 QUAD	2.5MG/ML	N71941 001
			AUG 17, 1988

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

/AP/	/SMITH/NEPHEW/SOLOPAK/	/2.5MG/ML/	/N71754/001/
			/SEP/06./1988/
/AP/		/2.5MG/ML/	/N71755/001/
			/SEP/06./1988/
AP	SOLOPAK	2.5MG/ML	N71754 001
			SEP 06, 1988
AP		2.5MG/ML	N71755 001
			SEP 06, 1988

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

/AP/	/ASTRA/	/2.5MG/ML/	/N72028/001/
		/EQ 0.05MG BASE/ML/	/APR/13./1989/
	2 ASTRA	2.5MG/ML;	N72028 001
		EQ 0.05MG BASE/ML	APR 13, 1989

EDETATE DISODIUM

INJECTABLE; INJECTION

DISODIUM EDETATE

/AP/	/STERIS/	/150MG/ML/	/N84356/001/
	2 STERIS	150MG/ML	N84356 001

EFLORNITHINE HYDROCHLORIDE

/INJECTABLE; INJECTION/

/ORNIDYL/

/MERRELL/DOW/

2 MERRELL DOW

/200MG/ML/

200MG/ML

/N19879/002/
/NOV/28./1990/
N19879 002
NOV 28, 1990

ENCAINIDE HYDROCHLORIDE

/CAPSULE//ORAL/
/ENKAID/
/+/BRISTOL/

/50MG/

/25MG/

/35MG/

a BRISTOL

25MG

a

35MG

a

50MG

/N18981/004/

/DEC/24,/1986/

/N18981/002/

/DEC/24,/1986/

/N18981/003/

/DEC/24,/1986/

N18981 002

DEC 24, 1986

N18981 003

DEC 24, 1986

N18981 004

DEC 24, 1986

ENOXACIN

TABLET; ORAL
PENETREX

/+/PARKE/DAVIS/

/400MG/

/200MG/

+ RHONE POULENC RORER 400MG

200MG

/N19616/005/

/DEC/31,/1991/

/N19616/004/

/DEC/31,/1991/

N19616 005

DEC 31, 1991

N19616 004

DEC 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; INJECTION

LOVENOX

RHONE POULENC RORER 30MG/0.3ML

N20164 001

MAR 29, 1993

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP STERLING WINTHROP 0.01MG/ML;2%

N40057 002

FEB 26, 1993

AP 0.02MG/ML;2%

N40057 001

FEB 26, 1993

LIDOCAINE HCL W/ EPINEPHRINE

/AP/ /BEL/MAR/ 0.01MG/ML;1%

/N80757/001/

/AP/ 0.01MG/ML;2%

/N80757/001/

a BEL MAR

0.01MG/ML;1%

N80820 001

a

0.01MG/ML;2%

N80757 001

EPINEPHRINE; PROCAINE HYDROCHLORIDE

/INJECTABLE//INJECTION/

/PROCAINE/HCL/W/EPINEPHRINE/

/BEL/MAR/

/0.02MG/ML;1%/

/0.02MG/ML;2%/

a BEL MAR

0.02MG/ML;1%

a

0.02MG/ML;2%

/N80758/001/

/N80759/001/

N80758 001

N80759 001

ERGOLOID MESYLATES

TABLET; ORAL

HYDERGINE

/SANDOZ/

/0.5MG/

a SANDOZ

0.5MG

/N17993/003/

N17993 003

TABLET; SUBLINGUAL

HYDROGENATED ERGOT ALKALOIDS

/AA/ /ZENITH/

/0.5MG/

a ZENITH

0.5MG

/N87186/001/

N87186 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

/AA/ /FISONS/

/2MG/

AA

LOTUS

2MG

/N87693/001/

/FEB/24,/1983/

N87693 001

FEB 24, 1983

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

/ERYC/SPRINKLES/

/+/FAULDING/

/125MG/

a FAULDING

125MG

/N50593/001/

/JUL/22,/1985/

N50593 001

JUL 22, 1985

GEL; TOPICAL

ERYGEL

/AT/ /HERBERT/

/2%

AT

+ HERBERT

2%

/N50617/001/

/OCT/21,/1987/

N50617 001

OCT 21, 1987

ERYTHROMYCIN

AT

STIEFEL

2%

N63211 001

JAN 29, 1993

ERYTHROMYCIN

TABLET, COATED PARTICLES; ORAL

/N50611/001/
/SEP/09/1986/

N50611 002
AUG 22, 1990

AUG 22, 1990
N50611 001

SEP 09, 1986
/N50611/002/

/N50611/002/
/AUG/22/1990/

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

2 LIFE LABS

N50610 001
NOV 07, 1986

EQ 250MG BASE/5ML

N62362 001
DEC 17, 1982

SOLUTION; TOPICAL

AT ERYTHRA-DERM PADDOCK 2%

N62687 001
FEB 05, 1988

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

/AB/	/KV/	/EQ 200MG BASE/5ML/
/AB/		/EQ 400MG BASE/5ML/

2 KV	EQ 200MG BASE/5ML
2	EQ 400MG BASE/5ML

/N62047/001/
/N62047/002/

N62047 001
N62047 002

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN LACTOBIONATE

AP	GENSIA	EQ 500MG BASE/VIAL
----	--------	--------------------

AP EQ 1GM BASE/VIAL

/AP/ /LYPHOMED/ /EQ '500MG' BASE/VIAL/

/EP/ EQ'IGM'BASE/VIAL/

2 LYPHOMED EQ 500MG BASE/VIAL

EQ 1GM BASE/VIAL

N63253 001
JUL 30, 1993

N63253 002
JUL 30, 1993

/N62604/001/
/NOV/24, /1986/

/N62604/002/
/NOV/24/1986/

N62604 001
NOV 24, 1986

N62604 002
NOV 24, 1986

SWAB: TOPICAL

AT C-SOLVE-2 2%

N62751 001
JUL 30, 1993

ESMOLOL HYDROCHLORIDEINJECTABLE; INJECTION
BREVIBLOC

+	ANAQUEST	10MG/ML
+		250MG/ML
	/DUPONT/	/10MG/ML/
		/250MG/ML/

N19386 001
AUG 15, 1988
N19386 002
DEC 31, 1986
/N19386/001/
/AUG/15,/1988/
/N19386/002/
/DEC/31,/1986/

ESTRADIOLTABLET; ORAL
ESTRACE

BRISTOL MYERS SQUIBB 0.5MG

N81295 001
JUN 30, 1993

ESTROGENS, CONJUGATEDCREAM; TOPICAL, VAGINAL
PREMARIN

+	AYERST	0.625MG/GM
/+//	WYETH/AYERST/	/0.625MG/GM/

N20216 001
/N83273/001/

TABLET; ORAL
CONJUGATED ESTROGENS

/2/ZENITH/	/0.3MG/
/2/	/0.625MG/
/2/	/1.25MG/
/2/	/2.5MG/

/N88569/001/
/NOV/29,/1984/
/N83373/001/
/N83601/001/
/N83602/001/

PREMARIN	
+	WYETH AYERST
/+//	

1.25MG
/2.5MG/
/1.25MG/
2.5MG

N04782 001
/N04782/002/
/N04782/001/
N04782 002

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

AB	WATSON LABS	0.75MG
AB		1.5MG
AB		3MG
AB		6MG

OGEN 1.25

/AB//+//	ABBOTT/	/1.5MG/
AB	ABBOTT	1.5MG

OGEN 2.5

AB	+ ABBOTT	3MG
/+//		/3MG/

OGEN 5

AB	ABBOTT	6MG
----	--------	-----

N81213 001
SEP 23, 1993
N81214 001
SEP 23, 1993
N81215 001
SEP 23, 1993
N81216 001
SEP 23, 1993

/N83220/002/
N83220 002

N83220 003
/N83220/003/

N83220 004

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

/TABLET;/ORAL-20/	
/NORLESTRIN/FE/1.50/	
/+//	PARKE/DAVIS/

a PARKE DAVIS	/0.05MG;75MG;1MG/
	0.05MG;75MG;1MG

/N16766/001/
N16766 001

/NORLESTRIN/FE/2.5/50/	
/+//	PARKE/DAVIS/
a PARKE DAVIS	

/0.05MG;75MG;2.5MG/
0.05MG;75MG;2.5MG

/N16854/001/
N16854 001

ETHINYL ESTRADIOL; FLUOXYMESTERONE

/TABLET;/ORAL/	
/HALODRIN/	
/+//	UPJOHN/

a UPJOHN	/0.02MG;1MG/
	0.02MG;1MG

/N11267/001/
N11267 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

LEVORA 0.15/30-21

>_ADD>	AB	SYNTEX	0.03MG;0.15MG
>_ADD>			
>_ADD>			

N73592 001
DEC 13, 1993

NORDETTE-21

>_ADD>	AB	+ WYETH AYERST	0.03MG;0.15MG
>_ADD>			

N18668 001
MAY 10, 1982

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28
 > ADD > LEVORA 0.15/30-28
 > ADD > AB SYNTEX 0.03MG;0.15MG N73594 001
 > ADD > DEC 13, 1993
 > ADD > NORDETTE-28
 > ADD > AB WYETH AYERST 0.03MG;0.15MG N18782 001
 > ADD > JUL 21, 1982

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
 AB NORETHIN 1/35E-21 0.035MG;1MG N71480 001
 APR 12, 1988
 /AB/ /SCHIAPPARELLI/SEARLE/0.035MG;1MG/ N71480/001/
 /APR/12/1988/

TABLET; ORAL-28
 AB NORETHIN 1/35E-28 0.035MG;1MG N71481 001
 APR 12, 1988
 /AB/ /SCHIAPPARELLI/SEARLE/0.035MG;1MG/ N71481/001/
 /APR/12/1988/

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

/TABLET;/ORAL-21/
 /NORLESTRIN/21/1/50/
 /+/PARKE/DAVIS/ 0.05MG;1MG/ N16749/001/
 @ PARKE DAVIS 0.05MG;1MG N16749 001
 /NORLESTRIN/21/2.5/50/
 /+/PARKE/DAVIS/ 0.05MG;2.5MG/ N16852/001/
 @ PARKE DAVIS 0.05MG;2.5MG N16852 001

ETHOSUXIMIDE

SYRUP; ORAL
 AA ETHOSUXIMIDE 250MG/5ML N81306 001
 COPLEY JUL 30, 1993
 AA ZARONTIN 250MG/5ML N80258 001
 PARKE DAVIS

ETHYNODIOL DIACETATE; MESTRANOL

/TABLET;/ORAL-21/
 /OVULEN-21/
 /+/SEARLE/ 1MG;0.1MG/ N16029/003/
 @ SEARLE 1MG;0.1MG N16029 003

/TABLET;/ORAL-28/
 /OVULEN-28/
 /SEARLE/ 1MG;0.1MG/ N16705/001/
 @ SEARLE 1MG;0.1MG N16705 001

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
 DIDRONEL
 + MGI 50MG/ML N19545 001
 APR 20, 1987
 /P/AND/5/ 50MG/ML/ N19545/001/
 /APR/20/1987/

FELBAMATE

SUSPENSION; ORAL
 FELBATOL
 + WALLACE 600MG/5ML N20189 003
 JUL 29, 1993

TABLET; ORAL
 FELBATOL
 + WALLACE 600MG N20189 002
 JUL 29, 1993
 400MG N20189 001
 JUL 29, 1993

> ADD > FENOFIBRATE

> ADD > CAPSULE; ORAL
 > ADD > LIPIDIL
 > ADD > + FOURNIER 100MG N19304 001
 > ADD > DEC 31, 1993

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL

FENTANYL

+ ANESTA

EQ 0.4MG BASE

N20195 003

OCT 04, 1993

EQ 0.2MG BASE

N20195 001

OCT 04, 1993

EQ 0.3MG BASE

N20195 002

OCT 04, 1993

FIBRINOGEN, I-125

> DLT > /INJECTABLE; INJECTION/
 > DLT > /RADIOISOTOPE-LABELED/(125/I)/FIBRINOGEN/(HUMAN)/SENSOR/
 > DLT > /ABBOTT/ /140/UCI/ML/ /N17787/001/
 > ADD > @ ABBOTT 140 UCI/ML N17787 001

FLUCONAZOLE

> ADD > POWDER FOR RECONSTITUTION; ORAL
 > ADD > DIFLUCAN
 > ADD > + PFIZER 200MG/5ML
 > ADD > N20090 002
 > ADD > DEC 23, 1993
 > ADD > 50MG/5ML
 > ADD > N20090 001
 > ADD > DEC 23, 1993

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

/At/ /PHARMADERM/ /0.01%/

/At/ /0.025%/

@ PHARMADERM 0.01%

@ 0.025%

/At/ /PHARMAFAIR/ /0.01%/

/At/ /0.025%/

@ PHARMAFAIR 0.01%

@ 0.025%

/N88047/001/

/DEC/16,/1982/

/N88045/001/

/DEC/16,/1982/

N88047 001

DEC 16, 1982

N88045 001

DEC 16, 1982

/N88499/001/

/AUG/02,/1984/

/N88506/001/

/AUG/02,/1984/

N88499 001

AUG 02, 1984

N88506 001

AUG 02, 1984

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

/At/ /PHARMADERM/ /0.025%/

@ PHARMADERM 0.025%

/At/ /PHARMAFAIR/ /0.025%/

@ PHARMAFAIR 0.025%

/N88046/001/

/DEC/16,/1982/

N88046 001

DEC 16, 1982

/N88507/001/

/FEB/27,/1984/

N88507 001

FEB 27, 1984

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

> ADD > AT BAUSCH AND LOMB 0.01%

> ADD > @ PENNEX PHARMS 0.01%

/At/ /PHARM/BASICS/ /0.01%/

N40059 001

DEC 20, 1993

N88312 001

JAN 27, 1984

/N88312/001/

/JAN/27,/1984/

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

> ADD > + HAMILTON PHARMA CA 0.025%;EQ 3.5MG BASE/GM N60700 001
 > DLT > /SYNTEX/ /0.025%;EQ 3.5MG BASE/GM/ /N60700/001/

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

/At/ /MARCHAR/ /50MG/ML/

@ MARCHAR 50MG/ML

/N87791/001/

/JAN/18,/1983/

N87791 001

JAN 18, 1983

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

PROZAC

LILLY

EQ 10MG BASE

N18936 006

DEC 23, 1992

FLUOXYMESTERONE

TABLET; ORAL
~~ANDRODIP-F/~~
 /BP/ /ICN/ 10MG/ N87196/001/
 @ ICN 10MG N87196 001

FLUOXYMESTERONE
 /BP/ /ICN/ 10MG/ N88221/001/
 @ ICN 10MG N88221 001
 MAY 05, 1983

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL
~~PROLIXIN~~
 AB APOTHECON 1MG N11751 004
 AB 2.5MG N11751 001
 AB 5MG N11751 003
 AB 10MG N11751 002
 AB + /SQUIBB/ 1MG /N11751/004/
 /AB/ 2.5MG /N11751/001/
 /AB/ 5MG /N11751/003/
 /AB/ 10MG /N11751/002/

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
~~PROLIXIN DECANOATE~~
 AO + APOTHECON 25MG/ML N16727 001
 /AO/ /SQUIBB/ 25MG/ML /N16727/001/

/TABLET;/EXTENDED/RELEASE;/ORAL/
 /PERMITIL/
 /+//SCHERING/ 1MG/ N12419/004/
 @ SCHERING 1MG N12419 004

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION
 PROLIXIN ENANTHATE
 + APOTHECON 25MG/ML N16110 001
 /SQUIBB/ 25MG/ML /N16110/001/

> ADD > FLUVASTATIN SODIUM
 > ADD > CAPSULE; ORAL
 > ADD > LESCOL
 > ADD > + SANDOZ EQ 40MG BASE N20261 002
 > ADD > EQ 20MG BASE DEC 31, 1993
 > ADD > N20261 001
 > ADD > DEC 31, 1993

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
~~PROLIXIN~~
 AA APOTHECON 5MG/ML N70533 001
 /AA/ /SQUIBB/ 5MG/ML /N70533/001/
 NOV 07, 1985
 /NOV/07/1985/

> ADD > AP FOLIC ACID 5MG/ML N81066 001
 > ADD > LOCH DEC 29, 1993

ELIXIR; ORAL
~~FLUPHENAZINE HCL~~
 AA COPLEY 2.5MG/5ML N81310 001
 APR 29, 1993

~~PROLIXIN~~
 AA APOTHECON 2.5MG/5ML N12145 003
 /SQUIBB/ 2.5MG/5ML /N12145/003/

TABLET; ORAL
~~FOLIC ACID~~
 /@/BOOTS/ 1MG /N84158/001/
 @ PHARMERAL 1MG N84158 001
 /AA/ /PIONEER/PHARMS/ 1MG /N88949/001/
 @ PIONEER PHARMS 1MG /SEP/13/1985/
 N88949 001
 SEP 13, 1985

INJECTABLE; INJECTION
~~PROLIXIN~~
 AP + APOTHECON 2.5MG/ML N11751 005
 /AP/ /SQUIBB/ 2.5MG/ML /N11751/005/

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

/AP/ /ASTRA/ /10MG/ML/

a ASTRA 10MG/ML

> DLT > /AP/ /WYETH/AYERST/ /10MG/ML/

> DLT >

> ADD > a WYETH AYERST 10MG/ML

> ADD >

SOLUTION; ORAL

FUROSEMIDE

AA PENNEX PHARMS 10MG/ML

/AA/ /PHARM/BASICS/ /10MG/ML/

TABLET; ORAL

FUROSEMIDE

/AB/ /PARKE/DAVIS/ /20MG/

/AB/ /40MG/

/AB/ /80MG/

a WARNER CHILCOTT 20MG

a 40MG

a 80MG

> ADD > GABAPENTIN

> ADD > CAPSULE; ORAL

> ADD > NEURONTIN

> ADD > + PARKE DAVIS 400MG

> ADD > 100MG

> ADD > 300MG

> ADD >

> ADD >

> ADD >

/N70014/001/

/SEP/09/1985/

N70014 001

SEP 09, 1985

/N18670/001/

/JUL/20/1982/

N18670 001

JUL 20, 1982

N70655 001

OCT 02, 1987

/N70655/001/

/OCT/02/1987/

/N18419/001/

/JAN/31/1983/

/N18419/002/

/JAN/31/1983/

/N18419/003/

/NOV/13/1984/

N18419 001

JAN 31, 1983

N18419 002

JAN 31, 1983

N18419 003

NOV 13, 1984

N20235 003

DEC 30, 1993

N20235 001

DEC 30, 1993

N20235 002

DEC 30, 1993

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

STERLING WINTHROP 287MG/ML

N20123 001

JAN 08, 1993

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

AB MYLAN 300MG

N73466 001

JAN 25, 1993

AB PUREPAC 300MG

N72929 001

JAN 29, 1993

LOPID

AB + PARKE DAVIS 300MG

N18422 002

TABLET; ORAL

GEMFIBROZIL

AB LEDERLE 600MG

N74270 001

SEP 27, 1993

AB LEMMON 600MG

N74256 001

OCT 31, 1993

LOPID

AB + PARKE DAVIS 600MG

N18422 003

NOV 20, 1986

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

/AT/ /PHARMADERM/ /EQ 1MG BASE/GM/

/N62530/001/

/JUL/05/1984/

a PHARMADERM

EQ 1MG BASE/GM

N62530 001

JUL 05, 1984

INJECTABLE; INJECTION

GENTAMICIN SULFATE

/AP/ /WYETH/AYERST/ /EQ 10MG BASE/ML/

/N62264/001/

/AP/ /EQ 40MG BASE/ML/

/N62264/002/

a WYETH AYERST

EQ 10MG BASE/ML

N62264 001

a EQ 40MG BASE/ML

N62264 002

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTICCONTAINER

/AP/	/ABBOTT/	/EQ 60MG BASE/100ML/	/N62588/006/
			/JAN/06./1986/
/AP/		/EQ 70MG BASE/100ML/	/N62588/007/
			/JAN/06./1986/
/AP/		/EQ 80MG BASE/100ML/	/N62588/008/
			/JAN/06./1986/
/AP/		/EQ 90MG BASE/100ML/	/N62588/009/
			/JAN/06./1986/
/AP/		/EQ 100MG BASE/100ML/	/N62588/010/
			/JAN/06./1986/
/AP/		/EQ 1.2MG BASE/ML/	/N62588/001/
			/JAN/06./1986/
/AP/		/EQ 1.4MG BASE/ML/	/N62588/002/
			/JAN/06./1986/
/AP/		/EQ 1.6MG BASE/ML/	/N62588/003/
			/JAN/06./1986/
/AP/		/EQ 1.8MG BASE/ML/	/N62588/004/
			/JAN/06./1986/
/AP/		/EQ 2MG BASE/ML/	/N62588/005/
			/JAN/06./1986/
Q	ABBOTT	EQ 60MG BASE/100ML	N62588 006
			JAN 06, 1986
Q		EQ 70MG BASE/100ML	N62588 007
			JAN 06, 1986
Q		EQ 80MG BASE/100ML	N62588 008
			JAN 06, 1986
Q		EQ 90MG BASE/100ML	N62588 009
			JAN 06, 1986
Q		EQ 100MG BASE/100ML	N62588 010
			JAN 06, 1986
Q		EQ 1.2MG BASE/ML	N62588 001
			JAN 06, 1986
Q		EQ 1.4MG BASE/ML	N62588 002
			JAN 06, 1986
Q		EQ 1.6MG BASE/ML	N62588 003
			JAN 06, 1986
Q		EQ 1.8MG BASE/ML	N62588 004
			JAN 06, 1986
Q		EQ 2MG BASE/ML	N62588 005
			JAN 06, 1986

OINTMENT; OPHTHALMIC

GENTAFAIR

/AT/	/PHARMAFAIR/	/EQ 3MG BASE/GM/	/N62443/001/
			/MAY/26./1983/
Q	PHARMAFAIR	EQ 3MG BASE/GM	N62443 001
			MAY 26, 1983

GLIPIZIDE

TABLET; ORAL

GLUCOTROL

+ PFIZER

10MG

N17783 002

MAY 08, 1984

2.5MG

N17783 003

MAY 11, 1993

5MG

N17783 001

MAY 08, 1984

/+/ROERIG/

/10MG/

/N17783/002/

/MAY/08./1984/

/5MG/

/N17783/001/

/MAY/08./1984/

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

/AP/ /LILLY/

/EQ 1MG BASE/VIAL/

/N12122/001/

/AP/ LILLY

EQ 1MG BASE/VIAL

N12122 001

/AP/ /QUAD/

/EQ 1MG BASE/VIAL/

/N71022/001/

/MAR/04./1987/

Q QUAD

EQ 1MG BASE/VIAL

N71022 001

MAR 04, 1987

GLUTETHIMIDE

CAPSULE; ORAL

DORIDEN

/Q/RHONE/POULENC/ROER//500MG/

/N69519/008/

GLYBURIDE

TABLET; ORAL

GLUBATE

/BX/ /HOECHST/ROUSSEL/

/1.5MG/

/N20055/001/

/APR/17./1992/

/BX/

/3MG/

/N20055/002/

/APR/17./1992/

Q HOECHST ROUSSEL

1.5MG

N20055 001

APR 17, 1992

Q

3MG

N20055 002

APR 17, 1992

GLYBURIDETABLET; ORAL
GLYNASE

/BX/ /UPJOHN/

/1.5MG/

/N20051/001/

/+/

/3MG/

/MAR/04./1992/

+ UPJOHN

6MG

/N20051/002/

/MAR/04./1992/

N20051 004

SEP 24, 1993

N20051 001

MAR 04, 1992

N20051 002

MAR 04, 1992

N20051 003

SEP 24, 1993

GONADORELIN ACETATEINJECTABLE; INJECTION
LUTREPULSE KIT

+ FERRING

0.8MG/VIAL

N19687 001

OCT 10, 1989

+

3.2MG/VIAL

N19687 002

OCT 10, 1989

/LUTREPULSE/PUMP/KIT/
/FERRING/

/0.8MG/VIAL/

/N19687/001/

/OCT/10./1989/

/3.2MG/VIAL/

/N19687/002/

/OCT/10./1989/

GONADOTROPIN, CHORIONICINJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

/AP/ /BEL/MAR/

/5,000 UNITS/VIAL/

/N17054/001/

/AP/

/10,000 UNITS/VIAL/

/N17054/002/

a BEL MAR

5,000 UNITS/VIAL

N17054 001

a

10,000 UNITS/VIAL

N17054 002

/EGLLUTEIN/

/AP/ /SQUIBB/

/10,000 UNITS/VIAL/

/N17056/001/

a SQUIBB

10,000 UNITS/VIAL

N17056 001

GOSERELIN ACETATEIMPLANT; IMPLANTATION
ZOLADEX

/+/ /IMPERIAL/CHEM/

/EQ/3.6MG/BASE/

/N19726/001/

/DEC/29./1989/

GOSERELIN ACETATEIMPLANT; IMPLANTATION
ZOLADEX

+ ZENECA

EQ 3.6MG BASE

N19726 001

DEC 29, 1989

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

/NEO-POLYXIN/

/AT/ /DOW/

/0.025MG/ML;EQ 1.75MG BASE/ML/

/10,000 UNITS/ML/

/N60427/001/

a DOW

0.025MG/ML;EQ 1.75MG BASE/ML;

10,000 UNITS/ML

N60427 001

>_ADD> GRANISETRON HYDROCHLORIDE

>_ADD> INJECTABLE; INJECTION

>_ADD> KYTRIL

>_ADD> + SMITHKLINE BEECHAM

EQ 3MG BASE/ML

N20239 001

>_ADD>

DEC 29, 1993

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL

GRISACTIN

/HYETH/AYERST/

/125MG/

/N50051/002/

a HYETH AYERST

125MG

N50051 002

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HCL

/KEY/PHARMS/

/125MG/

/N01546/001/

SCHERING

125MG

N01546 001

HALOFANTRINE HYDROCHLORIDE

/TABLET; ORAL/

/HALFAN/

/+/ /SMITHKLINE/BEECHAM/ /250MG/

/N20250/001/

a SMITHKLINE BEECHAM

250MG

N20250 001

JUL 24, 1992

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

/AB/	/LEDERLE/	/0.5MG/	/N72727/001/
			/SEP 19, 1989/
/AB/		/1MG/	/N72728/001/
			/SEP 19, 1989/
/AB/		/2MG/	/N72729/001/
			/SEP 19, 1989/
/AB/		/5MG/	/N72730/001/
			/SEP 19, 1989/
/AB/		/10MG/	/N72731/001/
			/SEP 19, 1989/
/AB/		/20MG/	/N72732/001/
			/SEP 19, 1989/
Q	LEDERLE	0.5MG	N72727 001
			SEP 19, 1989
Q		1MG	N72728 001
			SEP 19, 1989
Q		2MG	N72729 001
			SEP 19, 1989
Q		5MG	N72730 001
			SEP 19, 1989
Q		10MG	N72731 001
			SEP 19, 1989
Q		20MG	N72732 001
			SEP 19, 1989

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

Q	PENNEX PHARMS	EQ 2MG BASE/ML	N70710 001
			MAR 07, 1986
AA	PHARM ASSOC	EQ 2MG BASE/ML	N73037 001
			FEB 26, 1993
/AA/	/PHARM/BASICS/	/EQ 2MG BASE/ML/	/N70710/001/
			/MAR 07, 1986/
AA	SILARX	EQ 2MG BASE/ML	N73364 001
			SEP 28, 1993

INJECTABLE; INJECTION

HALOPERIDOL

AP	MARSAM	EQ 5MG BASE/ML	N72516 001
			FEB 25, 1993
AP		EQ 5MG BASE/ML	N72517 001
			FEB 25, 1993

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

/AP/	/SMITH/NEPHEW/SOLOPAK/	/EQ 5MG BASE/ML/	/N70801/001/
			/DEC 14, 1987/
/AP/		/EQ 5MG BASE/ML/	/N70864/001/
			/DEC 14, 1987/
AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001
			DEC 14, 1987
AP		EQ 5MG BASE/ML	N70864 001
			DEC 14, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION

LIQUAMIN SODIUM

/AP/	/ORGANON/	/20,000 UNITS/ML/	/N00552/001/
/AP/		/40,000 UNITS/ML/	/N00552/002/
Q	ORGANON	20,000 UNITS/ML	N00552 001
Q		40,000 UNITS/ML	N00552 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

TURGEX/XTTRIUM/

Q XTTRIUM

/3%/
3%

/N18375/001/
N18375 001

EMULSION; TOPICAL

HEXA-GERM/HUNTINGTON/

Q HUNTINGTON

/3%/
3%

/N17411/001/
N17411 001

PHISOHEX/STERLING/

Q STERLING

/3%/
3%

/N08402/001/
N08402 001

TURGEX/XTTRIUM/

Q XTTRIUM

/3%/
3%

/N19055/001/
N19055 001
NOV 30, 1984

/SOLUTION; TOPICAL//DIAL//ARMOUR/DIAL/

Q DIAL

/0.25%/
0.25%

/N17421/002/
N17421 002

/GERMA-MEDICA//HUNTINGTON/

Q HUNTINGTON

/1%/
1%

/N17412/001/
N17412 001

HEXACHLOROPHENE

/SOLUTION; TOPICAL/
/GERMA-MEDICA 'MG'/
/HUNTINGTON/
a HUNTINGTON

/0.25%/
0.25%

/N17412/002/
N17412 002

SPONGE; TOPICAL

/At/ /HEXASCRUB/
/PROF DSPLS/
a PROF DSPLS

/3%/
3%

/N18363/001/
N18363 001

/At/ /PHISO-SCRUB/
/STERLING/
a STERLING

/3%/
3%

/N17446/001/
N17446 001

/SCRUBTEAM/SURGICAL/SPONGEBRUSH/
/3M/
a 3M

/330MG/
330MG

/N17413/001/
N17413 001

HEXAFLUORENIUM BROMIDE

/INJECTABLE; INJECTION/
/MILAXEN/
/WALLACE/
a WALLACE

/20MG/ML/
20MG/ML

/N09789/003/
N09789 003

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION
HISTAMINE PHOSPHATE

/LILLY/
a LILLY

/EQ 0.1MG BASE/ML/
EQ 0.1MG BASE/ML

/N00734/003/
N00734 003

a

/EQ 0.2MG BASE/ML/
EQ 0.2MG BASE/ML

/N00734/002/
N00734 002

a

/EQ 1MG BASE/ML/
EQ 1MG BASE/ML

/N00734/001/
N00734 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

MYCODONE

AA PENNEX PHARMS

/1.5MG/5ML; 5MG/5ML

N88008 001
MAR 03, 1983

/AA/ /PHARM/BASICS/

/1.5MG/5ML; 5MG/5ML/

/N88008/001/
/MAR 03, 1983/

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

AP + CIBA

/20MG/ML/
/20MG/ML/

N08303 003
/N08303/003/

HYDRALAZINE HCL

/a SMITH/NEPHEW/SOLOPAK/20MG/ML/

AP

SOLOPAK

/20MG/ML

/N08517/001/
/AUG 22, 1985/
N88517 001
AUG 22, 1985

HYDRALAZINE HYDROCHLORIDE; RESERPINE

/TABLET; ORAL/

/SERPASIL-APRESOLINE/

/a CIBA/

/50MG; 0.2MG/
/25MG; 0.1MG/
25MG; 0.1MG
50MG; 0.2MG

/N09296/002/
/N09296/004/
N09296 004
N09296 002

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

a PENNEX PHARMS

50MG/5ML

N89661 001
JUN 20, 1988

/AA/

/PHARM/BASICS/

/50MG/5ML/

/N89661/001/
/JUN 20, 1988/

/AA/

/ROXANE/

/50MG/5ML/

/N88587/001/
/JUL 02, 1984/

ROXANE

50MG/5ML

N88587 001
JUL 02, 1984

TABLET; ORAL

HYDROCHLOROTHIAZIDE

/AB/

/INWOOD/

/25MG/

/N84776/001/

/AB/

a INWOOD

/50MG/

/N84776/002/

25MG

50MG

N84776 001

a

50MG

N84776 002

/AB/

/LEMMON/

/25MG/

/N88924/001/

/AB/

a LEMMON

/50MG/

/FEB 07, 1985/

25MG

50MG

/N88923/001/

a

25MG

N88924 001

a

50MG

FEB 07, 1985

a

50MG

N88923 001

a

50MG

FEB 07, 1985

/AB/

/PHARMAFAIR/

/25MG/

/N84325/001/

/AB/

a PHARMAFAIR

/50MG/

/N84324/001/

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	PHARMERAL	25MG	N84325 001
AB		50MG	N84324 001

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

/AB/	/SCHERING/	/25MG;100MG/	/N19046/001/
			/APR/06,1987/
/AB/		/25MG;200MG/	/N19046/002/
			/APR/06,1987/
/AB/	/	/25MG;300MG/	/N19046/003/
			/APR/06,1987/
	+ SCHERING	25MG;300MG	N19046 003
		25MG;100MG	APR 06, 1987
		25MG;200MG	N19046 001
			APR 06, 1987
			N19046 002
			APR 06, 1987
/AB/	/TRANSDATE HCl/	/25MG;100MG/	/N19174/001/
	/GLAXO/		/APR/10,1987/
/AB/		/25MG;200MG/	/N19174/002/
			/APR/10,1987/
/AB/		/25MG;300MG/	/N19174/003/
			/APR/10,1987/
	Q GLAXO	25MG;100MG	N19174 001
			APR 10, 1987
	Q	25MG;200MG	N19174 002
			APR 10, 1987
	Q	25MG;300MG	N19174 003
			APR 10, 1987

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

PRINZIDE 10-12.5

AB	MERCK	12.5MG;10MG	N19778 003
			NOV 18, 1993
/AB/	/PRINZIDE 12.5/	/12.5MG;20MG/	/N19778/001/
	/MERCK/		/FEB/16,1989/
	<u>PRINZIDE 20-12.5</u>		
AB	MERCK	12.5MG;20MG	N19778 001
			FEB 16, 1989

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

PRINZIDE 20-25

AB	+ MERCK	25MG;20MG	N19778 002
			FEB 16, 1989
/AB/	/PRINZIDE 25/	/25MG;20MG/	/N19778/002/
	/MERCK/		/FEB/16,1989/
	<u>ZESTORETIC 10-12.5</u>		
AB	ZENECA	12.5MG;10MG	N19888 003
			NOV 18, 1993
	<u>ZESTORETIC 20-12.5</u>		
AB	ZENECA	12.5MG;20MG	N19888 001
			SEP 20, 1990
	<u>ZESTORETIC 20-25</u>		
AB	ZENECA	25MG;20MG	N19888 002
			JUL 20, 1989
/AB/	/ZENECA/	/12.5MG;20MG/	/N19888/001/
			/SEP/20,1990/
/AB/	/ZENECA/	/25MG;20MG/	/N19888/002/
			/JUL/20,1989/

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

/AB/	/PHARMAFAIR/	/25MG;0.125MG/	/N85421/001/
	/	/50MG;0.125MG/	/N85420/001/
	Q PHARMERAL	25MG;0.125MG	N85421 001
	Q	50MG;0.125MG	N85420 001

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

/AB/	/UPSHER/SMITH/	/25MG;25MG/	/N87553/001/
	Q UPSHER SMITH	25MG;25MG	N87553 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	25MG;37.5MG	N73449 001
			SEP 23, 1993

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	BARRE	2.5%	N89682 001
			MAR 10, 1988
/AT/	/BIOCRIFT/	/0.5%/	/N80400/002/
/AT/		/1%/	/N80400/003/
/AT/		/2.5%/	/N80400/004/
	Q BIOCRIFT	0.5%	N80400 002
	Q	1%	N80400 003
	Q	2.5%	N80400 004
/AT/	/NASKA/	/2.5%/	/N89682/001/
			MAR 10, 1988
/AT/	/PHARMADERM/	/1%/	/N88845/001/
			FEB 27, 1986
	Q PHARMADERM	1%	N88845 001
			FEB 27, 1986

/INJECTABLES; INJECTION//CORTEF//UPJOHN/

	Q UPJOHN	/50MG/ML/	/N09864/001/
		50MG/ML	N09864 001

LOTION; TOPICAL

ACTICORT

AT	BAKER NORTON	1%	N86535 001
/AT/	/KEY PHARMS/	/1%/	/N86535/001/
/AT/	/BALNEAL-HC/	/1%/	/N88841/001/
			DEC 03, 1982
	Q SOLVAY	1%	N88041 001
			DEC 03, 1982

OINTMENT; TOPICAL

HYDROCORTISONE

AT	FOUGERA	2.5%	N81203 001
			MAY 28, 1993
/AT/	/PHARMADERM/	/1%/	/N88842/001/
			FEB 09, 1987
	Q PHARMADERM	1%	N88842 001
			FEB 09, 1987

TABLET; ORAL

HYDROCORTISONE

	Q FERRANTE	10MG	N80568 001
	Q	20MG	N80568 002
/BP/	/MK/	/10MG/	/N80568/001/
/BP/		/20MG/	/N80568/002/

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION; OTIC

/NEOMYCIN SULFATE; POLYMYXIN B SULFATE & HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/12;EQ 3.5MG BASE/ML/	/N62617/001/
		/10,000 UNITS/ML/	/SEP 18, 1985/
	Q PHARMAFAIR	1%;EQ 3.5MG BASE/ML;	N62617 001
		10,000 UNITS/ML	SEP 18, 1985

SUSPENSION/DROPS; OPHTHALMIC

/NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/12;EQ 3.5MG BASE/ML/	/N62623/001/
		/10,000 UNITS/ML/	/SEP 24, 1985/
	Q PHARMAFAIR	1%;EQ 3.5MG BASE/ML;	N62623 001
		10,000 UNITS/ML	SEP 24, 1985

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

/BP/	/BEL/MAR/	/25MG/ML/	/N83739/001/
/BP/		/50MG/ML/	/N83739/002/
	Q BEL MAR	25MG/ML	N83739 001
	Q	50MG/ML	N83739 002

/OINTMENT; TOPICAL//CORTEF/ACETATE//UPJOHN/

	Q UPJOHN	/EQ 1%/BASE/	/N08917/002/
		/2.5%/	/N08917/001/
	Q	EQ 1% BASE	N08917 002
		2.5%	N08917 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT; TOPICAL

NEO-CORTEF/UPJOHN/Q UPJOHN

	Q	/0.5%;EQ 3.5MG/BASE/GM/	/N60751/001/
		0.5%;EQ 3.5MG BASE/GM	N60751 001
		/2.5%;EQ 3.5MG/BASE/GM/	/N60751/003/
		2.5%;EQ 3.5MG BASE/GM	N60751 003

IBUPROFEN

TABLET; ORAL

IBUPROFEN
 AB NORTON HN 400MG
 AB 600MG
 AB 800MG

N71145 001
 SEP 23, 1986
 N71146 001
 SEP 23, 1986
 N71769 001
 MAY 08, 1987

IBUPROFEN
 /AB/ /PAR/ /400MG/
 3 PAR 300MG
 /IFEN/
 /AB/ /LUCHEN/ /400MG/
 /AB/ /600MG/
 /AB/ /800MG/

/N70328/001/
 /AUG/06/1985/
 N70328 001
 AUG 06, 1985
 /N71145/001/
 /SEP/23/1986/
 /N71146/001/
 /SEP/23/1986/
 /N71769/001/
 /MAY/08/1987/

IDOXURIDINE

/OINTMENT;/OPHTHALMIC/
 /STOXIL/
 /S/SMITHKLINE/BEECHAM/ /0.5%/
 3 SMITHKLINE BEECHAM 0.5%

SOLUTION/DROPS; OPHTHALMIC

/STOXIL/
 /At/ /SMITHKLINE/BEECHAM/ /0.1%/
 3 SMITHKLINE BEECHAM 0.1%

/N15868/001/
 N15868 001

/N13934/001/
 N13934 001

INDAPAMIDE

TABLET; ORAL

LOZOL
 RHONE POULENC RORER 1.25MG

N18538 002
 APR 29, 1993

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN
 > DLT > /AB/ /CHELSEA/ /50MG/
 > DLT >
 > ADD > 3 CHELSEA 50MG
 > ADD >

/N71635/001/
 /MAY/18/1987/
 N71635 001
 MAY 18, 1987

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION

IODOHIPPURATE SODIUM I 131
 /AB/ /CIS/ /0.2MCI/ML/
 AP SORIN 0.2MCI/ML

/N17313/001/
 N17313 001

IOHEXOL

/INJECTABLE;/INJECTION/
 /OMNIPAQUE/180/
 /STERLING/ /38.8%/
 /N18956/001/
 /DEC/26/1985/

/SOLUTION;/INJECTION;/ORAL/
 /OMNIPAQUE/240/
 /STERLING/ /51.8%/
 /N18956/002/
 /DEC/26/1985/
 /OMNIPAQUE/300/
 /STERLING/ /64.7%/
 /N18956/003/
 /DEC/26/1985/

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180
 + STERLING 38.8%
 OMNIPAQUE 240
 + STERLING 51.8%
 OMNIPAQUE 300
 + STERLING 64.7%

N18956 001
 DEC 26, 1985

N18956 002
 DEC 26, 1985

N18956 003
 DEC 26, 1985

IOTROLAN

/INJECTABLE;/INTRATHECAL/
/OSMOVIST/
/BERLEX/

/EQ/190MG/IODINE/ML/ /N19580/001/
/DEC/07,/1989/
/EQ/240MG/IODINE/ML/ /N19580/002/
/DEC/07,/1989/
N19580 001
DEC 07, 1989
N19580 002
DEC 07, 1989

a BERLEX

EQ 190MG IODINE/ML

a

EQ 240MG IODINE/ML

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ATROVENT
+ BOEHRINGER INGELHEIM 0.02%

N20228 001
SEP 29, 1993

IRON DEXTRAN

INJECTABLE; INJECTION
/INFERON/
/FISONS/
INFED

/EQ/50MG/IRON/ML/ /N10787/002/
/N10787/001/
/DEC/07,/1989/
N17441 001
N10787 002
N17441 001

> DLT >
> DLT >

BP + SCHEIN PHARM
IRON DEXTRAN
a FISONS
IRON/DEXTRAN/
/BP/ /STERIS/

EQ 50MG IRON/ML
EQ 50MG IRON/ML
EQ 50MG IRON/ML

> ADD >
> ADD >

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL

/AN/ /ASTRA/ /0.125%/
/N87937/001/
/NOV/15,/1982/
/N87937/001/
/NOV/15,/1982/
N87937 001
NOV 15, 1982
N87938 001
NOV 15, 1982
/AN/ /PARKE/DAVIS/ /1%/
/N85997/001/
/N85997/001/
N85997 001
N85889 001

a ASTRA

0.062%

a

0.125%

a PARKE DAVIS

0.5%

a

1%

ISOFLURANE

LIQUID; INHALATION

FORANE

AN + ANAQUEST 99.9%
AN ISOFLURANE 99.9%
ABBOTT

N17624 001

N74097 001
JAN 25, 1993

ISONIAZID

INJECTABLE; INJECTION
NYDRAZID

+ APOTHECON 100MG/ML
/SQUIBB/ /100MG/ML/

N08662 001
/N08662/001/

TABLET; ORAL

ISONIAZID

/AA/ /EON/LABS/ /100MG/ /N08678/002/
AA + EON LABS 100MG /N08678/003/
/AA/ /300MG/ /N08678/003/
AA + 300MG /N08941/001/
> DLT > /AA/ /MK/ /100MG/ /N08941/001/
> ADD > a MK 100MG /N08941/001/
> DLT > /AA/ /PHARMAVITE/ /100MG/ /N08941/001/
> ADD > a PHARMAVITE 100MG /N08941/001/
/AA/ /STANOLITE/ /300MG/ /N08126/002/
a EVERYLIFE 300MG /N08126/002/

ISOPROPAMIDE IODIDE

/TABLET;/ORAL/

DARBIT

/SMITHKLINE/BEECHAM/ /EQ/5MG/BASE/
a SMITHKLINE BEECHAM EQ 5MG BASE

/N10744/001/
N10744 001

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

AEROLONE

/AN/ /LILLY/ /0.25%/
+ LILLY 0.25%
/AN/ /ISOPROTERENOL HCL/ /0.25%/
/AN/ /PARKE/DAVIS/ /0.5%/
a PARKE DAVIS 0.25%
a 0.5%

/N07245/001/
N07245 001

/N08594/001/
/N08594/001/
N85994 001
N85540 001

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

<u>ISUPREL</u>			
/AN/	/STERLING/	/0.52/	/N06327/002/
	+ STERLING WINTHROP	0.5%	N06327 002
<u>VAP0-150</u>			
/AN/	/FISONS/	/0.52/	/N16813/001/
	@ FISONS	0.5%	N16813 001

TABLET; RECTAL, SUBLINGUAL

<u>ISUPREL</u>			
	/STERLING/	/15MG/	/N06328/002/
	@ STERLING	15MG	N06328 002

ISOSORBIDE DINITRATE

TABLET; ORAL

<u>SORBITRATE</u>			
/AB/	/ICI/	/20MG/	/N86405/002/
			AUG 21, 1990
/AB/		/30MG/	/N88124/001/
			AUG 21, 1990
/AB/		/40MG/	/N88125/001/
			AUG 21, 1990
AB	ZENECA	20MG	N86405 002
			AUG 21, 1990
AB		30MG	N88124 001
			AUG 21, 1990
AB		40MG	N88125 001
			AUG 21, 1990

ISOSORBIDE MONONITRATE

TABLET; ORAL

<u>ISM0</u>			
/AB/	/WYETH/	/20MG/	/N19091/001/
			DEC 30, 1991
BX +	WYETH	20MG	N19091 001
			DEC 30, 1991
<u>MONOKET</u>			
BX	SCHWARZ PHARMA	20MG	N20215 001
			JUN 30, 1993
		10MG	N20215 002
			JUN 30, 1993

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

<u>IMDUR</u>			
@ SCHERING PLOUGH	30MG		N20225 001
			AUG 12, 1993
	60MG		N20225 002
			AUG 12, 1993

KANAMYCIN SULFATE

CAPSULE; ORAL

<u>KANTREX</u>			
APOTHECON	EQ 500MG BASE		N62726 001
			MAR 06, 1987
/BRISTOL/	/EQ 500MG BASE/		/N62726/001/
			MAR 06, 1987

INJECTABLE; INJECTION

<u>KANTREX</u>			
AP	APOTHECON	EQ 75MG BASE/2ML	N61901 003
AP		EQ 500MG BASE/2ML	N61901 001
AP		EQ 1GM BASE/3ML	N61901 002
/AP/	/BRISTOL/	/EQ 75MG BASE/2ML/	/N61901/003/
/AP/		/EQ 500MG BASE/2ML/	/N61901/001/
/AP/		/EQ 1GM BASE/3ML/	/N61901/002/
<u>KLEBCIL</u>			
/AP/	/SMITHKLINE/BEECHAM/	/EQ 75MG BASE/2ML/	/N62170/001/
/AP/		/EQ 500MG BASE/2ML/	/N62170/002/
/AP/		/EQ 1GM BASE/3ML/	/N62170/003/
@	SMITHKLINE BEECHAM	EQ 75MG BASE/2ML	N62170 001
@		EQ 500MG BASE/2ML	N62170 002
@		EQ 1GM BASE/3ML	N62170 003

KETOPROFEN

CAPSULE; ORAL

<u>KETOPROFEN</u>			
AB	LEDERLE	25MG	N74014 001
			JAN 29, 1993
AB		50MG	N74014 002
			JAN 29, 1993
AB		75MG	N74014 003
			JAN 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

<u>ORUVAIL</u>			
+ WYETH AYERST	200MG		N19816 001
			SEP 24, 1993

LACTULOSE

SOLUTION; ORAL

/AA/ CEPHULAC /
/MERRELL/DOW/ /10GM/15ML/ /N17657/001/

/AA/ ENULOSE /
/BARRE/ /10GM/15ML/ /N17548/001/
/AUG/15./1988/

AA EVALOSE
COPLEY 10GM/15ML

LACTULOSE
@ PENNEX PHARMS 10GM/15ML
/AA/ /PHARM/BASICS/ /10GM/15ML/ /N71841/001/
/SEP/22./1988/

/LACTULOSE/
/SOLVAY/ /10GM/15ML/ /N17966/001/

AA LAXULOSE
TECHNLAB 10GM/15ML
N73686 001
MAY 28, 1993

SOLUTION; ORAL, RECTAL

AA ACTILAC
TECHNLAB 10GM/15ML
N73685 001
MAY 28, 1993

AA CEPHULAC
MERRELL DOW 10GM/15ML
N17657 001

AA ENULOSE
BARRE 10GM/15ML
N71548 001
AUG 15, 1988

/AA/ GENERLAC /
/PHARM/BASICS/ /10GM/15ML/ /N17842/001/
/SEP/27./1988/

@ PENNEX PHARMS 10GM/15ML
N71842 001
SEP 27, 1988

AA HEPTALAC
COPLEY 10GM/15ML
N73504 001
MAY 28, 1993

LACTULOSE
@ SOLVAY 10GM/15ML
/AA/ PORTALAC /
/SOLVAY/ /10GM/15ML/ /N17374/001/
/MAR/22./1989/

@ SOLVAY 10GM/15ML
N72374 001
MAR 22, 1989

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM
AP GENSLA EQ 50MG BASE/VIAL N81278 001
SEP 28, 1993
AP EQ 100MG BASE/VIAL N81277 001
SEP 28, 1993

POWDER FOR RECONSTITUTION; ORAL

LEUCOVORIN CALCIUM
> ADD > EQ 60MG BASE/VIAL N08107 003
> ADD > JAN 30, 1987
> DLT > /LEDERLE/ /EQ/60MG/BASE/VIAL/ /N08107/003/
> DLT > /JAN/30./1987/

TABLET; ORAL

LEUCOVORIN CALCIUM
AB IMMUNEX EQ 10MG BASE N71962 001
NOV 19, 1987
AB + EQ 15MG BASE N71104 001
MAR 04, 1987
BX EQ 5MG BASE N18459 001
JAN 30, 1986
/AB/ /LEDERLE/ /EQ/10MG/BASE/ /N1962/001/
/NOV/19./1987/

/AB//+/ /EQ/15MG/BASE/ /N71104/001/
/MAR/04./1987/

/BX/ /EQ/5MG/BASE/ /N18459/001/
/JAN/30./1986/

AB ROXANE EQ 5MG BASE N72733 001
FEB 22, 1993

AB EQ 10MG BASE N72734 001
FEB 22, 1993

AB EQ 15MG BASE N72735 001
FEB 22, 1993

AB EQ 25MG BASE N72736 001
FEB 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON
/+/TAP/ /1MG/0.2ML/ /N19010/001/
/APR/09./1985/

+ TAP 5MG/ML N19010 001
APR 09, 1985

5MG/ML N20263 001
APR 16, 1993

LEUPROLIDE ACETATEINJECTABLE; INJECTION
LUPRON DEPOT

+ TAP	3.75MG/VIAL	N20011 001
		OCT 22, 1990
+	7.5MG/VIAL	N19732 001
		JAN 26, 1989
	/3.75MG/VIAL/	/N20011/001/
		/OCT/22/1990/
	/7.5MG/VIAL/	/N19732/001/
		/JAN/26/1989/
LUPRON DEPOT-PED		
+ TAP	3.75MG/VIAL&7.5MG/VIAL	N20263 003
		APR 16, 1993
+	7.5MG/VIAL&7.5MG/VIAL	N20263 004
		APR 16, 1993
+	7.5MG/VIAL	N20263 002
		APR 16, 1993

LEVOCABASTINE HYDROCHLORIDESUSPENSION/DROPS; OPHTHALMIC
LIVOSTIN

+ IOLAB	EQ 0.05% BASE	N20219 001
		NOV 10, 1993

LEVOMETHADYL ACETATE HYDROCHLORIDECONCENTRATE; ORAL
ORLAAM

BIODEVELOPMENT	10MG/ML	N20315 001
		JUL 09, 1993
/BIOMETRICS/RES/	/10MG/ML/	/N20315/001/
		/JUL/09/1993/

LEVONORDEFIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

/INJECTABLE; INJECTION/

/RAVOCALINE/AND/NOVOCALIN/	/NEO-COBEFRIN/	
/COOK/WAITER/	/0.05MG/ML; 2%; 0.4%/	/N08592/007/
@ STERLING WINTHROP	0.05MG/ML; 2%; 0.4%	N08592 007

LIDOCAINE

/SUPPOSITORY; RECTAL/
/XYLOCAINE/
/ASTRA/

/100MG/

/N13077/001/

LIDOCAINE

/SUPPOSITORY; RECTAL/
/XYLOCAINE/
@ ASTRA

100MG

N13077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

/AP/ /ABBOTT/ /102/

@ ABBOTT 10%

/AP/ /BEL/MAR/ /12/

/AP/ /22/

@ BEL MAR 1%

@ 2%

/AP/ /BRISTOL/ /12/

/AP/ /22/

AP FUJISAWA 1%

AP 2%

@ 1%

@ 2%

/AP/ /LYPHOMED/ /12/

/AP/ /12/

/AP/ /22/

/AP/ /22/

@ LYPHOMED 1%

@ 2%

JELLY; TOPICAL

LIDOCAINE HCL

AT COPLEY 2%

N81318 001
APR 29, 1993

SOLUTION; ORAL

MYLOCAINE

AT PENNEX PHARMS 2%

/AT/ /PHARM/BASICS/ /22/

N87872 001
NOV 18, 1982
/N87872/001/
/NOV/18/1982/

SOLUTION; TOPICAL

MYLOCAINE

/AT/ /PHARM/BASICS/ /42/

@ PENNEX PHARMS 4%

/N87881/001/
/NOV/18/1982/
N87881 001
NOV 18, 1982

LINDANE

LOTION; TOPICAL

LINDANE

AT	PENNEX PHARMS	1%	N88190 001
			AUG 16, 1984
/AT/	/PHARM/BASICS/	/1%/	/N88190/001/
			/AUG/16./1984/

SHAMPOO; TOPICAL

LINDANE

AT	PENNEX PHARMS	1%	N88191 001
			SEP 18, 1984
/AT/	/PHARM/BASICS/	/1%/	/N88191/001/
			/SEP/18./1984/

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25			
FOREST LABS	0.0125MG;0.0031MG	N16807 001	
/RHONE/POULENC/ROERIG/	/0.0125MG;0.0031MG/	/N16807/001/	
THYROLAR-0.5			
FOREST LABS	0.025MG;0.00625MG	N16807 005	
/RHONE/POULENC/ROERIG/	/0.025MG;0.00625MG/	/N16807/005/	
THYROLAR-1			
FOREST LABS	0.05MG;0.0125MG	N16807 004	
/RHONE/POULENC/ROERIG/	/0.05MG;0.0125MG/	/N16807/004/	
THYROLAR-2			
FOREST LABS	0.1MG;0.025MG	N16807 002	
/RHONE/POULENC/ROERIG/	/0.1MG;0.025MG/	/N16807/002/	
THYROLAR-3			
+ FOREST LABS	0.15MG;0.0375MG	N16807 003	
/+ /RHONE/POULENC/ROERIG/	/0.15MG;0.0375MG/	/N16807/003/	
THYROLAR-5			
@ FOREST LABS	0.25MG;0.0625MG	N16807 006	
/@ /RHONE/POULENC/ROERIG/	/0.25MG;0.0625MG/	/N16807/006/	

LISINAPRIL

TABLET; ORAL

ZESTRIL

/AB/	/IMPERIAL/CHEM/	/5MG/	/N19777/001/
			/MAY/19./1988/
/AB/		/10MG/	/N19777/002/
			/MAY/19./1988/
/AB/		/20MG/	/N19777/003/
			/MAY/19./1988/
/AB/+ /		/40MG/	/N19777/004/
			/MAY/19./1988/

LISINAPRIL

TABLET; ORAL

ZESTRIL

AB	ZENECA	5MG	N19777 001
			MAY 19, 1988
AB		10MG	N19777 002
			MAY 19, 1988
AB		20MG	N19777 003
			MAY 19, 1988
AB +		40MG	N19777 004
			MAY 19, 1988
		2.5MG	N19777 005
			APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL

ESKALITH

/AB/+ /	/SMITHKLINE/BEECHAM/	/300MG/	/N17971/001/
	@ SMITHKLINE BEECHAM	300MG	N17971 001

LITHANE

/AB/	/MILES/	/300MG/	/N18833/001/
	@ MILES	300MG	JUL/18./1985/
			N18833 001
			JUL 18, 1985

LITHIUM CARBONATE

AB	PFIZER	300MG	N16834 001
----	--------	-------	------------

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

AA	PENNEX PHARMS	EQ 300MG CARBONATE/5ML	N70755 001
			MAY 21, 1986
/AA/	/PHARM/BASICS/	/EQ 300MG CARBONATE/5ML/	/N70755/001/
			/MAY/21./1986/

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

ALOMIDE

+ ALCON	EQ 0.1% BASE	N20191 001
		SEP 23, 1993

LORATADINE

TABLET; ORAL
CLARITIN
+ SCHERING

10MG

N19658 001
APR 12, 1993

LORAZEPAM

TABLET; ORAL
LORAZEPAM

/AB/ /PAR/

/0.5MG/

/N70675/001/
/DEC/01,1986/

/AB/

/1MG/

/N70676/001/
/DEC/01,1986/

/AB/

/2MG/

/N70677/001/
/DEC/01,1986/

Q PAR

0.5MG

N70675 001
DEC 01, 1986

Q

1MG

N70676 001
DEC 01, 1986

Q

2MG

N70677 001
DEC 01, 1986MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLOX
+ HICKAM
/STERLING/

EQ 85MG BASE/GM
/EQ/85MG/BASE/GM/

N16763 001
/N16763/001/

MANGANESE SULFATE

INJECTABLE; INJECTION
MANGANESE SULFATE
FUJISAWA

EQ 0.1MG MANGANESE/ML

N19228 001
MAY 05, 1987
/N19228/001/
/MAY/05,1987/

/LYPHOMED/

/EQ/0.1MG/MANGANESE/ML/

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER

AP

MCGAW

10GM/100ML

N20006 002
JUL 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP

MCGAW

15GM/100ML

N20006 003
JUL 26, 1993

MANNITOL

INJECTABLE; INJECTION

MANNITOL 20% IN PLASTIC CONTAINER

AP

MCGAW

20GM/100ML

N20006 004
JUL 26, 1993

MANNITOL 5% IN PLASTIC CONTAINER

AP

MCGAW

5GM/100ML

N20006 001
JUL 26, 1993

MASOPROCOL

CREAM; TOPICAL

ACTINEX

+ BLOCK DRUG

10%

N19940 001
SEP 04, 1992

/:/CHEMEX/

/10%/

/N19940/001/
/SEP/04,1992/

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

+ BRISTOL MYERS SQUIBB 40MG/ML

N20264 001
SEP 10, 1993

MENADIOL SODIUM DIPHOSPHATE

/INJECTABLE; INJECTION/

/SYNKAYVITE/

/ROCHE/

/5MG/ML/

/10MG/ML/

/37.5MG/ML/

/N03718/004/

/N03718/006/

/N03718/008/

Q ROCHE

5MG/ML

N03718 004

Q

10MG/ML

N03718 006

Q

37.5MG/ML

N03718 008

/TABLET; ORAL/

/SYNKAYVITE/

/ROCHE/

Q ROCHE

/5MG/

5MG

/N03718/010/

N03718 010

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL

AP	ASTRA	10MG/ML	N81002 001 JUL 30, 1993
/AP/		/25MG/ML/	/N89781/001/ MAR/31/1989/
/AP/		/50MG/ML/	/N89782/001/ MAR/31/1989/
/AP/		/50MG/ML/	/N89783/001/ MAR/31/1989/
/AP/		/75MG/ML/	/N89785/001/ MAR/31/1989/
/AP/		/100MG/ML/	/N89786/001/ MAR/31/1989/
/AP/		/100MG/ML/	/N89787/001/ MAR/31/1989/
	Q	25MG/ML	N89781 001 MAR 31, 1989
	Q	50MG/ML	N89782 001 MAR 31, 1989
	Q	50MG/ML	N89783 001 MAR 31, 1989
	Q	75MG/ML	N89785 001 MAR 31, 1989
	Q	100MG/ML	N89786 001 MAR 31, 1989
	Q	100MG/ML	N89787 001 MAR 31, 1989
AP	INTL MEDICATION	10MG/ML	N81309 001 AUG 30, 1993

TABLET; ORAL

MEPERIDINE HCL

AA	HALSEY	50MG	N80448 001
AA		100MG	N80448 002
/AA/	/PETHADOL/		
/AA/	/HALSEY/	/50MG/	/N80448/001/
/AA/		/100MG/	/N80448/002/

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

/AA/	/LEE LABS/	/400MG/	/N89538/001/ NOV/25/1987/
	Q LEE LABS	400MG	N89538 001 NOV 25, 1987
/S/	/PHARMAFAIR/	/400MG/	/N84153/001/
	Q PHARMERAL	400MG	N84153 001

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

PENTASA

+ MARION MERRELL DOW 250MG

N20049 001
MAY 10, 1993MESTRANOL; NORETHINDRONE

/TABLET;/ORAL-20/

/NORINYL/

/SYNTEX/

Q SYNTEX

/0.1MG;2MG/

0.1MG;2MG

/N13625/004/

N13625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

AB	ROBERTS	0.05MG;1MG	
/AB/	/SCHIAPPARELLI/SEARLE/	/0.05MG;1MG/	

N71539 001
APR 12, 1988
/N71539/001/
/APR/12/1988/

TABLET; ORAL-28

NORETHIN 1/50M-28

AB	ROBERTS	0.05MG;1MG	
/AB/	/SCHIAPPARELLI/SEARLE/	/0.05MG;1MG/	

N71540 001
APR 12, 1988
/N71540/001/
/APR/12/1988/MESTRANOL; NORETHYNODREL

/TABLET;/ORAL/

/ENDVID/

/S/SEARLE/

/0.15MG;0.85MG/

/5.075MG;5MG/

Q SEARLE

0.075MG;5MG

Q

0.15MG;9.85MG

/N10976/005/
/N10976/008/
N10976 008
N10976 005METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

Q PENNEX PHARMS 5%

/AN/ /PHARM/BASICS/ /52/

N72190 001
JUN 07, 1988
/N72190/001/
/JUN/07/1988/

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

AA PENNEX PHARMS 10MG/5ML
/AA/ /PHARM/BASICS/ /10MG/5ML/

N71656 001
OCT 13, 1987
/N71656/001/
/OCT/13/1987/

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

AP FUJISAWA EQ 10MG BASE/ML
AP EQ 10MG BASE/ML
/AP/ /LYPHOMED/ /EQ 10MG BASE/ML/
/AP/ /EQ 10MG BASE/ML/

N80431 001
N80722 001
/N80431/001/
/N80722/001/

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE

AA MALLINCKRODT 5MG
AA 10MG

N40050 001
APR 15, 1993
N40050 002
APR 15, 1993

TABLET, DISPERSIBLE; ORAL

METHADONE HCL

AA LILLY 40MG
AA MALLINCKRODT 40MG

N17058 001
N74184 001
APR 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPHETAMINE

/AA/ /LEMMON/ /10MG/
3 LEMMON 10MG

/N83889/001/
N83889 001

METHAMPHETAMINE HCL

/AA/ /LEMMON/ /5MG/
3 LEMMON 5MG
/AA/ /REXAR/ /10MG/
REXAR 10MG

/N86359/001/
N86359 001
/N84931/002/
N84931 002

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

ROBERTS 50MG
/SCHIAPPARELLI/SEARLE/50MG/

N07390 001
/N07390/001/

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB COPLEY 25MG
AB 50MG
AB GENEVA 25MG
AB 50MG

N40001 001
JUN 30, 1993
N40001 002
JUN 30, 1993
N40036 001
JUN 30, 1993
N40036 002
JUN 30, 1993

NEPTAZANE

AB LEDERLE 25MG
AB + 50MG

N11721 002
NOV 25, 1991
N11721 001

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHICILLIN

+ APOTHECON EQ 900MG BASE/VIAL N61449 001
+ EQ 3.6GM BASE/VIAL N61449 002
+ EQ 5.4GM BASE/VIAL N61449 003
/BRISTOL/ /EQ/900MG/BASE/VIAL/ /N61449/001/
/EQ/3.6GM/BASE/VIAL/ /N61449/002/
/EQ/5.4GM/BASE/VIAL/ /N61449/003/

METHOCARBAMOL

TABLET; ORAL

DELANIN

/AA/ /FERNDAL/ /500MG/
3 FERNDAL 500MG

/N85454/001/
N85454 001

METHOCARBAMOL

AA NYLOS TRADING 750MG
/3/ PHARMAFAIR/ /500MG/
/2/ /750MG/
3 PHARMERAL 500MG
3 750MG

N85033 001
/N84231/002/
/N84471/001/
N84231 002
N84471 001

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

/AA/ /PIONEER/PHARMS/ /500MG/

/AA/ /750MG/

a PIONEER PHARMS 500MG

a 750MG

> DLT > /AA/ /SOLVAY/ /500MG/

> DLT > /AA/ /750MG/

> ADD > a SOLVAY 500MG

> ADD > a 750MG

/AA/ /TABLICAPS/ /750MG/

/AA/ /UPSHER/SMITH/ /500MG/

/AA/ /750MG/

a UPSHER SMITH 500MG

a 750MG

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

/AP/ /AKORN/ /EQ 25MG BASE/ML/

/AP/ /LYPHOMED/ /EQ 25MG BASE/ML/

a LYPHOMED EQ 25MG BASE/ML

AP NORBROOK EQ 25MG BASE/ML

METHOXYFLURANE

/SOLUTION; INHALATION/

/PENTHRANE/

/ABBOTT/ /99.9%/

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

/AP/ /LYPHOMED/ /50MG/ML/

a LYPHOMED 50MG/ML

/N88731/001/

/DEC/13,/1985/

/N89082/001/

/DEC/13,/1985/

N88731 001

DEC 13, 1985

N89082 001

DEC 13, 1985

/N84448/001/

/N84449/001/

N84448 001

N84449 001

/N85033/001/

/N87453/001/

/N87454/001/

N87453 001

N87454 001

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

> DLT > /B*/ /CHELSEA/ /4MG/

> DLT > a CHELSEA 4MG

> ADD > a CHELSEA 4MG

> ADD > a CHELSEA 4MG

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

/M-PREDROL/

/BP/ /BEL MAR/ /40MG/ML/

/BP/ /80MG/ML/

a BEL MAR 40MG/ML

a 80MG/ML

OINTMENT; TOPICAL

MEDROL ACETATE

/UPJOHN/ /1%/

a UPJOHN 1%

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

/AP/ /ABBOTT/ /EQ 1GM BASE/VIAL/

a ABBOTT EQ 1GM BASE/VIAL

METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/ /LYPHOMED/ /EQ 40MG BASE/VIAL/

/AP/ /EQ 125MG BASE/VIAL/

/AP/ /EQ 500MG BASE/VIAL/

/AP/ /EQ 1GM BASE/VIAL/

a LYPHOMED EQ 40MG BASE/VIAL

a EQ 125MG BASE/VIAL

a EQ 500MG BASE/VIAL

a EQ 1GM BASE/VIAL

/N86161/001/

/FEB/09,/1982/

N86161 001

FEB 09, 1982

/N86666/001/

/N87135/001/

N86666 001

N87135 001

/N12421/002/

N12421 002

/N89576/001/

/FEB/22,/1991/

N89576 001

FEB 22, 1991

/N89143/001/

/MAR/28,/1986/

/N89144/001/

/MAR/28,/1986/

/N89187/001/

/MAR/28,/1986/

/N89189/001/

/MAR/28,/1986/

N89143 001

MAR 28, 1986

N89144 001

MAR 28, 1986

N89187 001

MAR 28, 1986

N89189 001

MAR 28, 1986

/N70652/001/

/JUN/03,/1986/

N70652 001

JUN 03, 1986

METHYLTESTOSTERONE

<u>CAPSULE; ORAL</u>			
<u>/METHYLTESTOSTERONE/</u>			
<u>/BP/</u>	<u>/HEATHER/</u>	<u>/10MG/</u>	<u>/N84967/001/</u>
	Q HEATHER	10MG	N84967 001
<u>TESTRED</u>			
<u>/BP/</u>	<u>/ICN/</u>	<u>/10MG/</u>	<u>/N83976/001/</u>
	BP + ICN	10MG	N83976 001
<u>TABLET; BUCCAL</u>			
<u>/ANDRODIP/</u>			
	<u>/ICN/</u>	<u>/5MG/</u>	<u>/N87222/001/</u>
	Q ICN	5MG	N87222 001
<u>TABLET; ORAL</u>			
<u>METHYLTESTOSTERONE</u>			
<u>/BP/</u>	<u>/INWOOD/</u>	<u>/10MG/</u>	<u>/N80839/001/</u>
<u>/BP/</u>		<u>/25MG/</u>	<u>/N80973/001/</u>
	Q INWOOD	10MG	N80839 001
	Q	25MG	N80973 001

METHYPRYLON

<u>/CAPSULE; ORAL/</u>			
<u>/NOLUDAR/</u>			
	<u>/ROCHE/</u>	<u>/300MG/</u>	<u>/N09660/008/</u>
	Q ROCHE	300MG	N09660 008
<u>/TABLET; ORAL/</u>			
<u>/NOLUDAR/</u>			
	<u>/ROCHE/</u>	<u>/200MG/</u>	<u>/N09660/004/</u>
	Q ROCHE	200MG	N09660 004

METOCLOPRAMIDE HYDROCHLORIDE

<u>INJECTABLE; INJECTION</u>			
<u>METOCLOPRAMIDE HCL</u>			
<u>/AB/</u>	<u>/ARORN/</u>	<u>/EQ 10MG BASE/2ML/</u>	<u>/N70892/001/</u>
			<u>/AUG/26./1988/</u>
<u>/AB/</u>	<u>/FUJISAWA/</u>	<u>/EQ 10MG BASE/2ML/</u>	<u>/N70293/001/</u>
			<u>/JAN/24./1986/</u>
	Q FUJISAWA	EQ 10MG BASE/2ML	N70293 001
	Q NORBROOK	EQ 10MG BASE/2ML	JAN 24, 1986
			N70892 001
			AUG 26, 1988

METOCLOPRAMIDE HYDROCHLORIDE

<u>SOLUTION; ORAL</u>			
<u>METOCLOPRAMIDE HCL</u>			
<u>AA</u>	<u>LEMMON</u>	<u>EQ 5MG BASE/5ML</u>	<u>N71315 001</u>
			JUN 30, 1993
<u>AA</u>	<u>LIQUIPHARM</u>	<u>EQ 5MG BASE/5ML</u>	<u>N71402 001</u>
			JUN 25, 1993
<u>AA</u>	<u>PENNEX PHARMS</u>	<u>EQ 5MG BASE/5ML</u>	<u>N70949 001</u>
			MAR 06, 1987
<u>/AA/</u>	<u>/PHARM/BASICS/</u>	<u>/EQ 5MG BASE/5ML/</u>	<u>/N70949/001/</u>
			<u>/MAR/06./1987/</u>
<u>TABLET; ORAL</u>			
<u>METOCLOPRAMIDE HCL</u>			
<u>AB</u>	<u>BIOCRAFT</u>	<u>EQ 5MG BASE</u>	<u>N72801 001</u>
			JUN 15, 1993
<u>AB</u>	<u>MUTUAL PHARM</u>	<u>EQ 10MG BASE</u>	<u>N71536 001</u>
			APR 28, 1993
<u>/AB/</u>	<u>/PAR/</u>	<u>/EQ 10MG BASE/</u>	<u>/N70342/001/</u>
			<u>/MAR/25./1986/</u>
	Q PAR	EQ 10MG BASE	N70342 001
			MAR 25, 1986

METOPROLOL TARTRATE

<u>INJECTABLE; INJECTION</u>			
<u>LOPRESSOR</u>			
<u>> ADD ></u>	<u>AP</u>	<u>+ GEIGY</u>	<u>1MG/ML</u>
<u>> ADD ></u>			<u>N18704 001</u>
			MAR 30, 1984
<u>METOPROLOL TARTRATE</u>			
<u>> ADD ></u>	<u>AP</u>	<u>STERIS</u>	<u>1MG/ML</u>
<u>> ADD ></u>			<u>N74032 001</u>
<u>> ADD ></u>	<u>AP</u>	<u>STERLING WINTHROP</u>	<u>1MG/ML</u>
<u>> ADD ></u>			DEC 21, 1993
			N74133 001
			DEC 21, 1993
<u>TABLET; ORAL</u>			
<u>LOPRESSOR</u>			
<u>> ADD ></u>	<u>AB</u>	<u>+ GEIGY</u>	<u>50MG</u>
<u>> ADD ></u>	<u>AB</u>	<u>+</u>	<u>100MG</u>
<u>> ADD ></u>			<u>N17963 001</u>
<u>> ADD ></u>	<u>AB</u>	<u>MUTUAL PHARM</u>	<u>50MG</u>
<u>> ADD ></u>			<u>N73653 001</u>
<u>> ADD ></u>			DEC 21, 1993
<u>> ADD ></u>	<u>AB</u>		<u>100MG</u>
<u>> ADD ></u>			<u>N73654 001</u>
<u>> ADD ></u>			DEC 21, 1993
<u>> ADD ></u>	<u>AB</u>	<u>MYLAN</u>	<u>50MG</u>
<u>> ADD ></u>			<u>N73666 001</u>
<u>> ADD ></u>			DEC 21, 1993
<u>> ADD ></u>	<u>AB</u>		<u>100MG</u>
<u>> ADD ></u>			<u>N73666 002</u>
			DEC 21, 1993

METRONIDAZOLE

<u>GEL; TOPICAL</u>			
METROGEL			
/+//CURATEK/	/0.75%/	/N19737/001/	
		/NOV/22,1988/	
+ GALDERMA	0.75%	N19737 001	
		NOV 22, 1988	
<u>TABLET; ORAL</u>			
/SABIC/			
/AB/ /SAYAGE/	/250MG/	/N70029/001/	
		/MAR/19,1988/	
/AB/	/500MG/	/N70731/001/	
		/JUN/08,1988/	
@ SAVAGE	250MG	N70029 001	
		MAR 19, 1988	
@	500MG	N70731 001	
		JUN 08, 1988	

MEZLOCILLIN SODIUM MONOHYDRATEINJECTABLE; INJECTION

<u>MEZLIN</u>			
/MILES/	/EQ/1GM/BASE/VIAL/	/N62333/001/	
@ MILES	EQ 1GM BASE/VIAL	N62333 001	
	EQ 1GM BASE/VIAL	N62372 005	
		JAN 13, 1983	
	/EQ/2GM/BASE/VIAL/	/N62333/002/	
@	EQ 2GM BASE/VIAL	N62333 002	
	/EQ/3GM/BASE/VIAL/	/N62333/003/	
@	EQ 3GM BASE/VIAL	N62333 003	
	/EQ/4GM/BASE/VIAL/	/N62333/004/	
@	EQ 4GM BASE/VIAL	N62333 004	

MICONAZOLE NITRATE

<u>CREAM; VAGINAL/</u>			
MONISTAT-7/			
/JOHNSON/RW/	/2%/	/N17739/001/	
<u>CREAM, SUPPOSITORY; TOPICAL, VAGINAL</u>			
MONISTAT DUAL-PAK			
+ JOHNSON RW	2%;200MG	N18888 002	
		OCT 17, 1988	

MICONAZOLE NITRATE

<u>LOTION; TOPICAL/</u>			
MONISTAT-DERM/			
+//JOHNSON/RW/	/2%/	/N17739/001/	
@ JOHNSON RW	2%	N17739 001	
<u>SUPPOSITORY; VAGINAL</u>			
<u>MICONAZOLE NITRATE</u>			
AB	ABLE	200MG	N73508 001
			NOV 19, 1993
<u>MONISTAT 3</u>			
AB	+ JOHNSON RW	200MG	N18888 001
			AUG 15, 1984
<u>MONISTAT-7/</u>			
/JOHNSON/RW/	/100MG/	/N18520/001/	
		/MAR/15,1982/	

MILRINONE LACTATEINJECTABLE; INJECTION

<u>MILRINONE LACTATE</u>			
+ STERLING	EQ 1MG BASE/ML	N19436 001	
		DEC 31, 1987	
/2/	/EQ/1MG/BASE/ML/	/N19436/001/	
		/DEC/31,1987/	

MINOCYCLINE HYDROCHLORIDEINJECTABLE; INJECTION

<u>MINOCIN</u>			
/LEDERLE/	/EQ/100MG/BASE/VIAL/	/N62139/001/	
@ LEDERLE	EQ 100MG BASE/VIAL	N62139 001	

> DLT >

> ADD >

MITOXANTRONE HYDROCHLORIDEINJECTABLE; INJECTION

<u>NOVANTRONE</u>			
+ IMMUNEX	EQ 2MG BASE/ML	N19297 001	
		DEC 23, 1987	
/LEDERLE/	/EQ/2MG/BASE/ML/	/N19297/001/	
		/DEC/23,1987/	

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
/DUPONT/

/200MG/

/250MG/

/300MG/

ROBERTS

200MG

250MG

300MG

/N19753/001/

/JUN/19,1990/

/N19753/002/

/JUN/19,1990/

/N19753/003/

/JUN/19,1990/

N19753 001

JUN 19, 1990

N19753 002

JUN 19, 1990

N19753 003

JUN 19, 1990

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN
+ PURDUE FREDERICK

200MG

N19516 005

NOV 08, 1993

NABILONE

/CAPSULE; ORAL/
/CESAMET/
/LILLY/

/1MG/

LILLY

1MG

/N18677/001/

/DEC/26,1985/

N18677 001

DEC 26, 1985

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCIL

AP APOTHECON

EQ 500MG BASE/VIAL

N62527 001

AUG 02, 1984

AP

EQ 1GM BASE/VIAL

N62527 002

AUG 02, 1984

AP

EQ 1GM BASE/VIAL

N62732 001

DEC 23, 1986

AP

EQ 2GM BASE/VIAL

N62527 003

AUG 02, 1984

AP

EQ 2GM BASE/VIAL

N62732 002

DEC 23, 1986

AP

EQ 10GM BASE/VIAL

N62527 004

AUG 02, 1984

/AP/ /BRISTOL/

/EQ 500MG BASE/VIAL/

/N62527/001/

/AUG/02,1984/

/AP/

/EQ 1GM BASE/VIAL/

/N62527/002/

/AUG/02,1984/

/AP/

/EQ 1GM BASE/VIAL/

/N62732/001/

/DEC/23,1986/

/AP/

/EQ 2GM BASE/VIAL/

/N62527/003/

/AUG/02,1984/

/AP/

/EQ 2GM BASE/VIAL/

/N62732/002/

/DEC/23,1986/

/AP/

/EQ 10GM BASE/VIAL/

/N62527/004/

/AUG/02,1984/

/POWDER FOR RECONSTITUTION; ORAL/

/UNIPEN/

/WYETH AYERST/

WYETH AYERST

/EQ 250MG BASE/5ML/

EQ 250MG BASE/5ML

/N50199/001/

N50199 001

NADOLOL

TABLET; ORAL
CORCARD

AB SQUIBB

20MG

N18063 005

OCT 28, 1986

AB

40MG

N18063 001

AB

40MG

N18064 001

AB

80MG

N18063 002

AB

80MG

N18064 002

NADOLOL

AB MYLAN

20MG

N74172 001

OCT 31, 1993

AB

40MG

N74172 002

OCT 31, 1993

AB

80MG

N74172 003

OCT 31, 1993

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

<u>NALBUPHINE HCL</u>	
/AP/	/ASTRA/
/AP/	/10MG/ML/
/AP/	/10MG/ML/
/AP/	/20MG/ML/
/AP/	/20MG/ML/
Q	ASTRA 10MG/ML
Q	10MG/ML
Q	20MG/ML
Q	20MG/ML
NALBUPHINE HYDROCHLORIDE	
ABBOTT	1.5MG/ML

/N72071/001/
 /APR/10,/1989/
 /N72072/001/
 /APR/10,/1989/
 /N72074/001/
 /APR/10,/1989/
 /N72075/001/
 /APR/10,/1989/
 N72071 001
 APR 10, 1989
 N72072 001
 APR 10, 1989
 N72074 001
 APR 10, 1989
 N72075 001
 APR 10, 1989
 N20200 001
 MAR 12, 1993

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

<u>NALOXONE HCL</u>	
/AP/	/ASTRA/
/AP/	/0.02MG/ML/
/AP/	/0.02MG/ML/
/AP/	/0.02MG/ML/
/AP/	/0.02MG/ML/
/AP/	/0.02MG/ML/
/AP/	/0.4MG/ML/
/AP/	/0.4MG/ML/
/AP/	/0.4MG/ML/
/AP/	/0.4MG/ML/
/AP/	/1MG/ML/
/AP/	/1MG/ML/
Q	ASTRA 0.02MG/ML
Q	0.02MG/ML
Q	0.02MG/ML
Q	0.02MG/ML
Q	0.4MG/ML
Q	0.4MG/ML
Q	0.4MG/ML
Q	0.4MG/ML
Q	1MG/ML
Q	1MG/ML
/AP/	/LYPHOMED/
Q	LYPHOMED 0.02MG/ML

/N72082/001/
 /APR/11,/1989/
 /N72083/001/
 /APR/11,/1989/
 /N72084/001/
 /APR/11,/1989/
 /N72085/001/
 /APR/11,/1989/
 /N72087/001/
 /APR/11,/1989/
 /N72088/001/
 /APR/11,/1989/
 /N72089/001/
 /APR/11,/1989/
 /N72090/001/
 /APR/11,/1989/
 /N72092/001/
 /APR/11,/1989/
 /N72093/001/
 /APR/11,/1989/
 /N70661/001/
 /NOV/17,/1986/
 N70661 001
 NOV 17, 1986

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALCAN
 /AP/ /DUPONT/ /0.4MG/ML/
 /AP/ /1MG/ML/
 /AP/ /1MG/ML/
 @ DUPONT 0.4MG/ML
 @ 1MG/ML
 @ 1MG/ML

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE
 /AD/ /LYPHOMED/ /100MG/ML/
 /AD/ /200MG/ML/
 @ LYPHOMED 100MG/ML
 @ 200MG/ML

NAPROXEN

TABLET; ORAL

NAPROXEN
 > ADD > AB COPLEY 250MG
 > ADD >
 > ADD > AB 375MG
 > ADD >
 > ADD > AB 500MG
 > ADD >
 > ADD > AB GENEVA 250MG
 > ADD >
 > ADD > AB 375MG
 > ADD >
 > ADD > AB 500MG
 > ADD >

NAPROXEN

TABLET; ORAL

NAPROXEN

LEDERLE 250MG
 > ADD > AB
 > ADD >
 > ADD > AB 375MG
 > ADD >
 > ADD > AB 500MG
 > ADD >
 > ADD > AB LEMMON 250MG
 > ADD >
 > ADD > AB 375MG
 > ADD >
 > ADD > AB 500MG
 > ADD >
 > ADD > AB MYLAN 250MG
 > ADD >
 > ADD > AB 375MG
 > ADD >
 > ADD > AB 500MG
 > ADD >
 > ADD > AB NOVOPHARM 250MG
 > ADD >
 > ADD > AB 375MG
 > ADD >
 > ADD > AB 500MG
 > ADD >
 > ADD > AB PUREPAC 250MG
 > ADD >
 > ADD > AB 375MG
 > ADD >
 > ADD > AB 500MG
 > ADD >

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

SYNTEX EQ 250MG BASE
 > ADD > AB /275MG/
 > DLT >
 > ADD > AB
 > ADD >
 > ADD > AB
 > DLT > /+/
 > DLT > /550MG/

NAPROXEN SODIUM

DANBURY PHARMA

EQ 250MG BASE
 > ADD > AB
 > ADD >
 > ADD > AB EQ 500MG BASE
 > ADD >

N74105 001
 DEC 21, 1993
 N74105 002
 DEC 21, 1993
 N74105 003
 DEC 21, 1993
 N74201 001
 DEC 21, 1993
 N74201 002
 DEC 21, 1993
 N74201 003
 DEC 21, 1993
 N74121 001
 DEC 21, 1993
 N74121 002
 DEC 21, 1993
 N74121 003
 DEC 21, 1993
 N74129 001
 DEC 21, 1993
 N74129 002
 DEC 21, 1993
 N74129 003
 DEC 21, 1993
 N74263 001
 DEC 21, 1993
 N74263 002
 DEC 21, 1993
 N74263 003
 DEC 21, 1993

N18164 001
 /N18164/001/
 N18164 003
 SEP 30, 1987
 /N18164/003/
 /SEP/30/1987/

N74195 001
 DEC 21, 1993
 N74195 002
 DEC 21, 1993

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

> ADD > AB	GENEVA	EQ 250MG BASE	N74162 001
> ADD >			DEC 21, 1993
> ADD > AB		EQ 500MG BASE	N74162 002
> ADD >			DEC 21, 1993
> ADD > AB	HAMILTON PHARM	EQ 250MG BASE	N74106 001
> ADD >			AUG 31, 1993
> DLT > /AB/		/215MG/	/N74106/001/
> DLT >			/AUG/31,1993/
> ADD > AB		EQ 500MG BASE	N74106 002
> ADD >			AUG 31, 1993
> DLT > /AB/		/550MG/	/N74106/002/
> DLT >			/AUG/31,1993/
> ADD > AB	LEMMON	EQ 250MG BASE	N74198 001
> ADD >			DEC 21, 1993
> ADD > AB		EQ 500MG BASE	N74198 002
> ADD >			DEC 21, 1993
> ADD > AB	NOVOPHARM	EQ 250MG BASE	N74142 001
> ADD >			DEC 21, 1993
> ADD > AB		EQ 500MG BASE	N74142 002
> ADD >			DEC 21, 1993
> ADD > AB	ROXANE	EQ 250MG BASE	N74257 001
> ADD >			DEC 21, 1993
> ADD > AB		EQ 500MG BASE	N74257 002
> ADD >			DEC 21, 1993

NEOMYCIN SULFATE

TABLET; ORAL

> DLT >	/MYCIPRADIN/		
> DLT > /AA/	/UPJOHN/	/EQ 350MG BASE/	/N60520/001/
> ADD >	@ UPJOHN	EQ 350MG BASE	N60520 001

NEOMYCIN SULFATE

/AA/	/EON LABS/	/EQ 350MG BASE/	/N61586/001/
	@ EON LABS	EQ 350MG BASE	N61586 001

NIACIN

/CAPSULE; ORAL/
/WAMPOCAP/
/WALLACE/
@ WALLACE

/500MG/	/N11073/003/
500MG	N11073 003

NIACIN

TABLET; ORAL

NIACIN

/AA/	/ZENITH/	/500MG/	/N83180/001/
	@ ZENITH	500MG	N83180 001

NICARDIPINE HYDROCHLORIDEINJECTABLE; INJECTION
CARDENE

> DLT >	/DUPONT/MERCK/	/2.5MG/ML/	/N19734/001/
> DLT >			/JAN/30,1992/
> ADD >	SYNTEX	2.5MG/ML	N19734 001
> ADD >			JAN 30, 1992

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	FLEMINGTON	10MG	N72781 001
			JUL 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

BC	MILES	30MG	N20198 001
			APR 21, 1993
BC		60MG	N20198 002
			APR 21, 1993
BC		90MG	N20198 003
			APR 21, 1993

PROCARDIA XL

BC +	PFIZER	30MG	N19684 001
			SEP 06, 1989
BC +		60MG	N19684 002
			SEP 06, 1989
BC +		90MG	N19684 003
			SEP 06, 1989
/+/		/30MG/	/N19684/001/
/+/		/60MG/	/SEP/06,1989/
/+/		/90MG/	/N19684/002/
			/SEP/06,1989/
			/N19684/003/
			/SEP/06,1989/

NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

/AB/	/ZENITH/	/50MG/	/N80078/002/
/AB/		/100MG/	/N80078/001/
	2 ZENITH	50MG	N80078 002
	2	100MG	N80078 001

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

+ P AND G 75MG;25MG

N20064 001
DEC 24, 1991

/CAPSULE; EXTENDED RELEASE; ORAL/
/MACROBID/
/+/P AND G/

/75MG;25MG/

/N20064/001/
/DEC 24, 1991/NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

AB	ZENITH	50MG	N73671 001
			JAN 28, 1993
AB		100MG	N73652 001
			JAN 28, 1993

NITROGLYCERIN

INJECTABLE; INJECTION

NITRO-BID

/MARION/MERRELL/DOW/ /10MG/ML/

2 MARION MERRELL DOW 10MG/ML

/N71159/001/
/FEB 28, 1990/
N71159 001
FEB 28, 1990NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HCL

AB	MYLAN	EQ 10MG BASE	N74234 001
			JUL 26, 1993
AB		EQ 25MG BASE	N74234 002
			JUL 26, 1993
AB		EQ 50MG BASE	N74234 003
			JUL 26, 1993
AB		EQ 75MG BASE	N74234 004
			JUL 26, 1993

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	BARRE	100,000 UNITS/GM	N62949 001
			JUN 13, 1988
/AT/	/NASKA/	/100,000 UNITS/GM/	/N62949/001/
			/JUN 13, 1988/
AT	TARO	100,000 UNITS/GM	N64022 001
			JAN 29, 1993

OINTMENT; TOPICAL

NYSTATIN

AT	BARRE	100,000 UNITS/GM	N62840 001
			NOV 13, 1987
/AT/	/NASKA/	/100,000 UNITS/GM/	/N62840/001/
			/NOV 13, 1987/

POWDER; ORAL

BARSTATIN 100

/AA/	/BARLAN/	/100%/	/N62489/001/
			/APR 27, 1988/
	2 BARLAN	100%	N62489 001
			APR 27, 1988

SUSPENSION; ORAL

MYCOSTATIN

AA	APOTHECON	100,000 UNITS/ML	N61533 001
/AA/	/BRISTOL/Myers/SQUIBB/	/100,000 UNITS/ML/	/N61533/001/
AA	BARRE	100,000 UNITS/ML	N62571 001
			OCT 29, 1985
/AA/	/NASKA/	/100,000 UNITS/ML/	/N62571/001/
			/OCT 29, 1985/

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

AA	PENNEX PHARMS	100,000 UNITS/ML	N62512 001
			OCT 29, 1984
a		100,000 UNITS/ML	N62835 001
			NOV 19, 1987
/AA/	/PHARM/BASICS/	/100,000 UNITS/ML/	/N62512/001/
			/OCT/29/1984/
/AA/		/100,000 UNITS/ML/	/N62835/001/
			/NOV/19/1987/
/AA/	/PHARMADERM/	/100,000 UNITS/ML/	/N62518/001/
			/JUL/06/1984/
a	PHARMADERM	100,000 UNITS/ML	N62518 001
			JUL 06, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	BARRE	100,000 UNITS/GM;0.1%	N63010 001
			DEC 20, 1988
/AT/	/NASKA/	/100,000 UNITS/GM;0.12/	/N63010/001/
			/DEC/20/1988/
/AT/	/PHARMADERM/	/100,000 UNITS/GM;0.12/	/N62596/001/
			/OCT/08/1985/
a	PHARMADERM	100,000 UNITS/GM;0.1%	N62596 001
			OCT 08, 1985

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	TARO	100,000 UNITS/GM;0.1%	N63305 001
			MAR 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

SANDOSTATIN

/SANDOZ/	/EQ/500UM/BASE/ML/	/N19667/001/
		/OCT/21/1988/
SANDOZ	EQ 0.05MG BASE/ML	N19667 001
		OCT 21, 1988
/EQ/100UM/BASE/ML/		/N19667/002/
		/OCT/21/1988/
	EQ 0.1MG BASE/ML	N19667 002
		OCT 21, 1988
	EQ 0.2MG BASE/ML	N19667 004
		JUN 12, 1991
/EQ/500UM/BASE/ML/		/N19667/003/
		/OCT/21/1988/
	EQ 0.5MG BASE/ML	N19667 003
		OCT 21, 1988
	EQ 1MG BASE/ML	N19667 005
		JUN 12, 1991

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

+ ALLERGAN	0.3%	N19921 001
		JUL 30, 1993

OXACILLIN SODIUM

CAPSULE; ORAL

PROSTAPHLIN

AB	APOTHECON	EQ 250MG BASE	N61450 002
> ADD >	AB +	EQ 500MG BASE	N61450 001
/AB/	/BRISTOL/	/EQ 250MG BASE/	/N61450/002/
> DLT >	/AB//+/	/EQ 500MG BASE/	/N50118/002/
/AB/		/EQ 500MG BASE/	/N61450/001/
> ADD >	a BRISTOL	EQ 500MG BASE	N50118 002

POWDER FOR RECONSTITUTION; ORAL

PROSTAPHLIN

AA	APOTHECON	EQ 250MG BASE/5ML	N61457 001
> DLT >	/AA/	/EQ 250MG BASE/5ML/	/N50194/001/
/AA/	/BRISTOL/	/EQ 250MG BASE/5ML/	/N61457/001/
> ADD >	a BRISTOL	EQ 250MG BASE/5ML	N50194 001

OXANDROLONE

TABLET; ORAL			
OXANDRIN			
> ADD >	+ BIO TECH GENERAL	2.5MG	N13718 001
> DLT >	/+//CIBEX/	/2.5MG/	/N13718/001/

OXPRENOLOL HYDROCHLORIDE

/CAPSULE; ORAL/			
/TRASICOR/			
/+//CIBA/			
		/160MG/	/N18166/004/
		/20MG/	/DEC/28./1983/
		/40MG/	/N18166/001/
		/80MG/	/DEC/28./1983/
		/160MG/	/N18166/002/
			/DEC/28./1983/
			/N18166/003/
			/DEC/28./1983/
Q CIBA	20MG		N18166 001
			DEC 28, 1983
Q	40MG		N18166 002
			DEC 28, 1983
Q	80MG		N18166 003
			DEC 28, 1983
Q	160MG		N18166 004
			DEC 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL			
<u>CHOLEDYL</u>			
/AA/	/PARKE/DAVIS/	/100MG/5ML/	/N09268/012/
			/NOV/27./1984/
	PARKE DAVIS	100MG/5ML	N09268 012
			NOV 27, 1984
/OXTRIPHYLLINE/			
/AA/	/PHARM/BASICS/	/100MG/5ML/	/N88243/001/
			/DEC/05./1983/
Q PENNEX PHARMS	100MG/5ML		N88243 001
			DEC 05, 1983
SYRUP; ORAL			
<u>CHOLEDYL</u>			
/AA/	/PARKE/DAVIS/	/50MG/5ML/	/N09268/011/
	PARKE DAVIS	50MG/5ML	N09268 011

OXTRIPHYLLINE

SYRUP; ORAL			
/OXTRIPHYLLINE PEDIATRIC/			
/AA/	/PHARM/BASICS/	/50MG/5ML/	/N88242/001/
			/DEC/05./1983/
Q PENNEX PHARMS	50MG/5ML		N88242 001
			DEC 05, 1983

OXYPHENBUTAZONE

TABLET; ORAL			
TANDEARIL			
Q GEIGY	100MG		N12542 004
			SEP 03, 1982
/Q/RHONE/POULENC/ROPER/	/100MG/		/N12542/004/
			/SEP/03./1982/

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION			
AREDIA			
+ CIBA GEIGY	60MG/VIAL		N20036 003
			MAY 06, 1993
+	90MG/VIAL		N20036 004
			MAY 06, 1993

PANCURONIUM BROMIDE

INJECTABLE; INJECTION			
<u>PANCURONIUM BROMIDE</u>			
/AP/	/ASTRA/	/2MG/ML/	/N72212/001/
			/MAR/31./1988/
Q ASTRA	2MG/ML		N72212 001
			MAR 31, 1988

PARAMETHASONE ACETATE

TABLET; ORAL			
HALDRONE			
/+//LILLY/		/2MG/	/N12772/006/
		/1MG/	/N12772/005/
Q LILLY	1MG		N12772 005
Q	2MG		N12772 006

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAXIL

/+/SMITHKLINE/BEECHAM/ EQ 10MG/BASE/

/N20031/001/

/DEC/29/1992/

/+/ EQ 50MG/BASE/

/N20031/004/

/DEC/29/1992/

a SMITHKLINE BEECHAM EQ 10MG BASE

N20031 001

DEC 29, 1992

EQ 40MG/BASE/

/N20031/005/

/DEC/29/1992/

a EQ 40MG BASE

N20031 005

DEC 29, 1992

a EQ 50MG BASE

N20031 004

DEC 29, 1992

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

/+/WYETH/AYERST/

/300,000 UNITS/ML/

/N50131/001/

+ WYETH AYERST

300,000 UNITS/ML

N50141 003

a

300,000 UNITS/ML

N50131 001

/300,000 UNITS/ML/

/N50141/003/

/TABLET; ORAL/

/BICILLIN/

/+/WYETH/AYERST/

/200,000 UNITS/

/N50128/001/

a WYETH AYERST

200,000 UNITS

N50128 001

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

PENICILLIN

/AA/ /BIOCRAFT/

/200,000 UNITS/5ML/

/N60307/002/

BIOCRAFT

200,000 UNITS/5ML

N60307 002

/AA/ /PENITIDS '1200'/

/200,000 UNITS/5ML/

/N62149/001/

/SQUIBB/

200,000 UNITS/5ML

N62149 001

a APOTHECON

200,000 UNITS/5ML

N62149 001

/AA/ /PENITIDS '4000'/

/400,000 UNITS/5ML/

/N62149/002/

/SQUIBB/

400,000 UNITS/5ML

N62149 002

a APOTHECON

400,000 UNITS/5ML

N62149 002

TABLET; ORAL

PENICILLIN G POTASSIUM

a APOTHECON

250,000 UNITS

N60392 003

/AB/ /SQUIBB/

/250,000 UNITS/

/N60392/003/

PENICILLIN G POTASSIUM

TABLET; ORAL

/PENITIDS '1200'/

/AB/

/SQUIBB/

/200,000 UNITS/

/N62155/001/

a APOTHECON

200,000 UNITS

N62155 001

/AB/

/PENITIDS '1250'/

/SQUIBB/

/250,000 UNITS/

/N62155/002/

a APOTHECON

250,000 UNITS

N62155 002

/AB/

/PENITIDS '4000'/

/SQUIBB/

/400,000 UNITS/

/N60392/004/

/AB/

a APOTHECON

400,000 UNITS

N60392 004

a

400,000 UNITS

N62155 003

/AB/

/PENITIDS '8000'/

/SQUIBB/

/800,000 UNITS/

/N60392/005/

/AB/

a APOTHECON

800,000 UNITS

N60392 005

a

800,000 UNITS

N62155 004

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

/DURACILLIN A.S./

/AB/

/LILLY/

/300,000 UNITS/ML/

/N60093/001/

a LILLY

300,000 UNITS/ML

N60093 001

PENICILLIN V

/POWDER FOR RECONSTITUTION; ORAL/

/V-CILLIN/

/+/LILLY/

/125MG/0.6ML/

/N60002/001/

a LILLY

125MG/0.6ML

N60002 001

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

/VEETIDS '1250'/

/AA/

/SQUIBB/

/EQ 125MG BASE/5ML/

/N61206/001/

/AA/

a APOTHECON

EQ 125MG BASE/5ML

N61206 001

a

EQ 125MG BASE/5ML

N62153 001

/AA/

/VEETIDS '1250'/

/SQUIBB/

/EQ 250MG BASE/5ML/

/N61206/002/

/AA/

a APOTHECON

EQ 250MG BASE/5ML

N61206 002

a

EQ 250MG BASE/5ML

N62153 002

PENICILLIN V POTASSIUM

<u>TABLET; ORAL</u>			
<u>BETAPEN-VK</u>			
AB	APOTHECON	EQ 250MG BASE	N61411 001
AB		EQ 500MG BASE	N61411 002
/AB/	/BRISTOL/	/EQ 250MG BASE/	/N61411/001/
/AB/		/EQ 500MG BASE/	/N61411/002/
/AB/	/VEETIUS '450'/		
/AB/	/SQUIBB/	/EQ 250MG BASE/	/N61164/001/
/AB/		/EQ 250MG BASE/	/N62156/002/
	APOTHECON	EQ 250MG BASE	N61164 001
		EQ 250MG BASE	N62156 002
/AB/	/VEETIUS '500'/		
/AB/	/SQUIBB/	/EQ 500MG BASE/	/N61164/002/
/AB/		/EQ 500MG BASE/	/N62156/001/
	APOTHECON	EQ 500MG BASE	N61164 002
		EQ 500MG BASE	N62156 001

PENTETATE CALCIUM TRISODIUM YB-169

> DLT >	/INJECTABLE; INJECTION/		
> DLT >	/TITERBIUM YB/169/DTPA/		
> DLT >	/3M/	/2MCI/ML/	/N17518/001/
> ADD >	APOTHECON	2MCI/ML	N17518 001

PENTOBARBITAL SODIUM

<u>INJECTABLE; INJECTION</u>			
<u>PENTOBARBITAL SODIUM</u>			
/AB/	/ELKINS SINN/	/50MG/ML/	/N83270/001/
	APOTHECON	50MG/ML	N83270 001

PERFLUBRON

<u>LIQUID; ORAL</u>			
<u>IMAGENT</u>			
+	ALLIANCE PHARM	100%	N20091 001
			AUG 13, 1993

> ADD > PERINDOPRIL ERBUMINE

> ADD >	<u>TABLET; ORAL</u>		
> ADD >	ACEON		
> ADD >	+ JOHNSON RM	8MG	N20184 003
> ADD >			DEC 30, 1993
> ADD >		2MG	N20184 001
> ADD >			DEC 30, 1993
> ADD >		4MG	N20184 002
> ADD >			DEC 30, 1993

PERMETHRIN

/LOTION; TOPICAL/		
/NIX/		
/AT/; 77 BURROUGHS WELLCOME/	/12/	/N19435/001/
		MAR 31, 1986
APOTHECON	1%	N19435 001
		MAR 31, 1986

PERPHENAZINE

/TABLET; EXTENDED RELEASE; ORAL/		
/TRILAFON/		
/; SCHERING/	/8MG/	/N11361/002/
APOTHECON	8MG	N11361 002

PHENDIMETRAZINE TARTRATE

<u>CAPSULE; ORAL</u>			
/STATOBEX/			
/AB/	/LEMMON/	/35MG/	/N85507/001/
	APOTHECON	35MG	N85507 001

<u>TABLET; ORAL</u>			
/ADPHEN/			
/AA/	/FERNDAL/	/35MG/	/N83655/001/
	APOTHECON	35MG	N83655 001
/AA/	/MELFAT/	/35MG/	/N83790/002/
	APOTHECON	35MG	N83790 002
/AA/	/METRA/	/35MG/	/N83754/001/
	FOREST PHARMS	35MG	N83754 001

<u>PHENDIMETRAZINE TARTRATE</u>			
/AA/	/ANABOLIC/	/35MG/	/N86020/001/
	APOTHECON	35MG	N86020 001

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

/AA/ /FERNDALE/ /35MG/
 @ FERNDALE 35MG
 /AA/ /GENEVA/ /35MG/
 @ SOLVAY 35MG

PHENMETRAZINE HYDROCHLORIDE

/TABLET; EXTENDED RELEASE; ORAL/
 /PRELUDIN/
 /+ /BOEHRINGER/INGELHEIM/75MG/
 @ BOEHRINGER INGELHEIM 75MG

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPLEX-P

/AA/ /LEMMON/ /30MG/
 /OBESTIN-30/
 /AA/ /FERNDALE/ /30MG/
 @ FERNDALE 30MG

PHENTERMINE HCL

@ LEMMON 30MG
 /AA/ /PHARM/BASICS/ /30MG/
 @ PHARM BASICS 30MG
 /AA/ /ZENITH/ /30MG/
 @ ZENITH 30MG

TABLET; ORAL

/1036/
 /AA/ /SOLVAY/ /8MG/
 @ SOLVAY 8MG

PHENYL BUTAZONE

CAPSULE; ORAL

BUTAZOLIDIN

/AA/ /+ /GEIGY/ /100MG/
 @ GEIGY 100MG

PHENYL BUTAZONE

CAPSULE; ORAL

PHENYL BUTAZONE

/AB/ /BARR/ /100MG/
 + BARR 100MG
 /AB/ /CHELSEA/ /100MG/
 @ CHELSEA 100MG
 /AB/ /GENEVA/ /100MG/
 @ GENEVA 100MG

TABLET; ORAL

BUTAZOLIDIN

/AB/ /+ /GEIGY/ /100MG/
 @ GEIGY 100MG

PHENYL BUTAZONE

/AB/ /BARR/ /100MG/
 + BARR 100MG
 /AB/ /CHELSEA/ /100MG/
 @ CHELSEA 100MG
 /AB/ /DANBURY/PHARMA/ /100MG/
 @ DANBURY PHARMA 100MG
 /AB/ /GENEVA/ /100MG/
 @ GENEVA 100MG

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC PLAIN

@ PENNEX PHARMS 5MG/5ML; 6.25MG/5ML N88897 001
 JAN 04, 1985
 /AA/ /PHARM/BASICS/ /5MG/5ML; 6.25MG/5ML/ N88897 001
 /JAN/04./1985/

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-30

> DLT > /PARKE/DAVIS/ /30MG/5ML/ N88762 002
 > DLT > @ PARKE DAVIS 30MG/5ML
 > ADD >

/N86834/001/
 /SEP/15./1983/
 N86834 001
 SEP 15, 1983
 /N83993/001/
 N83993 001

/N11752/003/
 N11752 003

/N86911/001/
 /N87144/001/
 N87144 001

N86911 001
 /N88430/001/
 /MAR/27./1984/
 N88430 001
 MAR 27, 1984
 /N86329/001/
 N86329 001

/N84035/001/
 N84035 001

/N08319/009/
 N08319 009

PHENYTOIN SODIUM, PROMPTCAPSULE; ORAL
PHENYTOIN SODIUM
/3/PHARMAFAIR/
2 PHARMERAL/100MG/
100MG/N85435/001/
N85435 001PHYTONADIONEINJECTABLE; INJECTION
AQUAMEPHYTON/BP/ /MSD/
BP + MSD/10MG/ML/
10MG/ML/N12223/001/
N12223 001/BP/+//ROCHE/
BP ROCHE/10MG/ML/
10MG/ML/N11745/003/
N11745 003PINDOLOLTABLET; ORAL
PINDOLOLAB GENEVA5MG

N73608 001

AB10MG

MAR 29, 1993

N73609 001

AB

NOVOPHARM

5MG

MAR 29, 1993

N73661 001

AB10MG

OCT 31, 1993

N73661 002

AB

PUREPAC

5MG

OCT 31, 1993

N74125 001

AB10MG

APR 28, 1993

N74125 002

AB

ZENITH

5MG

APR 28, 1993

N73687 001

AB10MG

FEB 26, 1993

N73687 002

FEB 26, 1993

PIPERACILLIN SODIUM; TAZOBACTAM SODIUMINJECTABLE; INJECTION
ZOSYN

+ LEDERLE

EQ 2GM BASE/VIAL;
EQ 250MG BASE/VIALN50684 001
OCT 22, 1993

+

EQ 3GM BASE/VIAL;
EQ 375MG BASE/VIALN50684 002
OCT 22, 1993

+

EQ 4GM BASE/VIAL;
EQ 500MG BASE/VIALN50684 003
OCT 22, 1993

+

EQ 36GM BASE/VIAL;
EQ 4.5GM BASE/VIALN50684 004
OCT 22, 1993PIROXICAMCAPSULE; ORAL
PIROXICAMAB MEPHA AG10MG

N74116 001

JUN 15, 1993

AB20MG

N74118 001

JUN 15, 1993

AB

MUTUAL PHARM

10MG

N73535 001

MAR 12, 1993

AB20MG

N73536 001

MAR 12, 1993

AB

ROXANE

10MG

N73651 001

FEB 26, 1993

AB20MG

N73651 002

FEB 26, 1993

PLICAMYCININJECTABLE; INJECTION
MITHRACIN

+ MILES

2.5MG/VIAL

N50109 001

>_ADD_>

/Pfizer/

/2.5MG/VIAL/

/N50109/001/

>_DLT_>

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM
BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

PEG-LYTEAA INVAMED236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT N73098 001

AUG 31, 1993

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATESOLUTION/DROPS; OPHTHALMIC
POLYTRIM

> ADD >	ALLERGAN	10,000 UNITS/ML;	N50567 001
> ADD >		EQ 1MG BASE/ML	OCT 20, 1988
> ADD >			
> DLT >	BURROUGHS/WEILCOME/	10,000 UNITS/ML;	/N50567/001/
> DLT >		EQ 1MG BASE/ML	/OCT/20, 1988/
> DLT >			

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

/AB/	K-LEASE	/8MEQ/	/N73398/001/
/AB/	ADRIA/	/10 MEQ/	/JAN/28, 1992/
/AB/		/10 MEQ/	/N72427/001/
/AB/		/10 MEQ/	/MAR/28, 1990/
AB	SAVAGE	8MEQ	N73398 001
AB		10 MEQ	JAN 28, 1992
			N72427 001
			MAR 28, 1990

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	FUJISAWA	2MEQ/ML	N84290 001
AP		2MEQ/ML	N87787 001
			APR 20, 1982
/AP/	LUITPOLD/	/2MEQ/ML/	/N80221/001/
/AP/		/2MEQ/ML/	/N80736/001/
	3 LUITPOLD	2MEQ/ML	N80221 001
	3	2MEQ/ML	N80736 001
/AP/	LYPHOMED/	/2MEQ/ML/	/N84290/001/
/AP/		/2MEQ/ML/	/N87787/001/
			/APR/20, 1982/

TABLET, EXTENDED RELEASE; ORAL

AB	K-8	8MEQ	N70998 001
	ALRA		JAN 25, 1993
	KAON CL		
	ADRIA/	6.7MEQ/	/N17046/001/
	SAVAGE	6.7MEQ	N17046 001
/BC/	KAON CL-10	/10MEQ/	/N17046/002/
BC	ADRIA/	10MEQ	N17046 002
	SAVAGE		

POTASSIUM CITRATE

/POWDER/FOR/RECONSTITUTION;/ORAL/

/POTASSIUM/CITRATE/		
/3//UNIV/TX/	/20MEQ/PACKET/	/N19647/001/
		/OCT/13, 1988/
	/10MEQ/PACKET/	/N19647/002/
		/OCT/13, 1988/
3 UNIV TX	10MEQ/PACKET	N19647 002
		OCT 13, 1988
3	20MEQ/PACKET	N19647 001
		OCT 13, 1988

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE		
/3//UNIV/TX/	/5MEQ/	/N19071/001/
		/AUG/30, 1985/
+ UNIV TX	10MEQ	N19071 002
		AUG 31, 1992
	5MEQ	N19071 001
		AUG 30, 1985

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL		
/3//BRISTOL/MYERS/SQUIBB/40MG/		/N19898/001/
		/OCT/31, 1991/
+ BRISTOL MYERS SQUIBB 40MG		N19898 004
		MAR 22, 1993
	20MG	N19898 003
		OCT 31, 1991

PRAZEPAM

> DLT >	/CAPSULE;/ORAL/		
> DLT >	/CENTRAX/		
> DLT >	/3//PARKE/DAVIS/	/10MG/	/N18144/002/
> DLT >	/3//	/20MG/	/N18144/003/
> DLT >			/MAY/10, 1982/
> DLT >		/5MG/	/N18144/001/
> ADD >	3 PARKE DAVIS	5MG	N18144 001
> ADD >	3	10MG	N18144 002
> ADD >	3	20MG	N18144 003
> ADD >			MAY 10, 1982
	/TABLET;/ORAL/		
	/CENTRAX/		
	/3//PARKE/DAVIS/	/10MG/	/N17415/001/

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

/N88007/001/
 /APR/19, /1983/
 N88007 001
 APR 19, 1983

2 PHARMAFAIR 0.5%;10%

PREDNISOLONE SODIUM PHOSPHATE

N20279 001
OCT 29, 1993

SOLUTION/DROPS; OPHTHALMIC

/N88415/001/
/FEB/29/1984/
N88415 001
FEB 29, 1984

Q PHARMAFAIR EQ 0.11% PHOSPHATE

/N19568/001/
 /SEP/23/1991/
 N19568 001
 SEP 23, 1991

2 HOECHST ROUSSEL 0.1%

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

/N80211/001/
N80211 001
/N80324/001/
N80324 001

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	STERIS	EQ 0.23% PHOSPHATE;10%	N73630 001
			MAY 27, 1993

AT VASOCIDIN EQ 0.23% PHOSPHATE;10% N18988 001
IOLAB AUG 26, 1988

PREDNISONE

N87771 001
AUG 06, 1993

SOLUTION; ORAL

PREDNISONE
@ PENNEX PHARMS

5MG/5ML

N89726 001
AUG 02, 1988

/N88032/001/
 /APR/15/1983/
 N88032 001
 APR 15, 1983

/AA/ /PHARM/BASICS/ /5MG/5ML/

/AA/ /ROXANE/ /5MG/5ML/

ROXANE **5MG/5ML**

AUG 02, 1988
/N88726/001/
/AUG/02,/1988/
/N88703/001/
/NOV/08,/1984/
N88703 001
NOV 08, 1984

/N88791/001/
/OCT/05,/1984/
N88791 001
OCT 05, 1984

TABLET; ORAL

AB UP JOHN 2.5MG
7BX/ /2.5MG/

N09986 005
/N09986/005/

PREDNISONE

TABLET; ORAL

METICORTEN

> ADD > AB + SCHERING
 > DLT > /BX/+/1/
 > DLT > /BX/+/5MG/
 > ADD > @

1MG
 /1MG/
 /5MG/
 5MG

N09766 002
 /N09766/002/
 /N09766/001/
 N09766 001

PREDNISONE

> DLT > /AB/ /HEATHER/
 /AB/
 /AB/
 /AB/
 /AB/

/5MG/
 /10MG/
 /20MG/
 /20MG/
 /50MG/

/N00320/001/
 /N84341/001/
 /N84417/001/
 /N85543/001/
 /N86946/001/

> ADD > @ HEATHER

5MG

N80320 001

@

10MG

N84341 001

@

20MG

N84417 001

@

20MG

N85543 001

@

50MG

N86946 001

> DLT > /BX/ /INWOOD/

/5MG/

/N80279/001/

> ADD > @ INWOOD

5MG

N80279 001

/BX/ /KV/

/5MG/

/N84236/001/

@ KV

5MG

N84236 001

BX NYLOS TRADING

5MG

N85115 001

/BX/ /TABLICAPS/

/5MG/

/N85115/001/

/BX/ /UPSHER SMITH/

/5MG/

/N87471/001/

/BX/

/20MG/

/N87470/001/

@ UPSHER SMITH

5MG

N87471 001

@

20MG

N87470 001

PROBENECID

TABLET; ORAL

PROBENECID

> DLT > /AB/ /CHELSEA/
 > DLT > /AB/
 > ADD > @ CHELSEA
 > ADD >

/500MG/
 /500MG/
 500MG

/N86150/002/
 /APR/23/1982/
 N86150 002
 APR 23, 1982

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PRONESTYL

AB APOTHECON
 AB
 AB +
 /AB/ /SQUIBB/
 /AB/ /SQUIBB/
 /AB/+/

250MG
 375MG
 500MG
 /250MG/
 /375MG/
 /500MG/

N07335 001
 N07335 004
 N07335 003
 /N07335/001/
 /N07335/004/
 /N07335/003/

INJECTABLE; INJECTION

PROCAINAMIDE HCL

/AP/ /LYPHOMED/
 /AP/

/100MG/ML/
 /500MG/ML/

/N80415/001/
 /NOV/17/1986/
 /N80416/001/
 /NOV/17/1986/

@ LYPHOMED

100MG/ML

N89415 001

@

500MG/ML

NOV 17, 1986

N89416 001

NOV 17, 1986

PRONESTYL

AP + APOTHECON
 AP +
 /AP/ /SQUIBB/
 /AP/

100MG/ML
 500MG/ML
 /100MG/ML/
 /500MG/ML/

N07335 002
 N07335 005
 /N07335/002/
 /N07335/005/

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL

/AP/ /BEL/MAR/
 /AP/ @ BEL MAR
 @

/1%/
 /2%/
 1%
 2%

/N80711/001/
 /N80756/001/
 N80711 001
 N80756 001

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

> DLT > /ACHROMYCIN/
 > DLT > /AB/ /LEDERLE/
 > DLT >
 > DLT >
 > ADD > @ LEDERLE
 > ADD > @

/40MG/VIAL; 250MG/VIAL/
 /40MG/VIAL; 100MG/VIAL/
 /40MG/VIAL; 100MG/VIAL/
 /40MG/VIAL; 100MG/VIAL/
 40MG/VIAL; 100MG/VIAL
 40MG/VIAL; 250MG/VIAL

/N50267/003/
 /N50267/002/
 /N50276/001/
 N50276 001
 N50276 003

TETRACYN

> DLT > /AB/ /PFIZER/
 > ADD >

/40MG/VIAL; 250MG/VIAL/
 40MG/VIAL; 250MG/VIAL

/N60285/003/
 N60285 003

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HCL

> DLT > /AB/ /CHELSEA/
 > DLT > /AB/
 > DLT > /AB/
 > ADD > @ CHELSEA
 > ADD > @
 > ADD > @

/250MG/
 /375MG/
 /500MG/
 250MG
 375MG
 500MG

/N85167/001/
 /N87020/001/
 /N87021/001/
 N85167 001
 N87020 001
 N87021 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL
COMPAZINE
 AB + SMITHKLINE BEECHAM 25MG N11127 002
PROCHLORPERAZINE
 AB G AND W 25MG N40058 001
 NOV 24, 1993

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL
 PROCHLORPERAZINE EDISYLATE
 @ PENNEX PHARMS EQ 10MG BASE/ML N88598 001
 OCT 25, 1984
 /N88598/001/
 /OCT/25/1984/
 /@/PHARM/BASICS/ /EQ/10MG/BASE/ML/

SYRUP; ORAL
 PROCHLORPERAZINE EDISYLATE
 @ PENNEX PHARMS EQ 5MG BASE/5ML N88597 001
 OCT 25, 1984
 /N88597/001/
 /OCT/25/1984/
 /@/PHARM/BASICS/ /EQ/5MG/BASE/5ML/

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL
 KEMADRIN
 /BURROUGHS/WELLCOME/ 2MG/ N09818/005/
 @ BURROUGHS WELLCOME 2MG N09818 005

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
SPARTINE
 /AB/ /WYETH/AYERST/ /25MG/ML/ N10349/009/

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
 PROMETHACON
 /BR/ /ALCON/ /25MG/ N84401/001/
 /BR/ /50MG/ N84402/001/
 BR POLYMEDICA 25MG N84901 001
 BR 50MG N84902 001

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE PLATIN
 @ PENNEX PHARMS 6.25MG/5ML N87953 001
 NOV 15, 1982
 /N87953/001/
 /NOV/15/1982/
 /AA/ /PHARM/BASICS/ /6.25MG/5ML/

TABLET; ORAL
 PROMETHAZINE HCL
 /BP/ /CIRCA/ /25MG/ N83204/001/
 @ CIRCA 25MG N83204 001
 /BP/ /ZENITH/ /50MG/ N83613/001/
 @ ZENITH 50MG N83613 001

PROPOFOL

INJECTABLE; INJECTION
 DIPRIVAN
 /ICI/ /10MG/ML/ N19627/001/
 + ZENECA 10MG/ML N19627 001
 OCT 02, 1989

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL
 PROPRANOLOL HCL
 @ PENNEX PHARMS 20MG/5ML N71984 001
 MAR 03, 1989
 @ 40MG/5ML N71985 001
 MAR 03, 1989
 /@/PHARM/BASICS/ /20MG/5ML/ N71984/001/
 /MAR/03/1989/ N71985/001/
 /@/ /40MG/5ML/ N71985/001/
 /MAR/03/1989/

/SUSPENSION;/ORAL/
 /INDERAL/
 /WYETH/AYERST/ /10MG/ML/ N19536/001/
 @ WYETH AYERST 10MG/ML N19536 001
 DEC 12, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL
 /AB/ /MYLAN/ /60MG/ /N72275/001/
 JUN/09,1989/ N72275 001
 JUN 09, 1989
 2 MYLAN 60MG

PROPYLIODONE

/SUSPENSION; INTRATRACHEAL/
 /DIONOSIL OILY/
 /GLAXO/ /60%/ /N09309/002/
 2 GLAXO 60% N09309 002

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE
 /AP/ /QUAD/ /10MG/ML/ /N89306/001/
 MAY/30,1986/ N89306 001
 MAY 30, 1986
 2 QUAD 10MG/ML

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
HISTAFED
 /AA/ /LIFE/LABS/ /30MG/5ML; 1.25MG/5ML/ /N88283/001/
 APR/20,1984/ N88283 001
 APR 20, 1984
 2 CENCI 30MG/5ML; 1.25MG/5ML

PYRANTEL PAMOATE

/SUSPENSION; ORAL/
 /ANTIMINTH/
 /+//ROERIG/ /EQ/250MG/BASE/5ML/ /N16883/001/

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON
 /AP/ /ICN/ /5MG/ML/ /N09830/001/
 AP ROCHE 5MG/ML N09830 001

PYRIDOSTIGMINE BROMIDE

SYRUP; ORAL
 MESTINON
 /ICN/ /60MG/5ML/ /N15193/001/
 ROCHE 60MG/5ML N15193 001

TABLET; ORAL
 MESTINON
 /+//ICN/ /60MG/ /N09829/002/
 + ROCHE 60MG N09829 002

TABLET, EXTENDED RELEASE; ORAL
 MESTINON
 /+//ICN/ /180MG/ /N11665/001/
 + ROCHE 180MG N11665 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
HEXA-BETALIN
 /AP/ /LILLY/ /100MG/ML/ /N80854/001/
 2 LILLY 100MG/ML N80854 001

PYRIDOXINE HCL
 /AP/ /BEL/MAR/ /100MG/ML/ /N80761/001/
 2 BEL MAR 100MG/ML N80761 001
 AP FUJISAWA 100MG/ML N80618 001
 /AP/ /LYPHOMED/ /100MG/ML/ /N80618/001/

QUAZEPAM

TABLET; ORAL
 DORAL
 /+//BAKER/NORTON/ /15MG/ /N18708/001/
 /DEC/27,1985/ N18708 001
 /FEB/26,1987/ N18708 001
 + WALLACE 15MG DEC 27, 1985
 7.5MG N18708 003
 FEB 26, 1987

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
 /DURAGIN/
 /PARKE/DAVIS/ /330MG/ /N17917/001/

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

/BP/ /QUINIDINE/

a WARNER CHILCOTT 330MG

N17917 001

QUINIDINE GLUCONATE

/AB/ /CHLSEA/

/324MG/

/N87785/001/
/JAN/24,/1983/> DLT > /AB/
> DLT >
> ADD >
> ADD >

a CHLSEA 324MG

N87785 001
JAN 24, 1983QUINIDINE SULFATE

TABLET; ORAL

/AB/ /QUINIDINE/

/AB/ /SOLVAY/ /100MG/

/AB/ /200MG/

/AB/ /300MG/

a SOLVAY 100MG

a 200MG

a 300MG

/N85299/001/

/N84932/001/

/N85298/001/

N85299 001

N84932 001

N85298 001

QUINIDINE SULFATE

/AB/ /PARKE/DAVIS/ /200MG/

a WARNER CHILCOTT 200MG

/N83879/001/

N83879 001

RAUWOLFIA SERPENTINA

TABLET; ORAL

RAUDIXIN

BP APOTHECON 50MG

BP + 100MG

/BP/ /SQUIBB/ /50MG/

/BP/+ /100MG/

N08842 001

N08842 002

/N08842/001/

/N08842/002/

RESERPINE

TABLET; ORAL

RESERPINE

/BP/ /LEMMON/ /0.1MG/

/BP/ /0.25MG/

a LEMMON 0.1MG

a 0.25MG

/N89020/001/
/MAR/07,/1985//N89019/001/
/MAR/07,/1985/

N89020 001

MAR 07, 1985

N89019 001

MAR 07, 1985

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

/BP/ /NAQUIVAL/

/BP/+ /SCHERING/

a SCHERING

/0.1MG;4MG/
0.1MG;4MG/N12265/003/
N12265 003RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

FLUMADINE

+ FOREST LABS

50MG/5ML

N19650 001
SEP 17, 1993

TABLET; ORAL

FLUMADINE

+ FOREST LABS

100MG

N19649 001
SEP 17, 1993> ADD > RISPERIDONE

> ADD > TABLET; ORAL

> ADD > RISPERDAL

> ADD > + JANSSEN

4MG

N20272 004
DEC 29, 1993

> ADD >

> ADD >

1MG

N20272 001
DEC 29, 1993

> ADD >

> ADD >

2MG

N20272 002
DEC 29, 1993

> ADD >

> ADD >

3MG

N20272 003
DEC 29, 1993

> ADD >

> ADD >

5MG

N20272 005
DEC 29, 1993

> ADD >

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

/AB/ /RITODRINE HCL/

/BP/ /QUAD/

/10MG/ML/

a QUAD

10MG/ML

/N70700/001/
/OCT/06,/1986/N70700 001
OCT 06, 1986

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

a PENNEX PHARMS

2.5%

N88228 001

SEP 01, 1983

/N88228/001/

/SEP/01./1983/

/AA/ /PHARM/BASICS/ /2.5%/

SERACTIDE ACETATE/INJECTABLE;/INJECTION/
/ACTHAP/SEL-SYNTHETIC/
/ARMOUR/

/40/UNITS/ML/

/N17861/001/

/80/UNITS/ML/

/N17861/002/

a ARMOUR

40 UNITS/ML

N17861 001

a

80 UNITS/ML

N17861 002

SILVER SULFADIAZINE/DRESSING/ TOPICAL/
/SILVADIAZ/

a BIOPLASTY

1%

N19608 001

NOV 30, 1989

/SILVADIAZ/
/ENQUAY/

/1%/

/N19608/001/
/NOV/30./1989/SODIUM BICARBONATE/INJECTABLE;/INJECTION/
/SODIUM/BICARBONATE/IN/PLASTIC/CONTAINER/
/ABBOTT/

/0.9MEQ/ML/

/N19443/001/

/JUN/03./1986/

/1MEQ/ML/

/N19443/002/

/JUN/03./1986/

a ABBOTT

0.9MEQ/ML

N19443 001

JUN 03, 1986

a

1MEQ/ML

N19443 002

JUN 03, 1986

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP

FUJISAWA

9MG/ML

N88911 001

FEB 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

/AA/

/LYPHOMED/

/9MG/ML/

/N88911/001/

/FEB/07./1985/

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

a FUJISAWA

234MG/ML

N19329 001

APR 22, 1987

/N19329/001/

/APR/22./1987/

/a/ /LYPHOMED/

/234MG/ML/

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

/SQUIBB/

/2MCI/VIAL/

/N13993/002/

a SQUIBB

2MCI/VIAL

N13993 002

SODIUM IODIDE, I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

/a/CIS/

/50/UCI/

/N17316/001/

a CIS

50 UCI

N17316 001

/100/UCI/

/N17316/002/

100 UCI

N17316 002

SOLUTION; ORAL

SODIUM IODIDE I 131

/CIS/

/50MCI/ML/

/N17315/001/

a CIS

50MCI/ML

N17315 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

a PENNEX PHARMS

453.6GM/BOT

N88786 001

SEP 11, 1984

/N88786/001/

/SEP/11./1984/

/AA/

/PHARM/BASICS/

/453.6GM/BOT/

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

a PENNEX PHARMS

15GM/60ML

N88717 001

SEP 11, 1984

/N88717/001/

/SEP/11./1984/

/AA/

/PHARM/BASICS/

/15GM/60ML/

SOMATROPIN, BIOSYNTHETICINJECTABLE; INJECTION
HUMATROPE

BX + LILLY	5MG/VIAL	N19640 004 MAR 08, 1987
NUTROPIN	5MG/VIAL	N20168 001 NOV 17, 1993
BX GENENTECH		
+	10MG/VIAL	N20168 002 NOV 17, 1993

SOYBEAN OILINJECTABLE; INJECTION
INTRALIPID 30%

> ADD >	KABI	30%	N19942 001 DEC 30, 1993
---------	------	-----	----------------------------

AP	<u>NUTRILIPID 10%</u> MCGAW	<u>10%</u>	N19531 001 MAY 28, 1993
----	--------------------------------	------------	----------------------------

AP	<u>NUTRILIPID 20%</u> MCGAW	<u>20%</u>	N19531 002 MAY 28, 1993
----	--------------------------------	------------	----------------------------

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

> DLT >	/B*/	/CHELSEA/	/25MG/	/N87078/001/
> ADD >		@ CHELSEA	25MG	N87078 001
	/AB/	/UPSHER/SMITH/	/25MG/	/N87554/001/
		@ UPSHER SMITH	25MG	N87554 001

STRONTIUM CHLORIDE, SR-89INJECTABLE; INJECTION
METASTRON

MEDI PHYSICS

1MCI/ML	N20134 001 JUN 18, 1993
---------	----------------------------

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+ MARION MERRELL DOW

1GM/10ML

N19183 001 DEC 16, 1993

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

/AT/	/SULFATE 10/	/102/	/N88000/001/
	@ PHARMAFAIR	10%	DEC 22, 1982

SULFADIAZINETABLET; ORAL
SULFADIAZINE

/ABBOTT/	/300MG/	/N04125/005/
@ ABBOTT	300MG	N04125 005

SULFADIAZINE SODIUM

> DLT >	/INJECTABLE; INJECTION/	
> DLT >	/SULFADIAZINE/SODIUM/	
> DLT >	/LEDERLE/	/250MG/ML/
> ADD >	@ LEDERLE	250MG/ML

/N04054/002/
N04054 002

SULFAMETHIZOLETABLET; ORAL
THIOSULFIL

/WYETH/AYERST/	/250MG/	/N08565/001/
@ WYETH AYERST	250MG	N08565 001

SULFAMETHOXAZOLETABLET; ORAL
SANTANOL-DS/

/ROCHE/	/1GM/	/N12715/003/
@ ROCHE	1GM	N12715 003

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

TRIMETH-SULFA

AB	BARRE	200MG/5ML; 40MG/5ML	N72289 001
----	-------	---------------------	------------

AB		200MG/5ML; 40MG/5ML	N72398 001
----	--	---------------------	------------

MAY 23, 1988
N72398 001
MAY 23, 1988

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

TRIMETH/SULFA

/AB/	/NASKA/	/200MG/5ML;40MG/5ML/	/N72289/001/
			/MAY/23./1988/
/AB/		/200MG/5ML;40MG/5ML/	/N72398/001/
			/MAY/23./1988/

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

> DLT >	/AB/	/CHELSEA/	/400MG;80MG/	/N70002/001/
> DLT >				/NOV/07./1984/
> DLT >	/AB/		/800MG;160MG/	/N70000/001/
> DLT >				/NOV/07./1984/
> ADD >		3 CHELSEA	400MG;80MG	N70002 001
> ADD >				NOV 07, 1984
> ADD >		3	800MG;160MG	N70000 001
> ADD >				NOV 07, 1984
	/B*/	/INTERPHARM/	/400MG;80MG/	/N71299/001/
				/OCT/27./1987/
	/B*/		/800MG;160MG/	/N71300/001/
				/OCT/27./1987/
		3 INTERPHARM	400MG;80MG	N71299 001
				OCT 27, 1987
		3	800MG;160MG	N71300 001
				OCT 27, 1987

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

/AB/	/HEATHER/	/500MG/	/N80189/001/
	3 HEATHER	500MG	N80189 001
	/3/PHARMAFAIR/	/500MG/	/N84385/001/
	3 PHARMERAL	500MG	N84385 001

SULFISOXAZOLE ACETYL/EMULSION;/ORAL/
/LIPID/SANTRISIN/

/ROCHE/

3 ROCHE

/EQ/1GM/BASE/5ML/
EQ 1GM BASE/5ML

/N09182/009/
N09182 009

SULFISOXAZOLE DIOLAMINE/OINTMENT;/OPHTHALMIC/
/SANTRISIN/
/ROCHE/

/EQ/4%/BASE/

/N08414/002/

SULFISOXAZOLE DIOLAMINE/OINTMENT;/OPHTHALMIC/
/SANTRISIN/

3 ROCHE

EQ 4% BASE

N08414 002

SULINDAC

TABLET; ORAL

SULINDAC

AB	MYLAN	150MG	N73038 001
			JUN 22, 1993
AB		200MG	N73039 001
			JUN 22, 1993

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

+ PARKE DAVIS

EQ 40MG BASE

N20070 004

EQ 10MG BASE

SEP 09, 1993

EQ 20MG BASE

N20070 001

EQ 30MG BASE

SEP 09, 1993

N20070 002

SEP 09, 1993

N20070 003

SEP 09, 1993

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

/3//STUART/

+ ZENECA

/EQ/10MG/BASE/

EQ 10MG BASE

/N17970/001/

N17970 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

/A-N/STANNOUS/AGGREGATED/ALBUMIN/

/BS/ /NORTH/AM/CHEM/

3 NORTH AM CHEM

/N/A/

N/A

/N17916/001/

N17916 001

AN-MAA

BS SORIN

N/A

/N/A/

N17792 001

/N17792/001/

/BS/ /TECHNETIUM/TC-99M/MAA/

/MEDI/PHYSICS/

3 MEDI PHYSICS

/N/A/

N/A

/N17773/001/

N17773 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

> DLT >	/INJECTABLE; INJECTION/		
> DLT >	/INSTANT/MICROSPHERES/		
> DLT >	/3M/	/N/A/	/N17832/001/
> ADD >	@ 3M	N/A	N17832 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION			
/AMERSCAN MDP KIT/			
/AP/	/AMERSHAM/	/N/A/	/N18335/001/
			/AUG/05/1982/
	@ AMERSHAM	N/A	N18335 001
			AUG 05, 1982

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL			
/MINITEC/			
	/SQUIBB/	/0.22-2.22CI/GENERATOR/	/N17339/001/
	@ SQUIBB	0.22-2.22CI/GENERATOR	N17339 001

TEMAZEPAM

CAPSULE; ORAL

<u>TEMAZEPAM</u>			
AB	DANBURY PHARMA	15MG	N71446 001
			MAY 21, 1993
AB		30MG	N71447 001
			MAY 21, 1993

TERAZOSIN HYDROCHLORIDETABLET; ORAL
HYTRIN

/+//ABBOTT/	/2MG/	/N19057/002/
		/AUG/07/1987/
+	ABBOTT	EQ 2MG BASE
		N19057 002
		AUG 07, 1987
+		EQ 2MG BASE
		N20223 002
		SEP 29, 1993
	/1MG/	/N19057/001/
		/AUG/07/1987/
		EQ 1MG BASE
		N19057 001
		AUG 07, 1987
		EQ 1MG BASE
		N20223 001
		SEP 29, 1993
	/5MG/	/N19057/003/
		/AUG/07/1987/
		EQ 5MG BASE
		N19057 003
		AUG 07, 1987
		EQ 5MG BASE
		N20223 003
		SEP 29, 1993
	/10MG/	/N19057/004/
		/AUG/07/1987/
		EQ 10MG BASE
		N19057 004
		AUG 07, 1987
		EQ 10MG BASE
		N20223 004
		SEP 29, 1993

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

TESTODERM		
+	ALZA	4MG/24HR
		N19762 001
		OCT 12, 1993
+		6MG/24HR
		N19762 002
		OCT 12, 1993

INJECTABLE; INJECTION

TESTOSTERONE

> DLT >	/STERIS/	/25MG/ML/	/N86420/001/
> DLT >			/MAY/10/1983/
> ADD >	@ STERIS	25MG/ML	N86420 001
> ADD >			MAY 10, 1983
> DLT >		/50MG/ML/	/N86419/001/
> DLT >			/AUG/23/1983/
> ADD >	@	50MG/ML	N86419 001
> ADD >			AUG 23, 1983

TESTOSTERONE CYPIONATEINJECTABLE; INJECTION
DEPO-TESTOSTERONE

> DLT >	/UPJOHN/	/50MG/ML/	/N85635/001/
> ADD >	Q UPJOHN	50MG/ML	N85635 001
<u>TESTOSTERONE CYPIONATE</u>			
> DLT >/Ad/	/STERIS/	/100MG/ML/	/N84401/001/
> DLT >/Ad/	/STERIS/	/200MG/ML/	/N84401/002/
> ADD >	Q STERIS	100MG/ML	N84401 001
> ADD >	Q	200MG/ML	N84401 002

TESTOSTERONE ENANTHATEINJECTABLE; INJECTION
TESTOSTERONE ENANTHATE

> DLT >/Ad/	/STERIS/	/100MG/ML/	/N83667/002/
> DLT >	/STERIS/	/100MG/ML/	/N83667/001/
> ADD >	Q STERIS	100MG/ML	N83667 001
> ADD >	Q	200MG/ML	N83667 002

TESTOSTERONE PROPIONATEINJECTABLE; INJECTION
TESTOSTERONE PROPIONATE

/Ad/	/BEL/MAR/	/25MG/ML/	/N80741/001/
/Ad/	/BEL/MAR/	/50MG/ML/	/N80742/001/
/Ad/	/BEL/MAR/	/100MG/ML/	/N80743/001/
	Q BEL MAR	25MG/ML	N80741 001
	Q	50MG/ML	N80742 001
	Q	100MG/ML	N80743 001
> DLT >/Ad/	/LILLY/	/50MG/ML/	/N80254/002/
> ADD >	Q LILLY	50MG/ML	N80254 002
/Ad/	/STERIS/	/25MG/ML/	/N80188/001/
> DLT >/Ad/	/STERIS/	/50MG/ML/	/N80188/002/
> DLT >/Ad/	/STERIS/	/100MG/ML/	/N85490/002/
/Ad/	/STERIS/	/100MG/ML/	/N80188/003/
	+ STERIS	25MG/ML	N80188 001
		100MG/ML	N80188 003
> DLT >		/25MG/ML/	/N85490/001/
> ADD >	Q	25MG/ML	N85490 001
> ADD >		50MG/ML	N80188 002
> ADD >	Q	50MG/ML	N85490 002
> DLT >		/100MG/ML/	/N83595/003/
> ADD >	Q	100MG/ML	N83595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

/AB/	/TETRACHEL/	/250MG/	/N60343/001/
/AB/	/RACHELLE/	/500MG/	/N60343/003/
	Q ANGUS	250MG	N60343 001
	Q	500MG	N60343 003
<u>TETRACYCLINE HCL</u>			
/AB/	/ICN/	/250MG/	/N60471/001/
	Q ICN	250MG	N60471 001

TABLET; ORAL

SUMYCIN

AB	APOTHECON	50MG	N61147 003
AB		100MG	N61147 002
AB		250MG	N61147 001
AB +		500MG	N61147 004
/AB/	/SQUIBB/	/50MG/	/N61147/003/
/AB/	/SQUIBB/	/100MG/	/N61147/002/
/AB/	/SQUIBB/	/250MG/	/N61147/001/
/AB//+/	/SQUIBB/	/500MG/	/N61147/004/

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

/AB/	/SQUIBB/	/1MCI/ML/	/N18548/001/
	Q SQUIBB	1MCI/ML	/DEC/30,1982/
			N18548 001
			DEC 30, 1982

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

/BC/+/	/GLAXO/	/260MG/	/N85983/001/
	Q WHITBY	260MG	/MAR/20,1985/
			N85983 001
			MAR 20, 1985
/BC/+/	/GLAXO/	/130MG/	/N87854/001/
	Q WHITBY	130MG	/MAR/20,1985/
			N87854 001
			MAR 20, 1985

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEOCLEAR L.A.-130

/BC/ /CENTRAL/PHARMS/ /130MG/

BC + CENTRAL PHARMS 130MG

/N86569/001/
/MAY/27,1982/
N86569 001
MAY 27, 1982

THEOCLEAR L.A.-260

/BC/ /CENTRAL/PHARMS/ /260MG/

BC + CENTRAL PHARMS 260MG

/N86569/002/
/MAY/27,1982/
N86569 002
MAY 27, 1982

ELIXIR; ORAL

/THEOPHYL-225/

/JOHNSON/RH/

a JOHNSON RH

/112.5MG/15ML/
112.5MG/15ML/N86485/001/
N86485 001THEOPHYLLINE

AA BARRE 80MG/15ML

N89223 001

/AA/ /NASKA/ /80MG/15ML/

MAY 27, 1988
/N89223/001/
/MAY/27,1988/
N86748 001
/N86748/001/AA PENNEX PHARMS 80MG/15ML
/AA/ /PHARM/BASICS/ /80MG/15ML/

TABLET; ORAL

QUIBRON-T

/+/ /BRISTOL/MYERS/ /300MG/

+ ROBERTS 300MG

/N88656/001/
/AUG/22,1985/
N88656 001
AUG 22, 1985

/THEOPHYL-225/

/JOHNSON/RH/

a JOHNSON RH

/225MG/
225MG/N84726/001/
N84726 001

/TABLET;/CHEWABLE;/ORAL/

/THEOPHYL/

/JOHNSON/RH/

a JOHNSON RH 100MG

/N86506/001/
/SEP/12,1985/
N86506 001
SEP 12, 1985

TABLET, EXTENDED RELEASE; ORAL

QUIBRON-T/SR

/BC/ /BRISTOL/MYERS/ /300MG/

BC ROBERTS 300MG

/N87563/001/
/JUN/21,1983/
N87563 001
JUN 21, 1983THEOPHYLLINE SODIUM GLYCINATE

/ELIXIR;/ORAL/

/SYNPHYLLATE/

/CENTRAL/PHARMS/

a CENTRAL PHARMS

/EQ/165MG/BASE/15ML/

EQ 165MG BASE/15ML

/N86333/008/

N06333 008

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

/AP/ /BEL/MAR/

/AP/ /BEL/MAR/

a BEL MAR

a

AP FUJISAWA

/AP/ /LYPHOMED/

/AP/ /STERIS/

/AP/ /STERIS/

+ STERIS

/100MG/ML/

/200MG/ML/

100MG/ML

200MG/ML

100MG/ML

/100MG/ML/

/200MG/ML/

/200MG/ML/

200MG/ML

200MG/ML

/N86718/001/

/N86712/001/

N80718 001

N80712 001

N80556 001

/N86556/001/

/N86571/002/

/N83534/002/

N80571 002

N83534 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HCL

a PENNEX PHARMS

30MG/ML

N88258 001

a

100MG/ML

JUL 25, 1983

N88227 001

JUL 05, 1983

/AA/ /PHARM/BASICS/

/30MG/ML/

/N88258/001/

/AA/

/100MG/ML/

/JUL/25,1983/

/N88227/001/

/JUL/05,1983/

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

/AB/	/PAR/	/10MG/	/N88351/001/
			/DEC/05, 1983/
/AB/		/15MG/	/N88352/001/
			/DEC/05, 1983/
/AB/		/25MG/	/N88336/001/
			/DEC/05, 1983/
/AB/		/50MG/	/N88322/001/
			/DEC/05, 1983/
/AB/		/100MG/	/N88480/001/
			/DEC/29, 1983/
	@ PAR	10MG	N88351 001
	@	15MG	DEC 05, 1983
	@	25MG	N88352 001
	@		DEC 05, 1983
	@	50MG	N88336 001
	@		DEC 05, 1983
	@	100MG	N88322 001
	@		DEC 05, 1983
/AB/	/ZENITH/	/100MG/	/N88480/001/
			/DEC/29, 1983/
	@ ZENITH	100MG	N88273 001
			OCT 03, 1983

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

> ADD >	+ IMMUNEX	15MG/VIAL	N11683 001
> DLT >	/3//LEDERLE/	/15MG/VIAL/	/N11683/001/

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

+ SMITHKLINE BEECHAM	EQ 20GM BASE/VIAL	N50497 004
+	EQ 30GM BASE/VIAL	N50497 005
		APR 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

+ SYNTEX	250MG
@	125MG
	/250MG/

N19979 002
OCT 31, 1991
N19979 001
MAR 24, 1993
/N19979/002/
/OCT/31, 1991/

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOPTIC-XE

+ MERCK	EQ 0.25% BASE
+	EQ 0.5% BASE

N20330 001
NOV 04, 1993
N20330 002
NOV 04, 1993

TABLET; ORAL

TIMOLOL MALEATE

AB	NOVOPHARM	5MG
AB		10MG
AB		20MG

N72648 001
JUN 16, 1993
N72649 001
JUN 16, 1993
N72650 001
JUN 16, 1993

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	BAUSCH AND LOMB	0.3%
----	-----------------	------

N64052 001
NOV 29, 1993

TOBREX

AT	+ ALCON	0.3%
AT		0.3%

N50541 001
N62535 001
DEC 13, 1984

TOLAZAMIDE

TABLET; ORAL		
TOLAZAMIDE		
/B*/ /INTERPHARM/	/250MG/	/N71270/001/
		/SEP/23, 1986/
/B*/	/500MG/	/N71271/001/
		/SEP/23, 1986/
a INTERPHARM	250MG	N71270 001
		SEP 23, 1986
a	500MG	N71271 001
		SEP 23, 1986

TOLMETIN SODIUM

CAPSULE; ORAL		
<u>TOLMETIN SODIUM</u>		
AB MYLAN	EQ 400MG BASE	N7393 001
		MAY 27, 1993

TABLET; ORAL		
<u>TOLMETIN SODIUM</u>		
AB GENEVA	EQ 600MG BASE	N74002 001
		SEP 27, 1993

TORSEMIDE

INJECTABLE; INJECTION		
DEMADEX		
+ BOEHRINGER MANNHEIM	10MG/ML	N20137 002
		AUG 23, 1993

TABLET; ORAL		
DEMADEX		
+ BOEHRINGER MANNHEIM	100MG	N20136 004
		AUG 23, 1993
	5MG	N20136 001
		AUG 23, 1993
	10MG	N20136 002
		AUG 23, 1993
	20MG	N20136 003
		AUG 23, 1993

TRANLYCYPROMINE SULFATE

TABLET; ORAL	
PARNATE	
+ SKF	EQ 10MG BASE

N12342 003
AUG 16, 1985

TRAZODONE HYDROCHLORIDE

TABLET; ORAL	
<u>DESYREL</u>	
AB APOTHECON	50MG
AB +	100MG
AB	150MG
	300MG

N18207 001
N18207 002
N18207 003
MAR 25, 1985
N18207 004
NOV 07, 1988

/AB/	/BRISTOL/MYERS/	/50MG/
/AB/	/+ /	/100MG/
/AB/		/150MG/
		/300MG/

/N18207/001/
/N18207/002/
/N18207/003/
/MAR/25, 1985/
/N18207/004/
/NOV/07, 1988/

<u>TRAZODONE HCL</u>	
AB MUTUAL PHARM	50MG
AB	100MG

N73136 001
MAR 24, 1993
N73137 001
MAR 24, 1993

TRETINOIN

/SHAB; /TOPICAL/	
/RETIN-A/	
/+ /	/JOHNSON/RW/
a JOHNSON RW	0.05% /
	0.05%

/N16921/002/
N16921 002

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION	
AZMACORT	
+ RHONE POULENC RORER	0.1MG/INH

N18117 001
APR 23, 1982
/N18117/001/
/APR/23, 1982/

/+ /	/0.25MG/INH/
------	--------------

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

Q PENNEX PHARMS	0.025%
Q	0.1%
Q	0.5%
/Q/PHARM/BASICS/	/0.025%/
/Q/	/0.1%/
/Q/	/0.5%/
/At/ PHARMADERM/	/0.025%/
/At/	/0.1%/
/At/	/0.5%/
Q PHARMADERM	0.025%
Q	0.1%
Q	0.5%
/At/ PHARMAFAIR/	/0.025%/
/At/	/0.1%/
/At/	/0.5%/
Q PHARMAFAIR	0.025%
Q	0.1%
Q	0.5%

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT PENNEX PHARMS	0.025%
AT	0.1%
/At/ /PHARM/BASICS/	/0.025%/
/At/	/0.1%/

N88094 001
SEP 01, 1983
N88095 001
SEP 01, 1983
N88096 001
SEP 01, 1983
/N88094/001/
/SEP/01/1983/
/N88095/001/
/SEP/01/1983/
/N88096/001/
/SEP/01/1983/
/N87990/001/
/JUL/07/1983/
/N87991/001/
/JUL/07/1983/
/N87992/001/
/JUL/07/1983/
N87990 001
JUL 07, 1983
N87991 001
JUL 07, 1983
N87992 001
JUL 07, 1983
/N87921/001/
/AUG/10/1982/
/N87912/001/
/AUG/10/1982/
/N87922/001/
/AUG/10/1982/
N87921 001
AUG 10, 1982
N87912 001
AUG 10, 1982
N87922 001
AUG 10, 1982

N88450 001
APR 01, 1985
N88451 001
APR 03, 1985
/N88450/001/
/APR/01/1985/
/N88451/001/
/APR/03/1985/

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT BARRE	0.5%
/At/ /NASKA/	/0.5%/
Q PENNEX PHARMS	0.025%
Q	0.1%
Q	0.5%
/Q/PHARM/BASICS/	/0.025%/
/Q/	/0.1%/
/Q/	/0.5%/
/At/ /PHARMADERM/	/0.025%/
/At/	/0.1%/
Q PHARMADERM	0.025%
Q	0.1%

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

AA /GENEVA/	/EQ 10MG BASE/ML/
AA	EQ 10MG BASE/ML

TRIFLUOPERAZINE HCL

Q PENNEX PHARMS	EQ 10MG BASE/ML
-----------------	-----------------

/AA/ /PHARM/BASICS/	/EQ 10MG BASE/ML/
---------------------	-------------------

TABLET; ORAL

AB /GENEVA/	/EQ 1MG BASE/	/N85785/001/
AB	/EQ 2MG BASE/	/N85786/001/
AB	/EQ 5MG BASE/	/N85789/001/
AB	/EQ 10MG BASE/	/N85788/001/

N89913 001
DEC 23, 1988
/N89913/001/
/DEC/23/1988/
N88090 001
SEP 01, 1983
N88091 001
SEP 01, 1983
N88092 001
SEP 01, 1983
/N88090/001/
/SEP/01/1983/
/N88091/001/
/SEP/01/1983/
/N88092/001/
/SEP/01/1983/
/N88692/001/
/AUG/02/1984/
/N88690/001/
/AUG/02/1984/
N88692 001
AUG 02, 1984
N88690 001
AUG 02, 1984

/N85787/001/
/APR/15/1982/

N85787 001
APR 15, 1982

N88143 001
JUL 26, 1983
/N88143/001/
/JUL/26/1983/

TRIFLUOPERAZINE HYDROCHLORIDE

<u>TABLET; ORAL</u>			
<u>TRIFLUOPERAZINE HCL</u>			
AB	GENEVA	EQ 1MG BASE	N85785 001
AB		EQ 2MG BASE	N85786 001
AB		EQ 5MG BASE	N85789 001
AB		EQ 10MG BASE	N85788 001

TRIFLUPROMAZINE

<u>/SUSPENSION; ORAL/</u>			
<u>/VESPRIN/</u>			
	<u>/SQUIBB/</u>	<u>/EQ/50MG/HCL/5ML/</u>	<u>/N11491/004/</u>
	@ APOTHECON	EQ 50MG HCL/5ML	N11491 004

TRIFLUPROMAZINE HYDROCHLORIDE

<u>INJECTABLE; INJECTION</u>			
<u>VESPRIN</u>			
AP	+ APOTHECON	10MG/ML	N11325 004
AP		20MG/ML	N11325 001
/AP/	<u>/SQUIBB/</u>	<u>/10MG/ML/</u>	<u>/N11325/004/</u>
/AP/		<u>/20MG/ML/</u>	<u>/N11325/001/</u>
<u>/TABLETS; ORAL/</u>			
<u>/VESPRIN/</u>			
	<u>/SQUIBB/</u>	<u>/50MG/</u>	<u>/N11123/003/</u>
		<u>/10MG/</u>	<u>/N11123/001/</u>
		<u>/25MG/</u>	<u>/N11123/002/</u>
	@ SQUIBB	10MG	N11123 001
	@	25MG	N11123 002
	@	50MG	N11123 003

TRIHENXYPHENIDYL HYDROCHLORIDE

<u>TABLET; ORAL</u>			
<u>TRIHENXYPHENIDYL HCL</u>			
AA	NYLOS TRADING	5MG	N85622 001
/AA/	<u>/TABLETS/</u>	<u>/5MG/</u>	<u>/N85622/001/</u>

TRIMEPAZINE TARTRATE

<u>SYRUP; ORAL</u>			
<u>TRIMEPAZINE TARTRATE</u>			
	@ PENNEX PHARMS	EQ 2.5MG BASE/5ML	N88285 001
			APR 11, 1985

TRIMEPAZINE TARTRATE

<u>SYRUP; ORAL</u>			
<u>TRIMEPAZINE TARTRATE</u>			
	<u>/@/PHARM/BASICS/</u>	<u>/EQ/2.5MG/BASE/5ML/</u>	<u>/N88285/001/</u>
			<u>/APR/11/1985/</u>

> ADD >	<u>TRIMETREXATE GLUCURONATE</u>		
> ADD >	<u>INJECTABLE; INJECTION</u>		
> ADD >	<u>NEUTREXIN</u>		
> ADD >	+ US BIOSCIENCE	EQ 25MG BASE/VIAL	N20326 001
> ADD >			DEC 17, 1993

TRIOXSALEN

<u>TABLET; ORAL</u>			
<u>TRISORALEN</u>			
	<u>/EIDEX/</u>	<u>/5MG/</u>	<u>/N12697/001/</u>
	ICN	5MG	N12697 001

TRIPLENNAMINE HYDROCHLORIDE

<u>TABLET; ORAL</u>			
<u>TRIPLENNAMINE HCL</u>			
/AA/	<u>/HEATHER/</u>	<u>/50MG/</u>	<u>/N83989/001/</u>
	@ HEATHER	50MG	N83989 001
AA	NYLOS TRADING	50MG	N85412 001
/AA/	<u>/TABLETS/</u>	<u>/50MG/</u>	<u>/N85412/001/</u>

TROPICAMIDE

<u>SOLUTION/DROPS; OPHTHALMIC</u>			
<u>MYDRXACYL</u>			
> DLT >	<u>/AT/</u>	<u>/ALCON/</u>	<u>/0.5%/</u>
> DLT >	<u>/AT/</u>		<u>/0.52/</u>
> ADD >	AT	+ ALCON	0.5%
> DLT >	<u>/AT/</u>		<u>/12/</u>
> DLT >	<u>/AT/</u>		<u>/12/</u>
> ADD >	AT	+	1%
> ADD >	@		0.5%
> ADD >	@		1%

<u>/N12111/002/</u>
<u>/N84305/001/</u>
N84305 001
<u>/N12111/004/</u>
<u>/N84306/001/</u>
N84306 001
N12111 002
N12111 004

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

/AP/ /QAD/ /3MG/ML/

Q QUAD 3MG/ML

/N89442/001/
/AUG/12/1988/
N89442 001
AUG 12, 1988VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

AB PHARMACAPS 250MG

N73484 001
JUN 29, 1993

SYRUP; ORAL

MYPROIC ACID

AA PENNEX PHARMS 250MG/5ML

N70868 001
JUL 01, 1986
/N70868/001/
/JUL/01/1986/

/AA/ /PHARM/BASICS/ /250MG/5ML/

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOCIN HCL IN PLASTIC CONTAINER

+ LILLY EQ 500MG BASE/100ML

N50671 001
APR 29, 1993

POWDER FOR RECONSTITUTION; ORAL

VANCOCIN HCL

AB LILLY EQ 250MG BASE/5ML

N61667 002
JUL 13, 1983

AB EQ 500MG BASE/6ML

N61667 001

AB VANCOLED
LEDERLE EQ 250MG BASE/5MLN63321 001
OCT 15, 1993

AB EQ 500MG BASE/6ML

N63321 003
OCT 15, 1993VASOPRESSIN TANNATE

> DLT > /INJECTABLE; INJECTION/

> DLT > /PITRESSIN/TANNATE/

> DLT > /PARKE/DAVIS/

> ADD > Q PARKE DAVIS

/5/PRESSOR/UNITS/ML/
5 PRESSOR UNITS/ML/N63402/001/
N03402 001> ADD > VENLAFAXINE HYDROCHLORIDE

> ADD >

TABLET; ORAL

> ADD >

EFFEXOR

> ADD >

+ WYETH AYERST

EQ 25MG BASE

N20151 002

> ADD >

> ADD >

+

EQ 100MG BASE

N20151 005

> ADD >

> ADD >

Q

EQ 12.5MG BASE

N20151 001

> ADD >

> ADD >

EQ 37.5MG BASE

N20151 006

> ADD >

> ADD >

EQ 50MG BASE

N20151 003

> ADD >

> ADD >

EQ 75MG BASE

N20151 004

> ADD >

DEC 28, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPTIN

/AP/ /KNOLL/ /2.5MG/ML/

AP + KNOLL

2.5MG/ML

/N18485/001/
N18485 001VERAPAMIL HCL

AP MARSAM 2.5MG/ML

N72233 001

AP 2.5MG/ML

FEB 26, 1993

N73485 001

SEP 27, 1993

TABLET; ORAL

VERAPAMIL HCL

AB WATSON LABS 40MG

N72923 001

AB 40MG

JUN 29, 1993

N72924 001

JUN 29, 1993

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

FUJISAWA 1MG/ML

N89515 001

/LYPHOMED/ /1MG/ML/

APR 29, 1987

/N89515/001/

/APR/29/1987/

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

Q STERLING

EQ 50,000 UNITS BASE N83187 001

VITAMIN A

/AA/ WHARTON/

/EQ 50,000 UNITS BASE/ N83665/001/

Q WHARTON

EQ 50,000 UNITS BASE N83665 001

/AA/ ZENITH/

/EQ 50,000 UNITS BASE/ N83035/001/

/AA/

/EQ 50,000 UNITS BASE/ N83190/001/

Q ZENITH

EQ 50,000 UNITS BASE N83035 001

Q

EQ 50,000 UNITS BASE N83190 001

INJECTABLE; INJECTION

AQUASOL A

/AP/ ASTRA/

/EQ 50,000 UNITS BASE/ML/ N06823/001/

ASTRA

EQ 50,000 UNITS BASE/ML N06823 001

VITAMIN A PALMITATE

/AP/ BEL/MAR/

/EQ 50,000 UNITS BASE/ML/ N80819/001/

Q BEL MAR

EQ 50,000 UNITS BASE/ML N80819 001

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

/BX/ DUPONT/

/2MG/ N09218/013/

/BX/

/2.5MG/ N09218/018/

/BX/ +/

/5MG/ N09218/007/

/BX/ +/

/10MG/ N09218/005/

+ DUPONT

2MG N09218 013

+

10MG N09218 005

2.5MG N09218 018

4MG N09218 023

AUG 24, 1993

5MG N09218 007

PANWARFIN

/BX/ ABBOTT/

/2MG/ N17020/001/

/BX/

/2.5MG/ N17020/002/

/BX/

/5MG/ N17020/003/

/BX/

/7.5MG/ N17020/004/

/BX/

/10MG/ N17020/005/

Q ABBOTT

2MG N17020 001

Q

2.5MG N17020 002

Q

5MG N17020 003

Q

7.5MG N17020 004

Q

10MG N17020 005

XENON, XE-133

GAS; INHALATION

XENON XE 133

/AA/ DUPONT/

/30MCI/VIAL/

/N17284/004/

/AA/

/40MCI/VIAL/

/N17284/005/

/AA/

/50MCI/VIAL/

/N17284/006/

/AA/

/60MCI/VIAL/

/N17284/007/

/AA/

/100MCI/VIAL/

/N17284/008/

AA

MEDI PHYSICS

/10MCI/VIAL/

N17687 002

AA

/20MCI/VIAL/

N17687 003

XYLOSE

POWDER; ORAL

XYLO-PFAN

/AA/ ADRIA/

/25GM/BOT/

/N17605/001/

AA

SAVAGE

/25GM/BOT/

N17605 001

ZINC SULFATEINJECTABLE; INJECTION/ZINC/SULFATE/LYPHOMED/

/EQ 1MG/ZINC/ML/

/N19229/002/

Q LYPHOMED

EQ 1MG ZINC/ML

/MAY 05, 1987/

N19229 002

MAY 05, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL

NEOPAP

/ALCON/

/120MG/

/N16401/001/

POLYMEDICA

120MG

N16401 001

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE
SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS

/SCHERING/

/500MG;3MG;60MG/

/N19453/001/

+ SCHERING PLOUGH

500MG;3MG;60MG

/MAY/22,/1987/

N19453 001

MAY 22, 1987

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

/ALUMINUM/HYDROXIDE/AND/MAGNESIUM/TRISILICATE/

/PENNEX/

/80MG;20MG/

/N89449/001/

a PENNEX

80MG;20MG

/NOV/27,/1987/

N89449 001

NOV 27, 1987

BACITRACIN; POLYMYXIN B SULFATE

/AEROSOL;/TOPICAL/

/ANTIBIOTIC/

/COMBE/

/500/UNITS/GM;/

/5,000/UNITS/GM/

/N50598/001/

a COMBE

500 UNITS/GM;
5,000 UNITS/GM

/SEP/22,/1986/

N50598 001

SEP 22, 1986

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

HIBISTAT

/STUART/

/0.5%/

/N18300/001/

+ ZENECA

0.5%

N18300 001

TINCTURE; TOPICAL

HIBITANE

/STUART/

/0.5%/

/N18049/001/

a ZENECA

0.5%

N18049 001

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

/SCHERING/

/8MG/

/N07638/001/

/12MG/

/N07638/002/

+ SCHERING PLOUGH

8MG

N07638 001

+

12MG

N07638 002

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DEMAZIN

/SCHERING/

/4MG;25MG/

/N18556/001/

+ SCHERING PLOUGH

4MG;25MG

/MAY/14,/1984/

N18556 001

MAY 14, 1984

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

/ISOLVOR/

/CIBA/

/8MG;120MG/

/N18747/001/

a FISONS

8MG;120MG

/MAR/06,/1986/

N18747 001

MAR 06, 1986

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

/SCHERING/

/8MG;120MG/

/N18397/001/

+ SCHERING PLOUGH

8MG;120MG

N18397 001

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

/SUSPENSION;/EXTENDED/RELEASE;/ORAL/

/PENTUSS/

/FISONS/

/EQ/4MG/MALEATE/5ML;/

/EQ/10MG/BASE/5ML/

/N18928/001/

a FISONS

EQ 4MG MALEATE/5ML;
EQ 10MG BASE/5ML

/AUG/14,/1985/

N18928 001

AUG 14, 1985

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX/SUSPENSION;/EXTENDED/RELEASE;/ORAL/
/CORSYM/
/FISONS/

	/EQ/4MG/MALEATE/5ML;/	/N18050/001/
	/EQ/37.5MG/HCL/5ML/	/JAN/04,1984/
3 FISONS	EQ 4MG MALEATE/5ML;	N18050 001
	EQ 37.5MG HCL/5ML	JAN 04, 1984

CLEMASTINE FUMARATE

TABLET; ORAL		
CLEMASTINE FUMARATE		
GENEVA	1.34MG	N73458 001
		OCT 31, 1993

CLOTRIMAZOLE

CREAM; TOPICAL		
CLOTRIMAZOLE		
TARO	1%	N72640 002
		AUG 31, 1993
LOTTRIMIN AF		
/SCHERING/	/1% /	/N17619/002/
		/OCT/27,1989/
+ SCHERING PLOUGH	1%	N17619 002
		OCT 27, 1989
CREAM; VAGINAL		
CLOTRIMAZOLE		
NMC	1%	N74165 001
		JUL 16, 1993
GYNE-LOTTRIMIN		
/SCHERING/	/1% /	/N18052/002/
		/NOV/30,1990/
+ SCHERING PLOUGH	1%	N18052 002
		NOV 30, 1990
CREAM, SUPPOSITORY; TOPICAL, VAGINAL		
GYNE-LOTTRIMIN COMBINATION PACK		
+ SCHERING PLOUGH	1%;100MG	N20289 002
		APR 26, 1993

CLOTRIMAZOLE

LOTION; TOPICAL		
LOTTRIMIN AF		
+ SCHERING	1%	N18813 002
		OCT 27, 1989
		/N18813/002/
		/OCT/27,1989/
		/1% /
SOLUTION; TOPICAL		
LOTTRIMIN AF		
/SCHERING/	/1% /	/N17613/002/
		/OCT/27,1989/
+ SCHERING PLOUGH	1%	N17613 002
		OCT 27, 1989
TABLET; VAGINAL		
GYNE-LOTTRIMIN		
/SCHERING/	/100MG/	/N17717/002/
		/NOV/30,1990/
+ SCHERING PLOUGH	100MG	N17717 002
		NOV 30, 1990

> DLT >
> DLT >
> ADD >
> ADD >

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL		
DISOPHROL		
/SCHERING/	/6MG;120MG/	/N13483/004/
		/SEP/13,1982/
SCHERING PLOUGH	6MG;120MG	N13483 004
		SEP 13, 1982
DRIXORAL		
/SCHERING/	/6MG;120MG/	/N13483/003/
		/SEP/13,1982/
+ SCHERING PLOUGH	6MG;120MG	N13483 003
		SEP 13, 1982

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL		
DIPHEN		
PENNEX PHARMS	12.5MG/5ML	N70118 001
		OCT 01, 1985
/PHARM/BASICS/	/12.5MG/5ML/	/N70118/001/
		/OCT/01,1985/
DIPHENHYDRAMINE HCL		
BARRE	12.5MG/5ML	N70497 001
		APR 25, 1989

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
/NASKA/

/12.5MG/5ML/

/N70447/001/
/APR/25./1989/IBUPROFEN

TABLET; ORAL
IBUPROFEN
/LUCHEM/

/200MG/

/N72901/001/
/DEC/19./1991/
/N72903/001/
/DEC/19./1991/

/200MG/

IBUPROFEN
NORTON HN

200MG

N71144 001
JAN 20, 1987
N72901 001
DEC 19, 1991
N72903 001
DEC 19, 1991

200MG

200MG

/IBUPROFEN/
/OHM/

/200MG/

/N71214/001/
/DEC/01./1986/

IBUPROFEN
/ZENITH/

/200MG/

/N71154/001/
/OCT/27./1987/
N71154 001
OCT 27, 1987

3 ZENITH

200MG

IBUPROFEN
OHM

200MG

N71214 001
DEC 01, 1986

/NEUVIL/
/LUCHEM/

/200MG/

/N71144/001/
/JAN/20./1987/INSULIN SUSP PROTAMINE ZINC BEEF/PORK

/INJECTABLE;/INJECTION/
/PROTAMINE;/ZINC;/Iletin/I (BEEF-PORK)/
/LILLY/

/40 UNITS/ML/
/100 UNITS/ML//N17932/001/
/N17932/002/
N17932 001
N17932 002

3 LILLY

40 UNITS/ML

3

100 UNITS/ML

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
WATSON LABS

1MG/5ML

N73062 001
MAY 28, 1993

TABLET; ORAL
LOPERAMIDE HCL
ABLE

2MG

N73528 001
NOV 30, 1993
N73254 001
JUL 30, 1993

NOVOPHARM

2MG

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT 7 COMBINATION PACK
+ ADVANCED CARE

2%;100MG

N20288 002
APR 26, 1993

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
ABLE

100MG

N73507 001
NOV 19, 1993OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUCLEAR
/SCHERING/

/0.025%/

SCHERING PLOUGH

0.025%

/N18471/001/
/MAY/30./1986/
N18471 001
MAY 30, 1986PSEUDOEPHEDRINE HYDROCHLORIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/SUDAFED/12/HOUR/
/BURROUGHS/HELLICOME/

/120MG/

3 BURROUGHS WELLICOME

120MG

/N17941/002/
N17941 002

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/CAPSULE;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /60MG;2.5MG/ /N19266/001/
/JAN/19./1985/

CAPSULE, EXTENDED RELEASE; ORAL

/ACTIFED/
/BURROUGHS/WELLCOME/ /120MG;5MG/ /N18996/001/
/JUN/17./1985/ N18996 001
JUN 17, 1985

/SYRUP;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /30MG/5ML;1.25MG/5ML/ /N11935/003/
/NOV/26./1982/
/TRIOFED/
/BARRE/ /30MG/5ML;1.25MG/5ML/ /N88115/001/
/MAR/04./1983/
/TRIPROSED/
/HALSEY/ /30MG/5ML;1.25MG/5ML/ /N88213/002/
/MAR/30./1984/

/TABLET;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /60MG;2.5MG/ /N11936/002/
/NOV/26./1982/
/TRI-SUDO/
/MD/PHARM/ /60MG;2.5MG/ /N85624/002/
/JAN/10./1984/
/TRIPRODRINE/
/DANEUR/PHARMA/ /60MG;2.5MG/ /N88112/001/
/JAN/20./1983/
/TRIPROSED/
/HALSEY/ /60MG;2.5MG/ /N88192/002/
/MAY/01./1984/
/TRIPROLIDINE/HCL/AND/PSEUDOEPHEDRINE/HCL/
/CHELSEA/ /60MG;2.5MG/ /N88118/002/
/JAN/26./1984/

TABLET, EXTENDED RELEASE; ORAL

/TRIPROLIDINE/AND/PSEUDOEPHEDRINE/HCL/
/KV/ /120MG;5MG/ /N72758/001/
/NOV/25./1991/

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

+ KV 120MG;5MG N72758 001
NOV 25, 1991

PSEUDOEPHEDRINE POLISTIREX

/SUSPENSION;/EXTENDED/RELEASE;/ORAL/
/PSEUDO-12/
/FISONS/ /EQ/60MG/HCL/5ML/ /N19401/001/
/JUN/19./1987/ N19401 001
JUN 19, 1987

a FISONS

EQ 60MG HCL/5ML

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

AFRINOL
/SCHERING/ /120MG/ /N18191/001/
+ SCHERING PLOUGH 120MG N18191 001

TRIPROLIDINE HYDROCHLORIDE

/SYRUP;/ORAL/
/ACTIDIL/
/BURROUGHS/WELLCOME/ /1.25MG/5ML/ /N11496/002/
/JUL/01./1983/ N11496 002
JUL 01, 1983

a BURROUGHS WELLCOME 1.25MG/5ML

/TABLET;/ORAL/
/ACTIDIL/
/BURROUGHS/WELLCOME/ /2.5MG/

a BURROUGHS WELLCOME 2.5MG

/N11110/002/
/JUL/01./1983/
N11110 002
JUL 01, 1983

> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 12 / DEC '93

INDIUM¹¹¹ CHLORIDE

SOLUTION; INJECTION
INDICLOR
AMERSHAM

N/A

N19862
DEC 29, 1992

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January thru November 1993]

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
2-O-DESULFATED HEPARIN TN= AEROPIN	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs. 7702 PARHAM ROAD RICHMOND VA 23294 DD 09/17/93 MA / /
5a8, MONOCLONAL ANTIBODY TO CD4 TN=	FOR USE IN POST-EXPOSURE PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE TO HUMAN IMMUNODEFICIENCY VIRUS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 12/20/93 MA / /
8-METHOXSALEN TN= UVADEX	FOR USE IN CONJUNCTION WITH THE UVAR PHOTOPHERESIS TO TREAT DIFFUSE SYSTEMIC SCLEROSIS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 06/22/93 MA / /
9- [3-PYRIDYLMETHYL]-9-DEAZAGUANI NE TN=	TREATMENT OF CUTANEOUS T-CELL LYMPHOMA.	BIOCRIST PHARMACEUTICALS, INCORPORATED 2190 PARKWAY LAKE DRIVE BIRMINGHAM AL 35244 DD 10/05/93 MA / /
AMINOSALICYLATE SODIUM TN=	TREATMENT OF CROHN'S DISEASE.	SYNCOM PHARMACEUTICALS, INC. 155 PASSAIC AVENUE FAIRFIELD NJ 07004 DD 04/06/93 MA / /
AMINOSIDINE TN= GABBROMICINA	TREATMENT OF TUBERCULOSIS.	KANYOK, THOMAS P. PHARM.D. UNIVERSITY OF RHODE ISLAND PROVIDENCE RI 02908-4735 DD 05/14/93 MA / /
AMINOSIDINE TN= GABBROMICINA	TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX.	KANYOK, THOMAS P. PHARM.D. UNIVERSITY OF RHODE ISLAND PROVIDENCE RI 02908-4735 DD 11/15/93 MA / /
AMIODARONE TN= AMIO-AQUEOUS	TREATMENT OF INCESSANT VENTRICULAR TACHYCARDIA.	ACADEMIC PHARMACEUTICALS, INC. 25720 SAUNDERS ROAD NORTH LAKE FOREST IL 60045 DD 08/17/93 MA / /
ANTI-THYMOCYTE SERUM TN= NASHVILLE RABBIT ANTI-THYMOCYTE SERUM	TREATMENT OF ALLOGRAFT REJECTION, INCLUDING SOLID ORGAN (KIDNEY, LIVER, HEART, LUNG, AND PANCREAS) AND BONE MARROW TRANSPLANTATION.	APPLIED MEDICAL RESEARCH 1600 HAYES STREET NASHVILLE TN 37203 DD 06/02/93 MA / /
APOMORPHINE HCL INJECTION TN=	TREATMENT OF THE ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	BRITANNIA PHARMACEUTICALS LTD FORUM HOUSE, BRIGHTON ROAD REDHILL, SURREY UK DD 04/22/93 MA / /
ATOVAQUONE TN= MEPRON	TREATMENT AND SUPPRESSION OF TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
ATOVAQUONE TN= MEPRON	PRIMARY PROPHYLAXIS OF HIV-INFECTED PERSONS AT HIGH RISK FOR DEVELOPING TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
BERACTANT TN= SURVANTA INTRATHECAL SUSPENSION	TREATMENT OF FULL-TERM NEWBORN INFANTS WITH RESPIRATORY FAILURE CAUSED BY MECONIUM ASPIRATION SYNDROME, PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN, OR PNEUMONIA AND SEPSIS.	ROSS LABORATORIES 625 CLEVELAND AVENUE COLUMBUS OH 43215 DD 12/20/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME <i>Generic/Chemical</i> <i>TN= Trade Name</i>	INDICATION DESIGNATED	SPONSOR & ADDRESS <i>DD=Date Designated</i> <i>MA=Marketing Approval</i>
BISPECIFIC ANTIBODY 520C9x22 TN=	IN VIVO SEROTHERAPY OF PATIENTS WITH OVARIAN CANCER.	MEDAREX 12 COMMERCE AVENUE WEST LEBANON NH 03784 DD 10/05/93 MA / /
BLEOMYCIN SULFATE TN= BLENOXANE	TREATMENT OF MALIGNANT PLEURAL EFFUSION.	BRISTOL-MYERS SQUIBB PO BOX 4000 PRINCETON NJ 08543-4000 DD 09/17/93 MA / /
BOVINE WHEY PROTEIN CONCENTRATE TN= IMMUNO-C	TREATMENT OF CRYPTOSPORIDIOSIS CAUSED BY THE PRESENCE OF CRYPTOSPORIDIUM PARVUM IN THE GASTROINTESTINAL TRACT OF PATIENTS WHO ARE IMMUNODEFICIENT/IMMUNOCOMPROMISED OR IMMUNOCOMPETENT.	BIOMUNE SYSTEMS, INCORPORATED 40 EAST SOUTH TEMPLE SUITE 310 SALT LAKE CITY UT 84111 DD 09/30/93 MA / /
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF NON-HODGKIN'S LYMPHOMA.	R.W. JOHNSON RESEARCH INSTITUTE ROUTE 202 SOUTH, P.O. BOX 300 RARITAN NJ 08869-0602 DD 04/19/93 MA / /
COLFOSCERIL PALMITATE, CETYL ALCOHOL, TYLOXAPOL TN= EXOSURF	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 01/11/93 MA / /
CY-1503 TN=	TREATMENT OF POST-ISCHEMIC REPERFUSION EDEMA FOLLOWING SURGICAL TREATMENT FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION.	CYTEL CORPORATION 3525 JOHN HOPKINS COURT SAN DIEGO CA 92121 DD 12/22/93 MA / /
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE TN=	TREATMENT OF CYSTIC FIBROSIS.	GENETIC THERAPY, INC. 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 DD 01/08/93 MA / /
DEPOFOAM ENCAPSULATED CYTARABINE TN=	TREATMENT OF NEOPLASTIC MENINGITIS.	DEPOTECH CORPORATION 11025 NORTH TORREY PINES ROAD, SUITE 100 LA JOLLA CA 92037 DD 06/02/93 MA / /
DISODIUM CLODRONATE TN=	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY.	DISCOVERY EXPERIMENTAL & DEVELOPMENT, INC 29949 S.R. 54 WEST WESLEY CHAPEL FL 33543 DD 06/16/93 MA / /
EPOETIN ALFA TN=	TREATMENT OF MYELODYSPLASTIC SYNDROME.	R.W. JOHNSON RESEARCH INSTITUTE ROUTE 202 SOUTH, BOX 300 RARITAN NJ 08869-0602 DD 12/20/93 MA / /
FACTOR XIII, RECOMBINANT TN=	TREATMENT OF CONGENITAL FACTOR XIII DEFICIENCY.	ZYMOGENETICS, INC. 4225 ROOSEVELT WAY SEATTLE WA 98105 DD 04/22/93 MA / /
HEMIN AND ZINC MESOPORPHYRIN TN= HEMEX	TREATMENT OF ACUTE PORPHYRIC SYNDROMES.	BONKOVSKY, HERBERT L. M.D. UNIVERSITY OF MASSACHUSETTS MEDICAL CTR WORCESTER MA 01655 DD 12/20/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE FOLLOWING BONE MARROW TRANSPLANTATION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= GAMIMUNE N	INFECTION PROPHYLAXIS IN PEDIATRIC PATIENTS AFFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94710 DD 02/18/93 MA / /
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= IMMUNE GLOBULIN INTRAVENOUS (HUMAN) IMMUNO, IVEEGAM	TREATMENT OF PATIENTS WITH ACUTE MYOCARDITIS.	IMMUNO CLINICAL RESEARCH CORPORATION 750 LEXINGTON AVENUE NEW YORK NY 10022 DD 11/22/93 MA / /
INTERFERON BETA (RECOMBINANT HUMAN) TN=	TREATMENT OF PRIMARY BRAIN TUMORS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 01/13/93 MA / /
INTERLEUKIN-3, HUMAN, RECOMBINANT TN=	FOR SEQUENTIAL ADMINISTRATION WITH SARGRAMOSTIM TO ACCELERATE NEUTROPHIL AND PLATELET RECOVERY IN PATIENTS UNDERGOING AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF HODGKIN'S DISEASE OR NON-HODGKIN'S LYMPHOMA.	SANDOZ PHARMACEUTICALS CORP. 59 ROUTE 10 EAST HANOVER NJ 07936-1080 DD 09/30/93 MA / /
LEVOCARNITINE TN= CARNITOR	TREATMENT OF PEDIATRIC CARDIOMYOPATHY.	SIGMA-TAU PHARMACEUTICALS, INC. 200 ORCHARD RIDGE DRIVE, SUITE 300 GAITHERSBURG MD 20878 DD 11/17/93 MA / /
LIPOSOMAL DAUNORUBICIN TN= DAUNOXOME	TREATMENT OF PATIENTS WITH ADVANCED HIV-ASSOCIATED KAPOSI'S SARCOMA.	VESTAR, INC. 650 CLIFFSIDE DRIVE SAN DIMAS CA 91773 DD 05/14/93 MA / /
MELATONIN TN=	TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS IN BLIND PEOPLE WITH NO LIGHT PERCEPTION.	SACK, ROBERT, M.D. 3181 S.W. SAM JACKSON PARK ROAD PORTLAND OR 97201-3098 DD 11/15/93 MA / /
METHOTREXATE TN= RHEUMATREX	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	LEDERLE LABORATORIES 401 N. MIDDLETOWN ROAD PEARL RIVER NY 10965-1299 DD 08/23/93 MA / /
MODAFINIL TN=	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN NARCOLEPSY.	CEPHALON, INC. 145 BRANDYWINE PARKWAY WEST CHESTER PA 19380-4245 DD 03/15/93 MA / /
MONOCLONAL ANTIBODY FOR IMMUNIZATION AGAINST LUPUS NEPHRITIS TN=	TREATMENT OF LUPUS NEPHRITIS.	MEDCLONE, INC. 2435 MILITARY AVENUE LOS ANGELES CA 90064 DD 01/07/93 MA / /
MONOLAURIN TN= GLYLORIN	TREATMENT OF CONGENITAL PRIMARY ICHTHYOSIS.	CELLEGY PHARMACEUTICALS, INC. 371 BEL MARIN KEYS, SUITE 210 NOVATO CA 94949 DD 04/29/93 MA / /
MYTOMYCIN-C TN=	TREATMENT OF REFRACTORY GLAUCOMA AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY.	IOP INCORPORATED 3100 AIRWAY AVENUE COSTA MESA CA 92626 DD 08/20/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME <i>Generic/Chemical</i> <i>TN= Trade Name</i>	INDICATION DESIGNATED	SPONSOR & ADDRESS <i>DD=Date Designated</i> <i>MA=Marketing Approval</i>
NITRIC OXIDE TN=	TREATMENT OF PERSISTENT PULMONARY HYPERTENSION IN THE NEWBORN.	OHMEDA PHARMACEUTICAL PRODUCTS DIVISION 110 ALLEN ROAD, PO BOX 804 LIBERTY CORNER NJ 07938-0804 DD 06/22/93 MA / /
POLY I: POLY C12U TN= AMPLIGEN	TREATMENT OF CHRONIC FATIGUE SYNDROME.	HEM PHARMACEUTICALS CORP. ONE PENN CENTER, SUITE 660 PHILADELPHIA PA 19103 DD 12/09/93 MA / /
PRIMAQUINE PHOSPHATE TN=	FOR USE IN COMBINATION WITH CLINDAMYCIN HYDROCHLORIDE IN THE TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA ASSOCIATED WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	STERLING WINTHROP INC. 90 PARK AVENUE NEW YORK NY 10016 DD 07/23/93 MA / /
PROSTAGLANDIN E1 ALPHA-CYCLODEXTRIN TN= VASOPROST	TREATMENT OF SEVERE PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (CRITICAL LIMB ISCHEMIA) IN PATIENTS WHERE OTHER PROCEDURES, GRAFTS OR ANGIOPLASTY, ARE NOT INDICATED.	SCHWARZ PHARMA 5600 WEST COUNTY LINE ROAD MEQUON WI 53092 DD 10/20/93 MA / /
PROTEIN C CONCENTRATE TN= PROTEIN C CONCENTRATE (HUMAN) VAPOR HEATED, IMMUNO	FOR USE IN THE PREVENTION AND TREATMENT OF PURPURA FULMINANS IN MENINGOCOCCEMIA.	IMMUNO CLINICAL RESEARCH CORP. 750 LEXINGTON AVENUE, 19TH FLOOR NEW YORK NY 10022 DD 04/22/93 MA / /
PROTIRELIN TN=	PREVENTION OF INFANT RESPIRATORY DISTRESS SYNDROME ASSOCIATED WITH PREMATURITY.	UCB PHARMACEUTICALS, INC. 5505-A ROBIN HOOD ROAD NORFOLK VA 23513 DD 08/24/93 MA / /
PULMONARY SURFACTANT REPLACEMENT, PORCINE TN= CUROSURF	FOR THE TREATMENT AND PREVENTION OF RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS.	CHIESI PHARMACEUTICALS, INC. 150 DANBURY ROAD RIDGEFIELD CT 06877 DD 08/02/93 MA / /
RECOMBINANT RETROVIRAL VECTOR - GLUCOCEREBROSIDASE TN=	FOR USE AS ENZYME REPLACEMENT THERAPY FOR PATIENTS WITH TYPES I, II, OR III GAUCHER DISEASE.	GENETIC THERAPY, INC. 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 DD 11/15/93 MA / /
RHO(D) IMMUNE GLOBULIN (HUMAN) TN= WINPHO SD	TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA.	RH PHARMACEUTICALS, INC. 104 CHANCELLOR MATHESON ROAD WINNIPEG, MANITOBA DD 11/09/93 MA / /
RII RETINAMIDE TN=	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	SPARTA PHARMACEUTICALS, INCORPORATED PO BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 05/06/93 MA / /
RILUZOLE TN=	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD, PO BOX 1200 COLLEGEVILLE PA 19426-0107 DD 03/16/93 MA / /
ROQUINIMEX TN= LINOMIDE	TO PROLONG TIME TO RELAPSE IN LEUKEMIA PATIENTS WHO HAVE UNDERGONE AUTOLOGOUS BONE MARROW TRANSPLANTATION.	KABI PHARMACIA, INC. 800 CENTENNIAL AVENUE PISCATAWAY NJ 08855-1327 DD 07/01/93 MA / /
SECALCIFEROL TN= OSTEO-D	TREATMENT OF FAMILIAL HYPOPHOSPHATEMIC RICKETS.	LEMMON COMPANY 650 CATHILL ROAD SELLERSVILLE PA 18960 DD 07/26/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME <i>Generic/Chemical</i> <i>TN= Trade Name</i>	INDICATION DESIGNATED	SPONSOR & ADDRESS <i>DD=Date Designated</i> <i>MA=Marketing Approval</i>
SODIUM BENZOATE/SODIUM PHENYLACETATE TN=	TREATMENT OF UREA CYCLE DISORDERS: CARBAMYLPHOSPHATE SYNTHETASE DEFICIENCY, ORNITHINE TRANSCARBAMYLASE DEFICIENCY, AND ARGININOSUCCINIC ACID SYNTHETASE DEFICIENCY.	BRUSILOW, SAUL W. M.D. JOHNS HOPKINS MEDICAL INSTITUTIONS BALTIMORE MD 21205 DD 11/17/93 MA / /
SODIUM PHENYLBUTYRATE TN=	TREATMENT OF UREA CYCLE DISORDERS: CARBAMYLPHOSPHATE SYNTHETASE DEFICIENCY, ORNITHINE TRANSCARBAMYLASE DEFICIENCY, AND ARGININOSUCCINIC ACID SYNTHETASE DEFICIENCY.	BRUSILOW, SAUL W. M.D. JOHNS HOPKINS MEDICAL INSTITUTIONS BALTIMORE MD 21205 DD 11/17/93 MA / /
SOMATROPIN TN= BIOTROPIN	TREATMENT OF CACHEXIA ASSOCIATED WITH AIDS.	BIO-TECHNOLOGY GENERAL CORPORATION 1250 BROADWAY, 20th FLOOR NEW YORK NY 10001 DD 02/12/93 MA / /
SUCRALFATE TN=	TREATMENT OF ORAL MUCOSITIS AND STOMATITIS FOLLOWING RADIATION THERAPY FOR HEAD AND NECK CANCER.	FUISZ TECHNOLOGIES, LTD. 3810 CONCORDE PARKWAY, SUITE 100 CHANTILLY VA 22021 DD 07/15/93 MA / /
SUCRASE (YEAST-DERIVED) TN= SACARASA	TREATMENT OF CONGENITAL SUCRASE-ISOMALTASE DEFICIENCY.	TREEM, WILLIAM R. M.D. HARTFORD HOSPITAL HARTFORD CT 06115 DD 12/10/93 MA / /
THALIDOMIDE TN=	TREATMENT OF THE CLINICAL MANIFESTATIONS OF MYCOBACTERIAL INFECTION CAUSED BY MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOUS MYCOBACTERIA.	CELGENE CORPORATION 7 POWDER HORN DRIVE WARREN NJ 07059 DD 01/12/93 MA / /
TOREMIFENE TN= ESTRINEX	TREATMENT OF DESMOID TUMORS.	ADRIA LABORATORIES P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 08/17/93 MA / /
TRETINOIN TN= TRETINOIN LF, IV	TREATMENT OF ACUTE AND CHRONIC LEUKEMIA.	ARGUS PHARMACEUTICALS, INC. 3400 RESEARCH FOREST DRIVE THE WOODLANDS TX 77381 DD 01/14/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN I TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN II TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 T-CELL COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
VASOACTIVE INTESTINAL POLYPEPTIDE TN=	TREATMENT OF ACUTE ESOPHAGEAL FOOD IMPACTION.	RESEARCH TRIANGLE PHARMACEUTICALS 200 WESTPARK CORPORATE CENTER DURHAM NC 27713 DD 06/23/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME

Generic/Chemical
TN= Trade Name

INDICATION DESIGNATED

SPONSOR & ADDRESS

DD=Date Designated
MA=Marketing Approval

Orphan Drug Approvals

ANTIHEMOPHILIC FACTOR (RECOMBINANT) TN= KOGENATE	PROPHYLAXIS AND TREATMENT OF BLEEDING IN INDIVIDUALS WITH HEMOPHILIA A OR FOR PROPHYLAXIS WHEN SURGERY IS REQUIRED IN INDIVIDUALS WITH HEMOPHILIA A.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94701 DD 09/25/89 MA 02/25/93
APROTININ TN= TRASYLOL	FOR PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE HOMOLOGOUS BLOOD TRANSFUSION REQUIREMENT IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS SURGERY IN THE COURSE OF REPEAT CORONARY ARTERY BYPASS GRAFT SURGERY, AND IN SELECTED CASES OF PRIMARY CORONARY ARTERY BYPASS GRAFT SURGERY WHERE THE RISK OF BLEEDING IS ESPECIALLY HIGH (IMPAIRED HEMOSTASIS, E.G. PRESENCE OF ASPIRIN OR OTHER COAGULOPATHY) OR WHERE TRANSFUSION IS UNAVAILABLE OR UNACCEPTABLE.	MILES, INC. 400 MORGAN LANE WEST HAVEN CT 06516 DD 11/17/93 MA 12/29/93
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF HAIRY CELL LEUKEMIA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 11/15/90 MA 02/26/93
DORNASE ALFA TN= PULMOZYME	TO REDUCE MUCOUS VISCOSITY AND ENABLE THE CLEARANCE OF AIRWAY SECRETIONS IN PATIENTS WITH CYSTIC FIBROSIS.	GENENTECH, INC. 460 POINT SAN BRUNO BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 01/16/91 MA 12/30/93
FELBAMATE TN= FELBATOL	TREATMENT OF LENNOX-GASTAUT SYNDROME.	WALLACE LABORATORIES 301B COLLEGE ROAD EAST PRINCETON NJ 08540 DD 01/24/89 MA 07/29/93
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= GAMIMUNE N	INFECTION PROPHYLAXIS IN PEDIATRIC PATIENTS AFFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94710 DD 02/18/93 MA 12/27/93
INTERFERON BETA, RECOMBINANT HUMAN TN=BETASERON	TREATMENT OF MULTIPLE SCLEROSIS.	CHIRON CORPORATION 4560 HORTON STREET EMERYVILLE CA 94608 DD 11/17/88 MA 07/23/93
LEUPROLIDE ACETATE TN= LUPRON INJECTION	TREATMENT OF CENTRAL PRECOCIOUS PUBERTY.	TAP PHARMACEUTICALS, INC. 2355 WAUKEGAN ROAD DEERFIELD IL 60015 DD 07/25/88 MA 04/16/93
LEVOMETHADYL ACETATE HYDROCHLORIDE TN=ORLAAM	TREATMENT OF HEROIN ADDICTS SUITABLE FOR MAINTENANCE ON OPIATE AGONISTS.	BIODEVELOPMENT CORPORATION 1300 NORTH 17TH STREET, SUITE 300 ARLINGTON VA 22209-2306 DD 01/24/84 MA 07/09/93
LODOXAMIDE TROMETHAMINE TN= ALOMIDE OPHTHALMIC SOLUTION	TREATMENT OF VERNAL KERATOCONJUNCTIVITIS.	ALCON LABORATORIES, INC. 6201 SOUTH FREEWAY FORT WORTH TX 76134 DD 10/16/91 MA 09/23/93
MEGESTROL ACETATE TN= MEGACE	TREATMENT OF PATIENTS WITH ANOREXIA, CACHEXIA, OR SIGNIFICANT WEIGHT LOSS ($\geq 10\%$ OF BASELINE BODY WEIGHT) AND CONFIRMED DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	BRISTOL-MYERS SQUIBB 2400 WEST LLOYD EXPRESSWAY EVANSVILLE IN 47721-0001 DD 04/13/88 MA 09/10/93

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS**NAME***Generic/Chemical**TN= Trade Name***INDICATION DESIGNATED****SPONSOR & ADDRESS***DD=Date Designated**MA=Marketing Approval***Orphan Drug Approvals**

SOMATROPIN FOR INJECTION
TN= NUTROPIN

TREATMENT OF GROWTH RETARDATION ASSOCIATED WITH CHRONIC
RENAL FAILURE.

GENENTECH, INC.
460 POINT SAN BRUNO BOULEVARD
SOUTH SAN FRANCISCO CA 94080
DD 08/04/89 MA 11/17/93

TRIMETREXATE GLUCURONATE
TN= NEUTREXIN

TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA
IN AIDS PATIENTS.

U.S. BIOSCIENCE, INC.
ONE TOWER BRIDGE, 100 FRONT STREET
WEST CONSHOHOCKEN PA 19428
DD 05/15/86 MA 12/17/93

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECMEBER 1993 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
-------------------------	------	--------------

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

BUMETANIDE (TABLET)	APR 23, 1993	
BUSIPRONE HYDROCHLORIDE (TABLET)	AUG 13, 1993	
CAPTAPRIL (TABLET)	MAY 13, 1993	
CEFACLOL (CAPSULE AND SUSPENSION)	APR 23, 1993	
CHOLESTRYRAMINE (POWDER)	JUL 15, 1993	
DICLOFENAC SODIUM (TABLET)	DEC 24, 1992	DEC 02, 1993
GLIPIZIDE (TABLET)	APR 23, 1993	
GLYBURIDE (TABLET)	APR 23, 1993	
GUANABENZ ACETATE (TABLET)	APR 23, 1993	
INDAPAMIDE (TABLET)	APR 23, 1993	
KETOPROFEN (CAPSULE)	APR 23, 1993	
ORAL EXTENDED (CONTROLLED RELEASE)	SEP 09, 1993	
PINDOLOL (TABLET)	APR 23, 1993	
RANITIDINE HYDROCHLORIDE (TABLET)	APR 23, 1993	
TRIAZOLAM (TABLET)	DEC 24, 1992	

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
---------------------------------	------------------------------	---------------	------------	------------------------	--------

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ACETAMINOPHEN; ASPIRIN; HYDROCODONE BITARTRATE CAPSULE; ORAL	150MG 180MG 2.5MG	92 P-0282/ CP3	MIKART	NEW COMBINATION	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYDROCODONE BITARTRATE CAPSULE; ORAL	150MG 180MG 5MG	92 P-0282/ CP1	MIKART	NEW COMBINATION	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYDROCODONE BITARTRATE CAPSULE; ORAL	150MG 180MG 7.5MG	92 P-0282/ CP2	MIKART	NEW COMBINATION NEW STRENGTH	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYDROCODONE BITARTRATE CAPSULE; ORAL	150MG 180MG 10MG	92 P-0282/ CP4	MIKART	NEW COMBINATION	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	150MG 180MG 2.5MG	92 P-0282/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	150MG 180MG 5MG	92 P-0282/ CP1	MIKART	NEW COMBINATION NEW DOSAGE FORM	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	150MG 180MG 7.5MG	92 P-0282/ CP2	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	150MG 180MG 10MG	92 P-0282/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM	APPROVED NOV 10, 1993
ACETAMINOPHEN; CODEINE PHOSPHATE CAPSULE; ORAL	500MG 45MG	93 P-0314/ CP1	MIKART	NEW DOSAGE FORM NEW STRENGTH	APPROVED NOV 10, 1993
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET; ORAL	500MG 45MG	93 P-0314/ CP1	MIKART	NEW STRENGTH	APPROVED NOV 10, 1993
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 50MG BASE/ML (10ML/VIAL) (20ML/VIAL)	92 P-0468/ CP1	BULL	NEW DOSAGE FORM	APPROVED SEP 01, 1993
AMINOSALICYLIC ACID GRANULES, ENTERIC-COATED; ORAL	4GM/PACKET	92 P-0356/ CP1	JACOBUS	NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 03, 1993

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CARBOPLATIN INJECTABLE; INJECTION	10MG/ML (5ML/VIAL) (15ML/VIAL) (45ML/VIAL)	92 P-0467/ CP1	BULL	NEW DOSAGE FORM	APPROVED MAY 20, 1993
CHLORPROMAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0284/ CP1	UDL	NEW STRENGTH	APPROVED JAN 07, 1993
CISPLATIN INJECTABLE; INJECTION	1MG/ML (200ML/VIAL)	93 P-0084/ CP1	FUJISAWA	NEW STRENGTH	APPROVED NOV 10, 1993
CYTARABINE INJECTABLE; INJECTION	20MG/ML (12.5ML/VIAL)	92 P-0381/ CP1	BRISTOL MYERS SQUIBB	NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 18, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (40ML/VIAL)	92 P-0365/ CP1	LYPHOMED	NEW STRENGTH	APPROVED FEB 11, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (100ML/CONTAINER)	93 P-0045/ CP1	MARSAM	NEW STRENGTH	APPROVED SEP 10, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (12.5MG/VIAL)	92 P-0355/ CP1	LEDERLE	NEW STRENGTH	APPROVED JAN 07, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/CONTAINER)	91 P-0460/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 11, 1993
LACTULOSE CRYSTAL; ORAL	10GM/PACKET	92 P-0370/ CP1	BENNETT AND COMPANY	NEW DOSAGE FORM	APPROVED JAN 07, 1993
METHYLPHENIDATE HYDROCHLORIDE; TABLET, EXTENDED RELEASE; ORAL	10MG	92 P-0400/ CP1	MD PHARM	NEW STRENGTH	APPROVED MAR 22, 1993
PREDNISOLONE SYRUP; ORAL	10MG/5ML	92 P-0439/ CP1	WE PHARMS	NEW STRENGTH	APPROVED MAY 20, 1993
PREDNISONE TABLET, CHEWABLE; ORAL	5MG 10MG	92 P-0336/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED NOV 10, 1993
PROPRANOLOL HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	10MG 20MG 60MG 80MG 90MG	93 P-0049/ CP1	FLEMINGTON PHARM	NEW DOSAGE FORM NEW STRENGTH	APPROVED SEP 01, 1993
TERBUTALINE SULFATE INJECTABLE; INJECTION	1MG/ML (0.25ML/CONTAINER)	92 P-0430/ CP1	STERLING WINTHROP	NEW STRENGTH	APPROVED MAR 18, 1993
TRIMETHOPRIM SOLUTION; ORAL	25MG/5ML	92 P-0500/ CP1	ASCENT PHARMS	NEW DOSAGE FORM	APPROVED MAY 20, 1993

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CROTAMITON GEL; TOPICAL	10%	92 P-0249/ CP1	HAMER	NEW DOSAGE FORM	DENIED NOV 10, 1993

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-20 SINGLE 32MG DOSE

REFERENCES

NEW INDICATION

I-87 RENAL IMAGING AGENT FOR USE IN CHILDREN
 I-88 MANAGEMENT OF ENDOMETRIOSIS
 I-89 EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
 I-90 INTENSIVE CARE UNIT SEDATION
 I-91 MONOTHERAPY USE FOR HYPERTENSION
 I-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
 I-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
 I-94 USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
 I-95 TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
 I-96 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
 I-97 ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
 I-98 TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY

REFERENCES

PATENT USE CODE

U-74 METHOD OF PROVIDING HYPNOTIC EFFECT
 U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
 U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
 U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
 U-78 ULCERATIVE COLITIS
 U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
 U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
 U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
 U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
 U-83 TREATMENT OF SEIZURES
 U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
 U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
 U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
 U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
 U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS
 U-89 TREATMENT OR PROPHYLAXIS OF EMESIS
 U-90 TREATMENT OF PSYCHOTIC DISORDERS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
18473 001	ALBUTEROL; VENTOLIN				I-93	JUL 20, 1996
19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS				I-93	JUL 20, 1996
19604 001	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4751071	JUN 14, 2005			
19604 002	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4751071	JUN 14, 2005		NS	DEC 23, 1995
		5061494	OCT 29, 2008			
>ADD>	18276 004 ALPRAZOLAM; XANAX	4572909	AUG 01, 2006		NCE	JUL 31, 1997
>DLT>	19787 001 AMLODIPINE BESYLATE; NORVASC	4572909	FEB 25, 2003		NCE	JUL 31, 1997
>ADD>	19787 002 AMLODIPINE BESYLATE; NORVASC	4572909	AUG 01, 2006		NCE	JUL 31, 1997
>DLT>	19787 002 AMLODIPINE BESYLATE; NORVASC	4572909	FEB 25, 2003		NCE	JUL 31, 1997
>ADD>	19787 003 AMLODIPINE BESYLATE; NORVASC	4572909	AUG 01, 2006		NCE	JUL 31, 1997
>DLT>	19787 003 AMLODIPINE BESYLATE; NORVASC	4572909	FEB 25, 2003		NCE	JUL 31, 1997
	20258 001 APRACLOINIDINE HYDROCHLORIDE; IOPIDINE	4517199	MAY 14, 2002	U-15	NS	JUL 30, 1996
>ADD>	20304 001 APROTININ BOVINE; TRASYLOL				NCE	DEC 29, 1998
	19402 001 ASTEMIZOLE; HISMANAL	4219559	AUG 26, 1999		NCE	DEC 29, 1993
	20045 001 AVOBENZONE; SHADE UVAGUARD	4522807	JUN 11, 2002		NC	DEC 07, 1995
		4387089	JUN 07, 2002			
		4252984	AUG 30, 1999			
	19807 001 BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
	19807 002 BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
>ADD>	19982 001 BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	19982 001 BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
>ADD>	19982 002 BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	19982 002 BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
>ADD>	20186 001 BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	20186 001 BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
					NC	FEB 26, 1996
>ADD>	20186 002 BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	20186 002 BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
					NC	FEB 26, 1996
>ADD>	20186 003 BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	20186 003 BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
					NC	FEB 26, 1996
>ADD>	20273 001 CALCIPOTRIENE; DOVONEX	4866048	SEP 12, 2006	U-88	NCE	DEC 29, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
18343 001	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
18343 002	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
18343 003	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
18343 005	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
20210 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
20210 002	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
20229 001	CLADRIBINE; LEUSTATIN				NCE	FEB 26, 1998
					ODE	FEB 26, 2000
>ADD>	20118 001 DESFLURANE; SUPRANE	4762856	SEP 18, 2006	U-67	NCE	SEP 18, 1997
>DLT>	20118 001 DESFLURANE; SUPRANE	4762856	AUG 09, 2005	U-67	NCE	SEP 18, 1997
>ADD>	20071 001 DESOGESTREL; DESOGEN	3927046	NOV 19, 1995		NC	DEC 10, 1995
>ADD>	20071 002 DESOGESTREL; DESOGEN	3927046	NOV 19, 1995		NC	DEC 10, 1995
>ADD>	20301 001 DESOGESTREL; ORTHO-CEPT	3927046	NOV 19, 1995		NC	DEC 10, 1995
>ADD>	20301 002 DESOGESTREL; ORTHO-CEPT	3927046	NOV 19, 1995		NC	DEC 10, 1995
	19287 001 DIAZEPAM; DIZAC	RE32393	SEP 18, 1996		NDF	JUN 18, 1996
>ADD>	20142 001 DICLOFENAC POTASSIUM; CATAFLAM				NDF	NOV 24, 1996
>ADD>	20142 002 DICLOFENAC POTASSIUM; CATAFLAM				NDF	NOV 24, 1996
	18723 001 DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 002 DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 003 DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19680 001 DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19794 001 DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
	19794 002 DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
	18651 001 DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 002 DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 003 DRONABINOL; MARINOL				ODE	DEC 22, 1999
	19879 002 EFLORNITHINE HYDROCHLORIDE; ORNIDYL	4399151	AUG 16, 2000		NCE	NOV 28, 1995
	19616 004 ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	19616 005 ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	20164 001 ENOXAPARIN SODIUM; LOVENOX				NCE	MAR 29, 1998
	20189 001 FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
		4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
	20189 002 FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
		4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
	20189 003 FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
		4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
>ADD>	19304 001 FENOFIBRATE; LIPIDIL				NCE	DEC 31, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20195 001 FENTANYL CITRATE; FENTANYL	4671953	JUN 09, 2004	U-87	NDF	OCT 04, 1996
>ADD>	20195 002 FENTANYL CITRATE; FENTANYL	4671953	JUN 09, 2004	U-87	NDF	OCT 04, 1996
>ADD>	20195 003 FENTANYL CITRATE; FENTANYL	4671953	JUN 09, 2004	U-87	NDF	OCT 04, 1996
>ADD>	20090 001 FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000			
>ADD>		4404216	OCT 16, 2003		NCE	JAN 29, 1995
>ADD>	20090 002 FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000			
>ADD>		4404216	OCT 16, 2003		NCE	JAN 29, 1995
	20073 001 FLUMAZENIL; MAZICON	4316839	MAR 03, 2003		NCE	DEC 20, 1996
	18936 001 FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003	U-84		
	18936 006 FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003	U-84		
		4314081	FEB 02, 2001			
		4194009	APR 19, 1994			
		4018895	APR 19, 1994	U-12		
		4626549	DEC 02, 2003	U-84		
	20101 001 FLUOXETINE HYDROCHLORIDE; PROZAC				NCE	DEC 31, 1998
>ADD>	20261 001 FLUVASTATIN SODIUM; LESCOL				NCE	DEC 31, 1998
>ADD>	20261 002 FLUVASTATIN SODIUM; LESCOL				NCE	DEC 31, 1998
	20068 001 FOSCARNET SODIUM; FOSCAVIR	4215113	JUN 06, 2000	U-64	NCE	SEP 27, 1996
>ADD>	20235 001 GABAPENTIN; NEURONTIN	4087544	MAY 02, 1995	U-86		
>ADD>		4024175	MAY 17, 1994		NCE	DEC 30, 1998
>ADD>	20235 002 GABAPENTIN; NEURONTIN	4087544	MAY 02, 1995	U-86		
>ADD>		4024175	MAY 17, 1994		NCE	DEC 30, 1998
>ADD>	20235 003 GABAPENTIN; NEURONTIN	4087544	MAY 02, 1995	U-86		
>ADD>		4024175	MAY 17, 1994		NCE	DEC 30, 1998
>ADD>	20123 001 GADODIAMIDE; OMNISCAN	4687659	AUG 18, 2004	U-76	NCE	JAN 08, 1998
	19596 001 GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4957939	MAR 03, 2004		I-94	AUG 17, 1996
	17783 003 GLIPIZIDE; GLUCOTROL				NCE	MAY 08, 1994
	20051 003 GLYBURIDE; GLYNASE	4916163	APR 10, 2007		NP	MAR 04, 1995
		4735805	APR 05, 2005		NCE	MAY 01, 1994
		4916163	APR 10, 2007		NP	MAR 04, 1995
	20051 004 GLYBURIDE; GLYNASE	4735805	APR 05, 2005		NCE	MAY 01, 1994
	19726 001 GOSERELIN ACETATE; ZOLADEX				I-88	FEB 02, 1996
>ADD>	20239 001 GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 12, 2006	U-89	NCE	DEC 29, 1998
	19032 001 GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19032 002 GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
>ADD>	19778 003 HYDROCHLOROTHIAZIDE; PRINZIDE 10-12.5				NS	NOV 18, 1996
	19888 003 HYDROCHLOROTHIAZIDE; ZESTORETIC 10-12.5				NS	NOV 18, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19891 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
					NDF	DEC 07, 1995
19892 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
					NDF	DEC 07, 1995
18538 002	INDAPAMIDE; LOZOL				NS	APR 29, 1996
					NCE	JUL 06, 1993
18956 001	IOHEXOL; OMNIPAUQUE 180	4250113	DEC 26, 1999		I-97	JUL 13, 1996
		4021481	MAY 03, 1994		NR	JUL 13, 1996
19710 005	IOVERSOL; OPTIRAY 350				I-48	JUL 27, 1996
20228 001	IPRATROPIUM BROMIDE; ATROVENT				NDF	SEP 29, 1996
20215 001	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
20215 002	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
					NS	JUN 30, 1996
20225 001	ISOSORBIDE MONONITRATE; IMDUR				NCE	DEC 30, 1996
					NDF	AUG 12, 1996
20225 002	ISOSORBIDE MONONITRATE; IMDUR				NCE	DEC 30, 1996
					NDF	AUG 12, 1996
19084 001	KETOCONAZOLE; NIZORAL	4335125	JUN 15, 1999		I-30	JAN 27, 1996
19700 001	KETOROLAC TROMETHAMINE; ACULAR	5110493	MAY 05, 2009	U-75	NCE	NOV 30, 1994
		4454151	JUN 12, 2001	U-75	NDF	NOV 09, 1995
		4089969	MAY 16, 1997	U-75		
20263 001	LEUPROLIDE ACETATE; LUPRON	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006			
		4728721	MAR 01, 2005		NP	APR 16, 1996
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
>ADD>	20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN			NCE	NOV 10, 1998
	18948 001	LEVOCARNITINE; CARNITOR			I-86	DEC 16, 1995
					ODE	DEC 16, 1999
	18948 002	LEVOCARNITINE; CARNITOR			I-86	DEC 16, 1995
					ODE	DEC 16, 1999
	20315 001	LEVOMETHADYL ACETATE HYDROCHLORIDE; ORLAAM			NCE	JUL 09, 1998
					ODE	JUL 09, 2000
	19558 001	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001	I-92	JUN 09, 1996
	19558 002	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001	I-92	JUN 09, 1996
	19558 003	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001	I-92	JUN 09, 1996
	19558 004	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001	I-92	JUN 09, 1996
	19777 001	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001	I-92	JUN 09, 1996
	19777 002	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001	I-92	JUN 09, 1996
	19777 003	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001	I-92	JUN 09, 1996
	19777 004	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001	I-92	JUN 09, 1996
	19777 005	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001	I-92	JUN 09, 1996
	20191 001	LODOXAMIDE TROMETHAMINE; ALOMIDE			NCE	SEP 23, 1998
					ODE	SEP 23, 2000
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	MAY 05, 2005	U-36	NCE FEB 21, 1997
	19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 1998	U-77	NCE APR 12, 1998
>ADD>	19940 001	MASOPROCOL; ACTINEX	4695590	SEP 05, 2006		NCE SEP 04, 1997
>DLT>	19940 001	MASOPROCOL; ACTINEX	4695590	SEP 22, 2004		NCE SEP 04, 1997
	20264 001	MEGESTROL ACETATE; MEGACE			ODE	SEP 10, 2000
	20049 001	MESALAMINE; PENTASA	4980173	DEC 25, 2007	U-78	
			4496553	JAN 29, 2002	U-78	NP MAY 10, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	JAN 22, 2006		NCE	JAN 22, 1997
20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006		NCE	JAN 22, 1997
19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
19356 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 2000		NCE	MAR 01, 1993
20150 001	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
20150 002	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
20150 003	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
20066 001	NICOTINE POLACRILEX; NICORETTE DS				NCE	JAN 13, 1994
20198 001	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
20198 002	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
20198 003	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
19921 001	OFLOXACIN; OCUFLOX	4551456	NOV 05, 2002	U-80	NDF	JUL 30, 1996
		4382892	MAY 10, 2000			
20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		D-20	FEB 02, 1996
					I-9	AUG 13, 1996
20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		NCE	JAN 04, 1996
20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		NCE	JAN 04, 1996
20036 001	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996	U-53		
20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
		3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
		3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
					NCE	AUG 13, 1998
20091 001	PERFLUBRON; IMAGENT				NCE	DEC 30, 1998
>ADD>	20184 001	PERINDOPRIL ERBUMINE; ACEON			NCE	DEC 30, 1998
>ADD>	20184 002	PERINDOPRIL ERBUMINE; ACEON			NCE	DEC 30, 1998
>ADD>	20184 003	PERINDOPRIL ERBUMINE; ACEON			NCE	DEC 30, 1998
	20014 001	PIRBUTEROL ACETATE; MAXAIR	4664107	MAY 12, 2004		
	19795 001	PODOFILOX; CONDYLOX			NCE	DEC 13, 1995
	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999	NCE	OCT 31, 1996
	19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	SEP 23, 1994
	20279 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	SEP 23, 1994
	19627 001	PROPOFOL; DIPRIVAN			I-90	MAR 08, 1996
	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	4996061	FEB 26, 2008		
		4929605	MAY 29, 2007	U-81		
		4254129	MAR 03, 1998	U-81		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
50689 001	RIFABUTIN; MYCOBUTIN				ODE	DEC 23, 1999
19649 001	RIMANTADINE HYDROCHLORIDE; FLUMADINE				NCE	SEP 17, 1998
19650 001	RIMANTADINE HYDROCHLORIDE; FLUMADINE				NCE	SEP 17, 1998
>ADD>	20272 001	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	20272 002	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	20272 003	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	20272 004	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	20272 005	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	19839 001	5248699	SEP 28, 2010	U-12		
>ADD>		4962128	OCT 09, 2007			
>ADD>	19839 002	5248699	SEP 28, 2010	U-12	NCE	DEC 30, 1996
>ADD>		4962128	OCT 09, 2007			
>ADD>	19839 003	5248699	SEP 28, 2010	U-12	NCE	DEC 30, 1996
>ADD>		4962128	OCT 09, 2007			
>ADD>	19839 004	5248699	SEP 28, 2010	U-12	NCE	DEC 30, 1996
>ADD>		4962128	OCT 09, 2007			
	19766 001	4444784	DEC 24, 2005	U-59	NCE	DEC 30, 1996
	19766 002	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 003	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 004	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	20168 001				I-98	NOV 17, 1996
>ADD>					ODE	NOV 17, 2000
>ADD>	20168 002				I-98	NOV 17, 1996
>ADD>					ODE	NOV 17, 2000
>ADD>	20134 001				NCE	JUN 18, 1998
>ADD>	19183 001				NDF	DEC 16, 1996
	19050 001				NR	MAR 19, 1996
					I-89	MAR 19, 1996
20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	MAR 28, 2006	U-72		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20070 001	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
20070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
20070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
20070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
19882 001	TECHNETIUM TC-99M MERTIATIDE KIT; TECHNESCAN MAG3				I-87	NOV 27, 1995
20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
18163 003	TEMAZEPAM; RESTORIL	5211954	MAY 18, 2010			
		5030632	JUL 09, 2008	U-70	NS	OCT 25, 1994
19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-3	I-96	SEP 29, 1996
19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-3	I-96	SEP 29, 1996
19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-3	I-96	SEP 29, 1996
19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-3	I-96	SEP 29, 1996
20223 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
		4112097	SEP 05, 1995			
		4026894	MAY 31, 1994		I-96	SEP 29, 1996
20223 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
		4112097	SEP 05, 1995			
		4026894	MAY 31, 1994		I-96	SEP 29, 1996
20223 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
		4112097	SEP 05, 1995			
		4026894	MAY 31, 1994		I-96	SEP 29, 1996
20223 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
		4112097	SEP 05, 1995			
		4026894	MAY 31, 1994		I-96	SEP 29, 1996
18949 001	TERFENADINE; SELDANE	4254129	MAR 03, 1998	U-81		
19762 001	TESTOSTERONE; TESTODERM				NDF	OCT 12, 1996
19762 002	TESTOSTERONE; TESTODERM				NDF	OCT 12, 1996
19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
		4051141	SEP 27, 1996		NCE	OCT 31, 1996
19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
		4051141	SEP 27, 1996		NCE	OCT 31, 1996
20330 001	TIMOLOL MALEATE; TIMOPTIC-XE				NP	NOV 04, 1996
20330 002	TIMOLOL MALEATE; TIMOPTIC-XE				NP	NOV 04, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20136 001	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
		4018929	APR 19, 1994		NCE	AUG 23, 1998
		RE30633	APR 19, 1994			
20136 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
		4018929	APR 19, 1994		NCE	AUG 23, 1998
		RE30633	APR 19, 1994			
20136 003	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
		4018929	APR 19, 1994		NCE	AUG 23, 1998
		RE30633	APR 19, 1994			
20136 004	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
		4018929	APR 19, 1994		NCE	AUG 23, 1998
		RE30633	APR 19, 1994			
20137 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
		4018929	APR 19, 1994		NCE	AUG 23, 1998
		RE30633	APR 19, 1994			
18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
		4215104	JUL 29, 1997			
>ADD>	19798 001	TRIAMCINOLONE ACETONIDE; NASACORT	4767612	AUG 30, 2005	U-85	NR JUL 11, 1994
>ADD>	20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4376858	MAR 15, 2000		NCE DEC 17, 1998
	18776 003	VECURONIUM BROMIDE; NORCURON	4297351	OCT 27, 1998		
			4237126	DEC 02, 1997		NCE APR 30, 1994
>ADD>	20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE DEC 28, 1998
>ADD>	20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE DEC 28, 1998
>ADD>	20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE DEC 28, 1998
>ADD>	20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE DEC 28, 1998
>ADD>	20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE DEC 28, 1998
>ADD>	20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE DEC 28, 1998
	19908 001	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE DEC 16, 1997
	19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE DEC 16, 1997